

SEQUENCE LISTING

<110> KITE PHARMA, INC.

<120> CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE

<130> K-1031.02US

<140> 15/475,681

<141> 2017-03-31

<150> 62/317,258

<151> 2016-04-01

<160> 284

<170> PatentIn version 3.5

<210> 1

<211> 220

<212> PRT

<213> Homo sapiens

<400> 1

Met	Leu	Arg	Leu	Leu	Leu	Ala	Leu	Asn	Leu	Phe	Pro	Ser	Ile	Gln	Val
1				5					10					15	

Thr	Gly	Asn	Lys	Ile	Leu	Val	Lys	Gln	Ser	Pro	Met	Leu	Val	Ala	Tyr
			20					25					30		

Asp	Asn	Ala	Val	Asn	Leu	Ser	Cys	Lys	Tyr	Ser	Tyr	Asn	Leu	Phe	Ser
		35					40					45			

Arg	Glu	Phe	Arg	Ala	Ser	Leu	His	Lys	Gly	Leu	Asp	Ser	Ala	Val	Glu
	50					55					60				

Val	Cys	Val	Val	Tyr	Gly	Asn	Tyr	Ser	Gln	Gln	Leu	Gln	Val	Tyr	Ser
65					70					75					80

Lys	Thr	Gly	Phe	Asn	Cys	Asp	Gly	Lys	Leu	Gly	Asn	Glu	Ser	Val	Thr
				85					90					95	

Phe	Tyr	Leu	Gln	Asn	Leu	Tyr	Val	Asn	Gln	Thr	Asp	Ile	Tyr	Phe	Cys
			100					105					110		

Lys	Ile	Glu	Val	Met	Tyr	Pro	Pro	Pro	Tyr	Leu	Asp	Asn	Glu	Lys	Ser
		115					120					125			

Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
130 135 140

Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
145 150 155 160

Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
165 170 175

Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
180 185 190

Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
195 200 205

Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser
210 215 220

<210> 2
<211> 90
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<223> Hinge Domain

<400> 2
cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60
tcacccttgt tccctgggtcc atccaagcca 90

<210> 3
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> Hinge Domain

<400> 3

Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
1 5 10 15

His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro
20 25 30

<210> 4

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<223> TM Domain

<400> 4

ttctgggtgt tggtcgtagt gggtggagtc ctcgcttggt actctctgct cgtcaccgtg 60

gcttttataa tcttctgggt t 81

<210> 5

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> TM Domain

<400> 5

Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
1 5 10 15

Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
20 25

<210> 6

<211> 123

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> Signaling/Costimulatory Domain

<400> 6

agatccaaaa gaagccgcct gtcctatagc gattacatga atatgactcc acgccgcct 60

ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 120

agc 123

<210> 7

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> Signaling/Costimulatory Domain

<400> 7

Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15

Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30

Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40

<210> 8

<211> 336

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> CD3z Activation Domain

<400> 8

```

agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggccca gaaccaactg      60
tataacgagc tcaacctggg acgcagggaag gagtatgacg ttttggacaa gcgcagagga      120
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat      180
gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg      240
agaaggggaa aagggcacga cggtttgtac cagggaactca gcactgctac gaaggatact      300
tatgacgctc tccacatgca agccctgccca cctagg                                336

```

<210> 9

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> CD3z Activation Domain

<400> 9

```

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1           5           10           15

```

```

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
          20           25           30

```

```

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
          35           40           45

```

```

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
          50           55           60

```

```

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65           70           75           80

```

```

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
          85           90           95

```

```

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
          100          105          110

```

<210> 10
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<223> Signal (leader) Peptide

<400> 10
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccg 63

<210> 11
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> Signal (leader) Peptide

<400> 11
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro
20

<210> 12
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> Linker

<400> 12
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
1 5 10 15

Lys Gly

<210> 13

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR1

<400> 13

Gly Phe Thr Phe Ser Ser Tyr

1 5

<210> 14

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR1

<400> 14

Phe Thr Phe Ser Ser Tyr

1 5

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR1

<400> 15

Gly Tyr Thr Phe Thr Ser Tyr

1

5

<210> 16

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR1

<400> 16

Gly Gly Ser Ile Ser Ser Ser Ser Tyr

1 5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR1

<400> 17

Gly Phe Thr Phe Ser Ser Tyr

1 5

<210> 18

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR1

<400> 18

Gly Phe Thr Phe Ser Ser Tyr Gly Met His

1 5 10

<210> 19
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VH CDR1

<400> 19
Gly Gly Thr Phe Ser Ser Tyr
1 5

<210> 20
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VH CDR1

<400> 20
Gly Phe Thr Phe Ser Ser Tyr
1 5

<210> 21
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VH CDR2

<400> 21
Ser Gly Ser Gly Gly Ser
1 5

<210> 22
<211> 15
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 22

Ser	Tyr	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	Lys	Gly
1				5					10				15	

<210> 23

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 23

Asn	Pro	Gly	Gly	Gly	Ser
1				5	

<210> 24

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 24

Ser	Tyr	Ser	Gly	Ser
1				5

<210> 25

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 25

Ser Ser Ser Ser Ser Thr
1 5

<210> 26

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 26

Ser Tyr Asp Gly Ser Asn
1 5

<210> 27

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 27

Ile Pro Ile Phe Gly Thr
1 5

<210> 28

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 28

Ser Tyr Asp Gly Ser Asn
1 5

<210> 29

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VH CDR3

<400> 29

Ala Glu Met Gly Ala Val Phe Asp Ile
1 5

<210> 30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VH CDR3

<400> 30

Asp Gly Thr Tyr Leu Gly Gly Leu Trp Tyr Phe Asp Leu
1 5 10

<210> 31

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VH CDR3

<400> 31
Glu Ser Trp Pro Met Asp Val
1 5

<210> 32
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VH CDR3

<400> 32
Gly Arg Gly Tyr Ala Thr Ser Leu Ala Phe Asp Ile
1 5 10

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VH CDR3

<400> 33
Gly Ser Gln Glu His Leu Ile Phe Asp Tyr
1 5 10

<210> 34
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VH CDR3

<400> 34
Thr Asp Phe Trp Ser Gly Ser Pro Pro Gly Leu Asp Tyr
1 5 10

<210> 35
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VH CDR3

<400> 35
Thr Pro Glu Tyr Ser Ser Ser Ile Trp His Tyr Tyr Tyr Gly Met Asp
1 5 10 15

Val

<210> 36
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VH CDR3

<400> 36
Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly Met Asp Val
1 5 10

<210> 37
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR1

<400> 37
Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala

1

5

10

<210> 38

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VL CDR1

<400> 38

Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp
1 5 10 15

<210> 39

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VL CDR1

<400> 39

Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10

<210> 40

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VL CDR1

<400> 40

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10

<210> 41
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR1

<400> 41
Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala
1 5 10

<210> 42
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR1

<400> 42
Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala
1 5 10

<210> 43
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR1

<400> 43
Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu
1 5 10 15

Ala

<210> 44
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR1

<400> 44
Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10

<210> 45
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR2

<400> 45
Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 46
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR2

<400> 46
Leu Gly Ser Asn Arg Ala Ser
1 5

<210> 47
<211> 7

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR2

<400> 47

Gly Ala Ser Thr Arg Ala Thr
1 5

<210> 48

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR2

<400> 48

Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 49

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR2

<400> 49

Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 50

<211> 7

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR2

<400> 50
Gly Ala Ser Ser Leu Gln Ser
1 5

<210> 51
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR2

<400> 51
Trp Ala Ser Thr Arg Glu Ser
1 5

<210> 52
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR2

<400> 52
Ser Ala Ser Thr Arg Ala Thr
1 5

<210> 53
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR3

<400> 53

Gln Gln Arg Ile Ser Trp Pro Phe Thr

1 5

<210> 54

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR3

<400> 54

Met Gln Gly Leu Gly Leu Pro Leu Thr

1 5

<210> 55

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR3

<400> 55

Gln Gln Tyr Ala Ala Tyr Pro Thr

1 5

<210> 56

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR3

<400> 56
Gln Gln Arg His Val Trp Pro Pro Thr
1 5

<210> 57
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR3

<400> 57
Gln Gln Arg Phe Tyr Tyr Pro Trp Thr
1 5

<210> 58
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR3

<400> 58
Gln Gln Ile Tyr Thr Phe Pro Phe Thr
1 5

<210> 59
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR3

<400> 59
Gln Gln Phe Ala His Thr Pro Phe Thr

1

5

<210> 60

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR3

<400> 60

Gln Gln His His Val Trp Pro Leu Thr

1

5

<210> 61

<211> 354

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VH DNA

<400> 61

gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60

tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt ccgccaggct 120

ccagggaagg ggctggagt ggtctcagct attagtggta gtggtggtag cacatactac 180

gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240

ctgcaaata acagcctgag agccgaggac acggcggtgt actactgcgc aagagccgag 300

atgggagccg tattcgacat atgggggtcag ggtacaatgg tcaccgtctc ctca 354

<210> 62

<211> 366

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VH DNA

<400> 62

caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc	60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct	120
ccaggcaagg ggctggagtg ggtggcagtt atatcgtatg atggaagtaa taaatactat	180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat	240
ctgcaaatga acagcctgag agccgaggac acggcgggtg actactgcgc cagagacggt	300
acttatctag gtggtctctg gtacttcgac ttatggggga gaggtacctt ggtcaccgtc	360
tcctca	366

<210> 63

<211> 348

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VH DNA

<400> 63

caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt	60
tcctgcaagg catctggata caccttcacc agctactata tgcactgggt gcgacaggcc	120
cctggacaag ggcttgagtg gatgggaata atcaaccctg gtggtggtag cacaagctac	180
gcacagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac	240
atggagctga gcagcctgag atctgaggac acggcgggtg actactgcgc cagagagagt	300
tggccaatgg acgtatgggg ccaggaaca actgtcaccg tctcctca	348

<210> 64

<211> 366

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VH DNA

<400> 64

cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc	60
acctgcactg tctctggtgg ctccatcagc agtagtagtt actactgggg ctggatccgc	120
cagccccag ggaaggggct ggagtggatt gggagtatct cctatagtgg gagcacctac	180
tacaaccctg ccctcaagag tcgagtcacc atatccgtag acacgtccaa gaaccagttc	240
tccctgaagc tgagttctgt gaccgccgca gacacggcgg tgtactactg cgccagaggc	300
aggggatatg caaccagctt agccttcgat atctgggggtc aggttacaat ggtcaccgtc	360
tcctca	366

<210> 65

<211> 357

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VH DNA

<400> 65

gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctgggggggtc cctgagactc	60
tcctgtgcag cctctggatt caccttcagt agctatagca tgaactgggt ccgccaggct	120
ccagggaagg ggctggagtg ggtttcaacc attagtagta gtagtagtac catatactac	180
gcagactctg tgaagggccg attcaccatc tccagagaca atgccaagaa ctcaactgtat	240
ctgcaaatga acagcctgag agctgaggac acggcgggtgt actactgcgc cagaggttct	300
caggagcacc tgattttcga ttattgggga cagggtacat tggtcaccgt ctcctca	357

<210> 66

<211> 366

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VH DNA

<400> 66

caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc	60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct	120
ccaggcaagg ggctggagtg ggtggcagtt atatcgtatg atggaagtaa taaatactat	180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat	240
ctgcaaatac acagcctgag agccgaggac acggcgggtg actactgcgc cagaactgac	300
ttctggagcg gatccccctc aggcttagat tactggggac agggtagatt ggtcaccgtc	360
tcctca	366

<210> 67

<211> 378

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VH DNA

<400> 67

caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc	60
tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc	120
cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaaactac	180
gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac	240
atggagctga gcagcctgag atctgaggac acggcgggtg actactgcgc cagaactcct	300
gaatactcct ccagcatatg gcactattac tacggcatgg acgtatgggg ccagggaaca	360
actgtcaccg tctcctca	378

<210> 68

<211> 369

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VH DNA

<400> 68

caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc	60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct	120
ccaggcaagg ggctggagtg ggtggcagtt atatcgtatg atggaagtaa taaatactat	180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat	240
ctgcaaatga acagcctgag agccgaggac acggcggtgt actactgcgt caaggggccg	300
ttgcaggagc cgccatacga ttatggaatg gacgtatggg gccagggaac aactgtcacc	360
gtctcctca	369

<210> 69

<211> 321

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VL DNA

<400> 69

gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc	60
ctctcctgca gggccagtca gagtgttagc aggtacttag cctggtacca acagaaacct	120
ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc	180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct	240
gaagattttg cagtttatta ctgtcagcag agaatctcct ggcctttcac ttttggcgga	300
gggaccaagg ttgagatcaa a	321

<210> 70

<211> 336

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VL DNA

<400> 70

gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc	60
atctcctgca ggtctagtca gaggctcctg catagtaatg gatacaacta tttggattgg	120
tacctgcaga agccagggca gtctccacag ctctgatct atttgggttc taatcgggcc	180
tccgggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc	240
agcagagtgg aggctgagga tgttgggggtt tattactgca tgcagggact cggcctcct	300
ctcacttttg gcggagggac caaggttgag atcaaa	336

<210> 71

<211> 318

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VL DNA

<400> 71

gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc	60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct	120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc	180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct	240
gaagattttg cagtttatta ctgtcagcag tacgccgcct accctacttt tggcggaggg	300
accaaggttg agatcaaa	318

<210> 72

<211> 321

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VL DNA

<400> 72

gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc	60
ctctcctgca gggccagtca gagtgttagc agctacttag cctggtacca acagaaacct	120
ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc	180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct	240
gaagattttg cagtttatta ctgtcagcag agacacgtct ggcctcctac ttttggcgga	300
gggaccaagg ttgagatcaa a	321

<210> 73

<211> 321

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VL DNA

<400> 73

gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc	60
ctctcctgca gggccagtca gagtgttagc aggtacttag cctggtacca acagaaacct	120
ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc	180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct	240
gaagattttg cagtttatta ctgtcagcag agattctact acccttggac ttttggcgga	300
gggaccaagg ttgagatcaa a	321

<210> 74

<211> 321

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VL DNA

<400> 74

gacatccagt tgacccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc	60
atcacttgtc gggcgagtca ggggtattagc agctgggttag cctgggtatca gcagaaacca	120
gggaaagccc ctaagctcct gatctatggt gcatccagtt tgcaaagtgg ggtcccatca	180
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct	240
gaagattttg caacttatta ctgtcagcag atatacacct tccctttcac ttttggcgga	300
gggaccaagg ttgagatcaa a	321

<210> 75

<211> 339

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VL DNA

<400> 75

gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc	60
atcaactgca agtccagcca gagtgtttta tacagctcca acaataagaa ctacttagct	120
tggtaccagc agaaaccagg acagcctcct aagctgctca ttactgggc atctaccgg	180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc	240
atcagcagcc tgcaggctga agatgtggca gtttattact gtcagcagtt cgcccacact	300
cctttcactt ttggcggagg gaccaagggtt gagatcaaa	339

<210> 76

<211> 321

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> VL DNA

<400> 76
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgtttagc agcaacttag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatagc gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag caccacgtct ggcctctcac ttttggcgga 300
gggaccaagg ttgagatcaa a 321

<210> 77
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>
<223> VH Protein

<400> 77
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Glu Met Gly Ala Val Phe Asp Ile Trp Gly Gln Gly Thr
100 105 110

Met Val Thr Val Ser Ser
115

<210> 78

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VH Protein

<400> 78

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Gly Thr Tyr Leu Gly Gly Leu Trp Tyr Phe Asp Leu Trp
100 105 110

Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 79

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VH Protein

<400> 79

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Ile Ile Asn Pro Gly Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Ser Trp Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

<210> 80

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VH Protein

<400> 80

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gly Arg Gly Tyr Ala Thr Ser Leu Ala Phe Asp Ile Trp
100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120

<210> 81

<211> 119

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VH Protein

<400> 81

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35

40

45

Ser Thr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Gly Ser Gln Glu His Leu Ile Phe Asp Tyr Trp Gly Gln Gly
 100 105 110

Thr Leu Val Thr Val Ser Ser
 115

<210> 82

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 polypeptide

<220>

<223> VH Protein

<400> 82

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Thr Asp Phe Trp Ser Gly Ser Pro Pro Gly Leu Asp Tyr Trp
100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 83

<211> 126

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VH Protein

<400> 83

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Thr Pro Glu Tyr Ser Ser Ser Ile Trp His Tyr Tyr Tyr Gly
100 105 110

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125

<210> 84

<211> 123

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VH Protein

<400> 84

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly Met Asp Val
100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 85

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VL Protein

<400> 85

Glu	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly
1				5					10					15	

Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser	Val	Ser	Arg	Tyr
			20					25					30		

Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile
		35					40					45			

Tyr	Asp	Ala	Ser	Asn	Arg	Ala	Thr	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly
	50					55					60				

Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro
65					70					75					80

Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	Gln	Arg	Ile	Ser	Trp	Pro	Phe
				85					90					95	

Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys
			100					105		

<210> 86

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VL Protein

<400> 86

Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Leu	Ser	Leu	Pro	Val	Thr	Pro	Gly
1				5					10					15	

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95

Leu Gly Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 87

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VL Protein

<400> 87

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser

65

70

75

80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ala Ala Tyr Pro Thr
 85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 88

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VL Protein

<400> 88

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg His Val Trp Pro Pro
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 89

<211> 107

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VL Protein

<400> 89

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Phe Tyr Tyr Pro Trp
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 90

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VL Protein

<400> 90

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile Tyr Thr Phe Pro Phe
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 91

<211> 113

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VL Protein

<400> 91

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
20 25 30

Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95

Phe Ala His Thr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
100 105 110

Lys

<210> 92

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VL Protein

<400> 92

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His His Val Trp Pro Leu
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 93

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VH CDR1

<400> 93

Gly Gly Ser Ile Ser Ser Tyr
1 5

<210> 94

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VH CDR1

<400> 94

Gly Gly Ser Ile Ser Ser Gly Gly Phe
1 5

<210> 95

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VH CDR1

<400> 95

Gly Tyr Thr Leu Thr Glu Leu
1 5

<210> 96
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VH CDR1

<400> 96
Gly Phe Thr Phe Ser Ser Tyr
1 5

<210> 97
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VH CDR2

<400> 97
Tyr Tyr Ser Gly Ser
1 5

<210> 98
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VH CDR2

<400> 98
His His Ser Gly Ser
1 5

<210> 99
<211> 6

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 99

Asp Pro Glu Asp Gly Glu
1 5

<210> 100

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR2

<400> 100

Ser Tyr Asp Gly Ser Asp
1 5

<210> 101

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR3

<400> 101

Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr
1 5 10

<210> 102

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR3

<400> 102

Leu	Val	Tyr	Cys	Gly	Gly	Asp	Cys	Tyr	Ser	Gly	Phe	Asp	Tyr
1				5					10				

<210> 103

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR3

<400> 103

Glu	Ser	Arg	Gly	Ile	Gly	Trp	Pro	Tyr	Phe	Asp	Tyr
1				5					10		

<210> 104

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VH CDR3

<400> 104

Glu	Arg	Tyr	Ser	Gly	Arg	Asp	Tyr
1				5			

<210> 105

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> VL CDR1

<400> 105

Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
1 5 10

<210> 106

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VL CDR1

<400> 106

Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
1 5 10

<210> 107

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VL CDR1

<400> 107

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10

<210> 108

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> VL CDR1

<400> 108
Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr
1 5 10

<210> 109
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR2

<400> 109
Asp Ala Ser Asn Leu Glu Thr
1 5

<210> 110
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR2

<400> 110
Asp Ala Ser Asn Leu Glu Thr
1 5

<210> 111
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR2

<400> 111
Gly Ala Ser Ser Leu Lys Ser

<210> 112
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR2

<400> 112
Gly Ala Ser Thr Arg Ala Thr
1 5

<210> 113
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR3

<400> 113
Gln Gln Tyr Gly Asn Leu Pro Phe Thr
1 5

<210> 114
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> VL CDR3

<400> 114
Gln Gln Tyr Gly Asn Leu Pro Phe Thr
1 5

<210> 115
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR3

<400> 115
Gln Gln Ser Tyr Ser Thr Pro Ile Thr
1 5

<210> 116
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> VL CDR3

<400> 116
Gln Gln Tyr Asp Thr Trp Pro Phe Thr
1 5

<210> 117
<211> 366
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
<223> VH DNA

<400> 117
caggtgcagc tgcaggaatc cggaccgggg ctggtgaagc ccagcgagac tctgagtctc 60
acgtgtacag tttctggagg tagcattagc tcctactatt ggtcatggat aaggcagccc 120
cccgggaagg gattggaatg gatcggctat atttactaca gtgggagcac caattacaac 180
ccctcactga agtctagagt tacaatcagc gttgacacct caaagaatca gttcagtttg 240

aaattgtcta gcgtcacagc agctgataca gccgtctatt attgtgtttc tctgggtctat	300
tgcggtgggg attgttacag tggctttgac tattgggggc aggggtactct gggttacagtt	360
tctttcc	366

<210> 118
 <211> 372
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
 <223> VH DNA

<400> 118	
caggtacagc tgcaggaatc tgggcccgga cttgtcaagc caagtcagac actttctctt	60
acatgtaccg tgagcggcgg aagtataagc agtggaggct tttactggtc ttggatacgg	120
cagcaccag gcaaaggctt ggagtggatt ggatacattc atcattcagg atctacacac	180
tataatccat cccttaagtc ccgggtcacc attagcattg atacgtctaa gaatctgttc	240
agtctcaggc tgtcctccgt cactgctgcc gacacagccg tgtactactg cgcctccttg	300
gtttactgcg gaggcgactg ttatagcggc tttgattatt gggggcaggg gaccctcgta	360
accgtgagct ct	372

<210> 119
 <211> 363
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
 <223> VH DNA

<400> 119	
caggtccaac tggtgcagtc cggagccgaa gtcaagaaac caggtgcctc cgtaaagtg	60
agttgcaaag tctctggata cactctgacc gagctctcta tgcactgggt ccggcaggcc	120
cccggcaagg gattggaatg gatgggcggg ttcgatcctg aggacggaga gactatctac	180

gctcaaaaat tccagggacg agtgactgtg accgaagaca ctagtaccga cactgcctac	240
atggaacttt cctctctgcg atcagaagat accgcagtgt actactgtgc tactgaatct	300
aggggcattg gatggcccta cttcgattac tggggtcagg gaactctggg gactgtctcc	360
agc	363

<210> 120
 <211> 351
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
 <223> VH DNA

<400> 120	
caggtccagt tggtcgaaag tggcgggtgg gtagtgcagc cgggccgcag tttgaggctt	60
tcctgtgcgg cttcaggctt tactttttcc agctatggaa tgcactgggt gcggcaggcc	120
cccggcaaag gacttgagtg ggtggccgtc atttcttatg acggatcaga taagtactac	180
gtggacagcg tcaagggcag attcaccatc tctagggaca acagtaaaaa tagactctac	240
ctccagatga atagcctcag agctgaagac acggccgtct actattgtgc tcgggagcgg	300
tatagtggca gagactactg ggggcagggc acactcgтта cagtgagtag c	351

<210> 121
 <211> 324
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
 <223> VL DNA

<400> 121	
gacatccagt tgacacagag cccgagttcc ttgtccgcct ccgtcgggga tagagtgtca	60
tttacctgtc aggctctca ggatattaat aactttctga attggtatca gcaaaagccc	120
ggaaaggcac ccaagctggt gattttacgac gccagtaacc tggagacagg cgtgccctcc	180

cggtttagtg gtagcggaag cggtagcgat tttaccttta ctatcagctc tctccaaccc	240
gaagacattg caacctacta ttgtcaacaa tatggaaacc tgccttttac atttggcggc	300
ggcaccaagg tggagattaa gcgg	324

<210> 122
 <211> 324
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
 <223> VL DNA

<400> 122 gatatccagc tcaactcaaag cccctctagt ctctctgcct cagtggggga tcgggtcagt	60
tttacttgtc aagcttcaca ggatatcaac aacttcctta attggtatca gcagaagcca	120
ggaaaagcac ccaagctgct catctatgat gcctcaaatt tggagacggg tgttcccagt	180
cgattctctg ggtaggggtc cgggaccgac tttacgttta cgatctcctc tctgcagccc	240
gaagacatcg ccacatacta ttgtcaacag tacggcaact tgcctttcac atttgggggc	300
gggactaagg ttgaaatcaa gagg	324

<210> 123
 <211> 324
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
 <223> VL DNA

<400> 123 gatattcaga tgactcaatc tccttcttct ctgtccgctt ccgtgggcga tagagtgacc	60
attacttgta gggcgtccca gtcaatctcc agttatttga attggtatca gcagaagccc	120
gggaaagcac ctaagctggt gatcagcggg gcttctagcc tgaagagtgg ggtaccttca	180
cggttcagcg gaagcggaag cggaaccgat ttcaccctga ctatcagcag cctgccacct	240

gaggactttg caacttacta ctgccaacag tcatacagca ctccgatcac tttcggccag 300
 ggcacccggc tcgaaatcaa gcgc 324

<210> 124
 <211> 324
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
 <223> VL DNA

<400> 124
 gagattgtta tgaccagag tcctgcgacc ctctcagtca gccccgggga gcgcgcaact 60
 ttgtcttgca gagctagtca gtccgtgtcc tctcttctga catggtacca gcaaaagccc 120
 gggcaggctc cgcgcctttt gatctttggg gcttcaacaa gagccactgg gattccccgca 180
 cgattctctg gtcctgggag cgggtactggt ttcaccctga cgattagcag tctccagagc 240
 gaggacttcg ccgtatacta ctgccagcag tacgatacgt ggccattcac ttttggacca 300
 gggactaaag tggattttaa gcgc 324

<210> 125
 <211> 122
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> VH AA

<400> 125
 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
 20 25 30
 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile

35

40

45

Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
 85 90 95

Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
 100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 126

<211> 124

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VH AA

<400> 126

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
 20 25 30

Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
 35 40 45

Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
 50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
 65 70 75 80

Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 127

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VH AA

<400> 127

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30

Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 128

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VH AA

<400> 128

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 129

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VL AA

<400> 129

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> 130

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> VL AA

<400> 130

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> 131

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> VL AA

<400> 131

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Ser Gly Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro

65

70

75

80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile
 85 90 95

Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
 100 105

<210> 132

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 polypeptide

<220>

<223> VL AA

<400> 132

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
 20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
 85 90 95

Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
 100 105

<210> 133

<211> 1437

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> FS-21495CARDNAHxL

<400> 133

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccggaggtgc agctgttgga gtctggggga ggcttggtac agcctggggg gtccctgaga	120
ctctcctgtg cagcctctgg attcaccttt agcagctatg ccatgagctg ggtccgccag	180
gctccaggga aggggctgga gtgggtctca gctattagtg gtagtggtgg tagcacatac	240
tacgcagact ccgtgaaggg ccggttcacc atctccagag acaattcaa gaacacgctg	300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgcaagagcc	360
gagatgggag ccgtattcga catatggggg cagggtacaa tggtcaccgt ctcctcaggg	420
tctacatccg gctccgggaa gcccggaagt ggcgaaggta gtacaaaggg ggaaattgtg	480
ttgacacagt ctccagccac cctgtctttg tctccagggg aaagagccac cctctcctgc	540
agggccagtc agagtgttag caggtactta gcctgggtacc aacagaaacc tggccaggct	600
cccaggctcc tcatctatga tgcattcaac agggccactg gcatcccagc caggttcagt	660
ggcagtgggg ctgggacaga cttcactctc accatcagca gcctagagcc tgaagatttt	720
gcagtttatt actgtcagca gagaatctcc tggcctttca cttttggcgg agggaccaag	780
gttgagatca aacgggccgc tgcccttgat aatgaaaagt caaacggaac aatcattcac	840
gtgaagggca agcacctctg tccgtcacc ttgttcctg gtccatcaa gccattctgg	900
gtgttggtcg tagtgggtgg agtcctcgct tgttactctc tgctcgtcac cgtggctttt	960
ataatcttct gggttagatc caaaagaagc cgctgctcc atagcgatta catgaatatg	1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat	1080
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag	1140
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt	1200
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc	1260
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata	1320

ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1380
 actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc taggttaa 1437

<210> 134
 <211> 478
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 polypeptide

<220>
 <223> FS-21495CARHxL

<400> 134
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
 20 25 30

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
 35 40 45

Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys
 50 55 60

Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr
 65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 100 105 110

Ala Val Tyr Tyr Cys Ala Arg Ala Glu Met Gly Ala Val Phe Asp Ile
 115 120 125

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Ser Thr Ser Gly
 130 135 140

Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val
145 150 155 160

Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala
165 170 175

Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala Trp
180 185 190

Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala
195 200 205

Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser
210 215 220

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe
225 230 235 240

Ala Val Tyr Tyr Cys Gln Gln Arg Ile Ser Trp Pro Phe Thr Phe Gly
245 250 255

Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu
260 265 270

Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
275 280 285

Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
290 295 300

Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
305 310 315 320

Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
325 330 335

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
340 345 350

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val

355

360

365

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
 370 375 380

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
 385 390 395 400

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
 405 410 415

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
 420 425 430

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
 435 440 445

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
 450 455 460

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 465 470 475

<210> 135

<211> 1437

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 polynucleotide

<220>

<223> FS-21495CARDNALxH

<400> 135

atggcactcc ccgtaactgc tctgctgctg ccgttgatc tgctcctgca cgccgcacgc 60

ccggaaattg tgttgacaca gtctccagcc accctgtctt tgtctccagg ggaaagagcc 120

accctctcct gcagggccag tcagagtgtt agcaggtact tagcctggta ccaacagaaa 180

cctggccagg ctcccaggct cctcatctat gatgcatcca acagggccac tggcatccca 240

gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctagag 300

cctgaagatt ttgcagttta ttactgtcag cagagaatct cctggccttt cacttttggc	360
ggagggacca aggttagat caaacggggg tctacatccg gctccgggaa gcccggaagt	420
ggcgaaggta gtacaaaggg ggaggtgcag ctgttggagt ctgggggagg cttggtacag	480
cctgggggggt ccctgagact ctctgtgca gcctctggat tcaccttag cagctatgcc	540
atgagctggg tccgccaggc tccagggaag gggctggagt gggctctcagc tattagtgg	600
agtggtagta gcacatacta cgcagactcc gtgaagggcc gggtcaccat ctccagagac	660
aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga cacggcgggtg	720
tactactgcg caagagccga gatgggagcc gtattcgaca tatgggggtca gggtagaatg	780
gtcaccgtct cctcagccgc tgcccttgat aatgaaaagt caaacggaac aatcattcac	840
gtgaagggca agcacctctg tccgtcacc ttgttccctg gtccatccaa gccattctgg	900
gtgttggtcg tagtgggtgg agtcctcgct tgttactctc tgctcgtcac cgtggctttt	960
ataatcttct gggtagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg	1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat	1080
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag	1140
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt	1200
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc	1260
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata	1320
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc	1380
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc taggtaa	1437

<210> 136

<211> 478

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> FS-21495CARLxH

<400> 136

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1								5			10			15	

His Ala Ala Arg Pro Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45

Ser Val Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60

Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95

Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg
100 105 110

Ile Ser Trp Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125

Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140

Thr Lys Gly Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
145 150 155 160

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
165 170 175

Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
180 185 190

Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala
195 200 205

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
210 215 220

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
225 230 235 240

Tyr Tyr Cys Ala Arg Ala Glu Met Gly Ala Val Phe Asp Ile Trp Gly
245 250 255

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu
260 265 270

Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
275 280 285

Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
290 295 300

Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
305 310 315 320

Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
325 330 335

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
340 345 350

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
355 360 365

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
370 375 380

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
385 390 395 400

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
405 410 415

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
420 425 430

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
435 440 445

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
450 455 460

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 137
<211> 1464
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> PC-21497CARDNAHxL

<400> 137
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgga gtctggggga ggcgtggtcc agcctgggag gtccctgaga 120
ctctcctgtg cagcgtctgg attcaccttc agtagctatg gcatgcactg ggtccgccag 180
gctccaggca aggggctgga gtgggtggca gttatatcgt atgatggaag taataaatac 240
tatgcagact ccgtgaaggg ccgattcacc atctccagag acaattccaa gaacacgctg 300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgccagagac 360
ggtacttatc taggtggtct ctggtacttc gacttatggg ggagaggtag cttggtcacc 420
gtctcctcag ggtctacatc cggctccggg aagcccggaa gtggcgaagg tagtacaaag 480
ggggatattg tgatgactca gtctccactc tccctgcccg tcacccttgg agagccggcc 540
tccatctcct gcaggtctag tcagagcctc ctgcatagta atggatacaa ctatttggat 600
tggtacctgc agaagccagg gcagtctcca cagctcctga tctatttggg ttctaatacgg 660
gcctccgggg tccctgacag gttcagtggc agtggatcag gcacagattt tacactgaaa 720
atcagcagag tggaggctga ggatgttggg gtttattact gcatgcaggg actcggcctc 780
cctctcactt ttggcggagg gaccaagggt gagatcaaac gggccgctgc ctttgataat 840
gaaaagtcaa acggaacaat cattcacgtg aagggaagc acctctgtcc gtcacccttg 900
ttccctggtc catccaagcc attctgggtg ttggctgtag tgggtggagt cctcgcttgt 960

tactctctgc tcgtcaccgt ggctttttata atcttctggg ttagatccaa aagaagccgc 1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggcccccac aaggaaacac 1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1140
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1200
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1260
ggtggcaaac caagacgaaa aaacccccag gagggctctct ataatgagct gcagaaggat 1320
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1380
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1440
atgcaagccc tgccacctag gtaa 1464

<210> 138
<211> 487
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<220>
<223> PC-21497CARHxL

<400> 138
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45

Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60

Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr
65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

85

90

95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 100 105 110

Ala Val Tyr Tyr Cys Ala Arg Asp Gly Thr Tyr Leu Gly Gly Leu Trp
 115 120 125

Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly
 130 135 140

Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
 145 150 155 160

Gly Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro
 165 170 175

Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His
 180 185 190

Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
 195 200 205

Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val
 210 215 220

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
 225 230 235 240

Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln
 245 250 255

Gly Leu Gly Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
 260 265 270

Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile
 275 280 285

His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
 290 295 300

Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320

Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335

Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350

Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365

Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
370 375 380

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480

Met Gln Ala Leu Pro Pro Arg
485

<210> 139

<211> 1464

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> PC-21497CARDNALxH

<400> 139

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccggatattg tgatgactca gtctccactc tccctgcccc tcacccctgg agagccggcc	120
tccatctcct gcaggtctag tcagagcctc ctgcatagta atggatacaa ctatttggat	180
tggtacctgc agaagccagg gcagtctcca cagctcctga tctatttggg ttctaatacg	240
gcctccgggg tccctgacag gttcagtggc agtggatcag gcacagattt tacactgaaa	300
atcagcagag tggaggctga ggatgttggg gtttattact gcatgcaggg actcggcctc	360
cctctcactt ttggcggagg gaccaagggt gagatcaaac ggggggtctac atccggctcc	420
gggaagcccc gaagtggcga aggtagtaca aaggggcagg tgcagctggg ggagtctggg	480
ggaggcgtgg tccagcctgg gaggtccctg agactctcct gtgcagcgtc tggattcacc	540
ttcagtagct atggcatgca ctgggtccgc caggctccag gcaaggggct ggagtgggtg	600
gcagttatat cgtatgatgg aagtaataaa tactatgcag actccgtgaa gggccgattc	660
accatctcca gagacaattc caagaacacg ctgtatctgc aaatgaacag cctgagagcc	720
gaggacacgg cgggtgtacta ctgcgccaga gacggtactt atctaggtgg tctctggtac	780
ttcgacttat gggggagagg taccttggtc accgtctcct cagccgctgc ctttgataat	840
gaaaagtcaa acggaacaat cattcacgtg aagggcaagc acctctgtcc gtcacccttg	900
ttccctggtc catccaagcc attctgggtg ttggctgtag tgggtggagt cctcgcttgt	960
tactctctgc tcgtcaccgt ggcttttata atcttctggg ttagatccaa aagaagccgc	1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac	1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc	1140
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac	1200
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg	1260
ggtggcaaac caagacgaaa aaacccccag gaggtctctt ataatagagct gcagaaggat	1320
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg	1380

cacgacgggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1440
atgcaagccc tgccacctag gtaa 1464

<210> 140
<211> 487
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<220>
<223> PC-21497CARHxL

<400> 140
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu
20 25 30

Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln
35 40 45

Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln
50 55 60

Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg
65 70 75 80

Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
85 90 95

Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr
100 105 110

Tyr Cys Met Gln Gly Leu Gly Leu Pro Leu Thr Phe Gly Gly Gly Thr
115 120 125

Lys Val Glu Ile Lys Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly
130 135 140

Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Gln Leu Val Glu Ser Gly
145 150 155 160

Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala
165 170 175

Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala
180 185 190

Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser
195 200 205

Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
210 215 220

Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala
225 230 235 240

Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Thr Tyr Leu Gly
245 250 255

Gly Leu Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val
260 265 270

Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile
275 280 285

His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
290 295 300

Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320

Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335

Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350

Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365

Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
370 375 380

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480

Met Gln Ala Leu Pro Pro Arg
485

<210> 141
<211> 1428
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> AJ-21508CARDNAHxL

<400> 141
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgca gtctggggct gaggtgaaga agcctggggc ctcagtgaag 120
gtttcctgca aggcattctgg atacaccttc accagctact atatgcactg ggtgacgacag 180
gcccctggac aagggttga gtggatggga ataatacaacc ctggtggtgg tagcacaagc 240

tacgcacaga agttccaggg cagagtcacc atgaccaggg acacgtccac gagcacagtc	300
tacatggagc tgagcagcct gagatctgag gacacggcgg tgtactactg cgccagagag	360
agttggccaa tggacgtatg gggccagggg acaactgtca ccgtctcctc aggggtctaca	420
tccggctccg ggaagcccgg aagtggcgaa ggtagtataa agggggaaat agtgatgacg	480
cagtctccag ccaccctgtc tgtgtctcca ggggaaagag ccaccctctc ctgcagggcc	540
agtcagagtg ttagcagcaa cttagcctgg taccagcaga aacctggcca ggctcccagg	600
ctcctcatct atgggtgcatc caccagggcc actggtatcc cagccagggtt cagtggcagt	660
gggtctggga cagagttcac tctcaccatc agcagcctgc agtctgaaga ttttgagtt	720
tattactgtc agcagtagcg cgcctaccct acttttggcg gagggaccaa gggtgagatc	780
aaacgggccc ctgcccttga taatgaaaag tcaaacggaa caatcattca cgtgaagggc	840
aagcacctct gtccgtcacc cttgttcctt ggtccatcca agccattctg ggtgttggtc	900
gtagtgggtg gagtccctgc ttgttactct ctgctcgtca ccgtggcttt tataatcttc	960
tgggttagat ccaaaagaag cgcctgctc catagcgatt acatgaatat gactccacgc	1020
cgccctggcc ccacaaggaa acactaccag ctttacgcac cacctagaga tttcgctgcc	1080
tatcgagca gggatgaagt ttccagatct gcagatgcac cagcgtatca gcagggccag	1140
aaccaactgt ataacgagct caacctggga cgcagggag agtatgacgt tttggacaag	1200
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt	1260
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa	1320
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg	1380
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa	1428

<210> 142

<211> 475

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> AJ-21508CARHxL

<400> 142

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
35 40 45

Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln
50 55 60

Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Gly Gly Gly Ser Thr Ser
65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser
85 90 95

Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Arg Glu Ser Trp Pro Met Asp Val Trp Gly
115 120 125

Gln Gly Thr Thr Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly
130 135 140

Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val Met Thr
145 150 155 160

Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu
165 170 175

Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln
180 185 190

Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr
195 200 205

Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr

210

215

220

Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val
 225 230 235 240

Tyr Tyr Cys Gln Gln Tyr Ala Ala Tyr Pro Thr Phe Gly Gly Gly Thr
 245 250 255

Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn
 260 265 270

Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu
 275 280 285

Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly
 290 295 300

Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe
 305 310 315 320

Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn
 325 330 335

Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr
 340 345 350

Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser
 355 360 365

Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr
 370 375 380

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
 385 390 395 400

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
 405 410 415

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
 420 425 430

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
435 440 445

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
450 455 460

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 143

<211> 1428

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> AJ-21508CARDNALxH

<400> 143

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccggaaatag tgatgacgca gtctccagcc accctgtctg tgtctccagg ggaaagagcc	120
accctctcct gcagggccag tcagagtgtt agcagcaact tagcctggta ccagcagaaa	180
cctggccagg ctcccaggct cctcatctat ggtgcatcca ccagggccac tggatatcca	240
gccagggttca gtggcagtggt gtctgggaca gagttcactc tcaccatcag cagcctgcag	300
tctgaagatt ttgcagttta ttactgtcag cagtacgccg cctaccctac ttttggcgga	360
gggaccaagg ttgagatcaa acgggggtct acatccggct ccgggaagcc cggaagtggc	420
gaaggtagta caaaggggca ggtgcagctg gtgcagtctg gggctgaggt gaagaagcct	480
ggggcctcag tgaaggtttc ctgcaaggca tctggataca ccttcaccag ctactatatg	540
cactgggtgc gacaggcccc tggacaaggg cttgagtgga tgggaataat caaccctggt	600
ggtggtagca caagctacgc acagaagttc cagggcagag tcaccatgac cagggaacacg	660
tccacgagca cagtctacat ggagctgagc agcctgagat ctgaggacac ggcggtgtac	720
tactgcgcca gagagagttg gccaatggac gtatggggcc agggaacaac tgtcaccgtc	780
tcctcagccg ctgcccttga taatgaaaag tcaaacggaa caatcattca cgtgaagggc	840

aagcacctct gtccgtcacc cttgttcctt ggtccatcca agccattctg ggtgttggtc 900
tagtggggtg gtagtctcgc ttgttactct ctgctcgtca ccgtggcttt tataatcttc 960
tgggttagat ccaaaagaag ccgcctgctc catagcgatt acatgaatat gactccacgc 1020
cgccctggcc ccacaaggaa acactaccag ccttacgcac cacctagaga tttcgctgcc 1080
tatcggagca gggatgaagt ttccagatct gcagatgcac cagcgtatca gcagggccag 1140
aaccaactgt ataacgagct caacctggga cgcagggaag agtatgacgt tttggacaag 1200
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt 1260
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa 1320
ggagagcggg gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg 1380
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa 1428

<210> 144

<211> 475

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> AJ-21508CARLxH

<400> 144

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30

Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45

Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60

Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
85 90 95

Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110

Ala Ala Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
115 120 125

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
130 135 140

Lys Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
145 150 155 160

Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
165 170 175

Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
180 185 190

Trp Met Gly Ile Ile Asn Pro Gly Gly Gly Ser Thr Ser Tyr Ala Gln
195 200 205

Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr
210 215 220

Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
225 230 235 240

Tyr Cys Ala Arg Glu Ser Trp Pro Met Asp Val Trp Gly Gln Gly Thr
245 250 255

Thr Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn
260 265 270

Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu
275 280 285

Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly
290 295 300

Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe
305 310 315 320

Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn
325 330 335

Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr
340 345 350

Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser
355 360 365

Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr
370 375 380

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
385 390 395 400

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
405 410 415

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
420 425 430

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
435 440 445

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
450 455 460

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 145

<211> 1449

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> NM-21517CARDNAHxL

<400> 145

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcagctgc agctgcagga gtcggggcca ggactgggtga agccttcgga gaccctgtcc	120
ctcacctgca ctgtctctgg tggctccatc agcagtagta gttactactg gggctggatc	180
cgccagcccc cagggaaggg gctggagtgg attgggagta tctcctatag tgggagcacc	240
tactacaacc cgtccctcaa gagtcgagtc accatatccg tagacacgtc caagaaccag	300
ttctccctga agctgagttc tgtgaccgcc gcagacacgg cgggtgtacta ctgcgccaga	360
ggcaggggat atgcaaccag cttagccttc gatatctggg gtcagggtac aatggtcacc	420
gtctcctcag ggtctacatc cggctccggg aagcccggaa gtggcgaagg tagtaciaag	480
ggggaaattg tgttgacaca gtctccagcc accctgtctt tgtctccagg ggaaagagcc	540
accctctcct gcagggccag tcagagtgtt agcagctact tagcctggta ccaacagaaa	600
cctggccagg ctcccaggct cctcatctat gatgcatcca acagggccac tggcatccca	660
gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctagag	720
cctgaagatt ttgcagttta ttactgtcag cagagacacg tctggcctcc tacttttggc	780
ggagggacca aggttagat caaacgggcc gctgcccttg ataataaaaa gtcaaacgga	840
acaatcattc acgtgaaggg caagcacctc tgtccgtcac cttgttccc tgggtccatcc	900
aagccattct ggggtgttggc cgtagtgggt ggagtcctcg cttgttactc tctgctcgtc	960
accgtggctt ttataatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat	1020
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca	1080
ccacctagag atttcgctgc ctatcgagc aggggtgaagt tttccagatc tgcagatgca	1140
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcaggga	1200
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga	1260
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc	1320
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac	1380
cagggactca gactgctac gaaggatact tatgacgctc tccacatgca agccctgcca	1440
cctaggtaa	1449

<210> 146
<211> 482
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>
<223> NM-21517CARHxL

<400> 146
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45

Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro
50 55 60

Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr
65 70 75 80

Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr
85 90 95

Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp
100 105 110

Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Tyr Ala Thr Ser Leu
115 120 125

Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly
130 135 140

Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
145 150 155 160

Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro
165 170 175

Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser
180 185 190

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
195 200 205

Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser
210 215 220

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
225 230 235 240

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg His Val Trp Pro
245 250 255

Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
260 265 270

Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
275 280 285

His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
290 295 300

Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
305 310 315 320

Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
325 330 335

Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
340 345 350

Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
355 360 365

Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln

370

375

380

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
385 390 395 400

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
405 410 415

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
420 425 430

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
435 440 445

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
450 455 460

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
465 470 475 480

Pro Arg

<210> 147

<211> 1449

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> NM-21517CARDNALxH

<400> 147

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60

ccggaaattg tgttgacaca gtctccagcc accctgtctt tgtctccagg ggaaagagcc 120

accctctcct gcagggccag tcagagtgtt agcagctact tagcctggta ccaacagaaa 180

cctggccagg ctcccaggct cctcatctat gatgcatcca acagggccac tggcatccca 240

gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctagag 300

cctgaagatt ttgcagttta ttactgtcag cagagacacg tctggcctcc tacttttggc	360
ggagggacca aggttagat caaacggggg tctacatccg gctccgggaa gcccggaagt	420
ggcgaaggta gtacaaaggg gcagctgcag ctgcaggagt cgggcccagg actggtgaag	480
ccttcggaga ccctgtccct cacctgcact gtctctgggtg gctccatcag cagtagtagt	540
tactactggg gctggatccg ccagccccc ggggaaggggc tggagtggat tgggagtatc	600
tcctatagtg ggagcaccta ctacaacccg tccctcaaga gtcgagtcac catatccgta	660
gacacgtcca agaaccagtt ctccctgaag ctgagttctg tgaccgccgc agacacggcg	720
gtgtactact gcgccagagg caggggatat gcaaccagct tagccttcga tatctgggggt	780
caggggtacaa tggtcaccgt ctctcagcc gctgcccttg ataataaaaa gtcaaacgga	840
acaatcattc acgtgaaggg caagcacctc tgtccgtcac cttgttccc tgggtccatcc	900
aagccattct ggggtgttgggt cgtagtgggt ggagtcctcg cttgttactc tctgctcgtc	960
accgtggctt ttataatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat	1020
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca	1080
ccacctagag atttcgctgc ctatcggagc aggggtgaagt tttccagatc tgcagatgca	1140
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa	1200
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga	1260
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc	1320
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac	1380
cagggactca gactgctac gaaggatact tatgacgctc tccacatgca agccctgcca	1440
cctaggtaa	1449

<210> 148

<211> 482

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> NM-21517CARLxH

<400> 148

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45

Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60

Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95

Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg
100 105 110

His Val Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125

Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140

Thr Lys Gly Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys
145 150 155 160

Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile
165 170 175

Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys
180 185 190

Gly Leu Glu Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr
195 200 205

Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
210 215 220

Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
225 230 235 240

Val Tyr Tyr Cys Ala Arg Gly Arg Gly Tyr Ala Thr Ser Leu Ala Phe
245 250 255

Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ala Ala
260 265 270

Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
275 280 285

His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
290 295 300

Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
305 310 315 320

Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
325 330 335

Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
340 345 350

Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
355 360 365

Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
370 375 380

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
385 390 395 400

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
405 410 415

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
420 425 430

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
435 440 445

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
450 455 460

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
465 470 475 480

Pro Arg

<210> 149
<211> 1440
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> TS-21522CARDNAHxL

<400> 149
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaggtgc agctggtgga gtctggggga ggcttggtac agcctggggg gtccctgaga 120
ctctcctgtg cagcctctgg attcaccttc agtagctata gcatgaactg ggtccgccag 180
gctccaggga aggggctgga gtgggtttca accattagta gtagtagtag taccatatac 240
tacgcagact ctgtgaaggg ccgattcacc atctccagag acaatgcaa gaactcactg 300
tatctgcaaa tgaacagcct gagagctgag gacacggcgg tgtactactg cgccagaggt 360
tctcaggagc acctgatttt cgattattgg ggacagggtta cattgggtcac cgtctcctca 420
gggtctacat ccggctccgg gaagcccgga agtggcgaag gtagtacaaa gggggaaatt 480
gtgttgacac agtctccagc caccctgtct ttgtctccag gggaaagagc caccctctcc 540
tgcagggccca gtcagagtgt tagcaggtac ttagcctggg accaacagaa acctggccag 600
gctcccaggc tcctcatcta tgatgcatcc aacagggccca ctggcatccc agccagggttc 660
agtggcagtg ggtctgggac agacttcact ctcacatca gcagcctaga gcctgaagat 720
tttgagttt attactgtca gcagagattc tactaccctt ggacttttgg cggagggacc 780

aaggttgaga tcaaacgggc cgctgccctt gataatgaaa agtcaaacgg aacaatcatt	840
cacgtgaagg gcaagcacct ctgtccgtca cccttgttcc ctggtccatc caagccattc	900
tgggtgttgg tcgtagtggg tggagtcctc gcttgttact ctctgctcgt caccgtggct	960
tttataatct tctgggtag atccaaaaga agccgcctgc tccatagcga ttacatgaat	1020
atgactccac gccgccctgg cccacaagg aaacactacc agccttacgc accacctaga	1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat	1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac	1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac	1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa	1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc	1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa	1440

<210> 150

<211> 479

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> TS-21522CARHxL

<400> 150

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5				10					15		

His	Ala	Ala	Arg	Pro	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu
			20					25					30		

Val	Gln	Pro	Gly	Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe
		35					40					45			

Thr	Phe	Ser	Ser	Tyr	Ser	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys
	50					55					60				

Gly	Leu	Glu	Trp	Val	Ser	Thr	Ile	Ser	Ser	Ser	Ser	Ser	Thr	Ile	Tyr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

65					70					75					80
Tyr	Ala	Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala
				85					90					95	
Lys	Asn	Ser	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr
			100					105					110		
Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Gly	Ser	Gln	Glu	His	Leu	Ile	Phe	Asp
		115					120					125			
Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Ser	Thr	Ser
		130				135					140				
Gly	Ser	Gly	Lys	Pro	Gly	Ser	Gly	Glu	Gly	Ser	Thr	Lys	Gly	Glu	Ile
145					150					155					160
Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly	Glu	Arg
				165					170					175	
Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser	Val	Ser	Arg	Tyr	Leu	Ala
			180					185					190		
Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile	Tyr	Asp
		195					200					205			
Ala	Ser	Asn	Arg	Ala	Thr	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly	Ser	Gly
	210					215					220				
Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro	Glu	Asp
225					230					235					240
Phe	Ala	Val	Tyr	Tyr	Cys	Gln	Gln	Arg	Phe	Tyr	Tyr	Pro	Trp	Thr	Phe
				245					250					255	
Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Ala	Ala	Ala	Leu	Asp	Asn
			260					265					270		
Glu	Lys	Ser	Asn	Gly	Thr	Ile	Ile	His	Val	Lys	Gly	Lys	His	Leu	Cys
		275					280					285			

Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300

Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320

Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335

Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350

Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365

Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380

Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400

Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415

Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430

Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445

Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460

Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 151

<211> 1440

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> TS-21522CARDNALxH

<400> 151

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccggaaattg tgttgacaca gtctccagcc accctgtctt tgtctccagg ggaaagagcc	120
accctctcct gcagggccag tcagagtgtt agcaggtact tagcctggta ccaacagaaa	180
cctggccagg ctcccaggct cctcatctat gatgcatcca acagggccac tggcatccca	240
gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctagag	300
cctgaagatt ttgcagttta ttactgtcag cagagattct actacccttg gacttttggc	360
ggagggacca aggttagat caaacggggg tctacatccg gctccgggaa gcccggaagt	420
ggcgaaggta gtacaaaggg ggaggtgcag ctggtggagt ctgggggagg cttggtacag	480
cctgggggggt ccctgagact ctctgtgca gcctctggat tcaccttcag tagctatagc	540
atgaactggg tccgccaggc tccagggaag gggctggagt gggtttcaac cattagtagt	600
agtagtagta ccatatacta cgcagactct gtgaagggcc gattcaccat ctccagagac	660
aatgccaaga actcactgta tctgcaaatg aacagcctga gagctgagga cacggcggtg	720
tactactgcg ccagaggttc tcaggagcac ctgattttcg attattgggg acagggtaca	780
ttggtcaccg tctcctcagc cgctgccctt gataatgaaa agtcaaacgg aacaatcatt	840
cacgtgaagg gcaagcacct ctgtccgtca cccttgttcc ctggtccatc caagccattc	900
tgggtgttgg tcgtagtggg tggagtcctc gcttgttact ctctgctcgt caccgtggct	960
tttataatct tctgggttag atccaaaaga agccgcctgc tccatagcga ttacatgaat	1020
atgactccac gccgccctgg cccacaagg aaacactacc agccttacgc accacctaga	1080
gatttcgctg cctatcgag caggggtgaag ttttccagat ctgcagatgc accagcgtat	1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac	1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac	1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa	1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc	1380

agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa 1440

<210> 152

<211> 479

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> TS-21522CARLxH

<400> 152

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
20 25 30

Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45

Ser Val Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60

Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95

Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg
100 105 110

Phe Tyr Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125

Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140

Thr Lys Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
145 150 155 160

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
165 170 175

Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
180 185 190

Glu Trp Val Ser Thr Ile Ser Ser Ser Ser Thr Ile Tyr Tyr Ala
195 200 205

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
210 215 220

Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
225 230 235 240

Tyr Tyr Cys Ala Arg Gly Ser Gln Glu His Leu Ile Phe Asp Tyr Trp
245 250 255

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn
260 265 270

Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285

Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300

Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320

Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335

Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350

Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365

Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380

Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400

Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415

Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430

Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445

Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460

Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 153
<211> 1449
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> RY-21527CARDNAHxL

<400> 153
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgga gtctggggga ggcgtggtcc agcctgggag gtccctgaga 120
ctctcctgtg cagcgtctgg attcaccttc agtagctatg gcatgcactg ggtccgccag 180
gctccaggca aggggctgga gtgggtggca gttatatcgt atgatggaag taataaatac 240
tatgcagact ccgtgaaggg ccgattcacc atctccagag acaattccaa gaacacgctg 300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgccagaact 360
gacttctgga gcggatcccc tccaggctta gattactggg gacagggtac attggtcacc 420

gtctcctcag ggtctacatc cggctccggg aagcccggaa gtggcgaagg tagtacaaag	480
ggggacatcc agttgaccca gtctccatct tccgtgtctg catctgtagg agacagagtc	540
accatcactt gtcgggcgag tcagggtatt agcagctggg tagcctggta tcagcagaaa	600
ccagggaag cccctaagct cctgatctat ggtgcatcca gtttgcaaag tgggggtcca	660
tcaaggttca gcggcagtgg atctgggaca gatttcactc tcaccatcag cagcctgcag	720
cctgaagatt ttgcaactta ttactgtcag cagatataca cttcccttt cacttttggc	780
ggagggacca aggttgagat caaacgggcc gctgcccttg ataataaaaa gtcaaacgga	840
acaatcattc acgtgaagg caagcacctc tgtccgtcac cttgttccc tgggtccatcc	900
aagccattct ggggtgttggg cgtagtgggt ggagtcctcg cttgttactc tctgctcgtc	960
accgtggctt ttataatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat	1020
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca	1080
ccacctagag atttcgctgc ctatcggagc aggggtgaagt tttccagatc tgcagatgca	1140
ccagcgtatc agcagggccca gaaccaactg tataacgagc tcaacctggg acgcagggaa	1200
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga	1260
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc	1320
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac	1380
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca	1440
cctaggtaa	1449

<210> 154
 <211> 482
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 polypeptide

<220>
 <223> RY-21527CARHxL

<400> 154
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45

Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60

Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr
65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Arg Thr Asp Phe Trp Ser Gly Ser Pro Pro
115 120 125

Gly Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140

Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
145 150 155 160

Gly Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val
165 170 175

Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
180 185 190

Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
195 200 205

Ile Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
210 215 220

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln

225					230					235					240
Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Ile	Tyr	Thr	Phe	Pro
				245					250					255	
Phe	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Ala	Ala	Ala
			260					265					270		
Leu	Asp	Asn	Glu	Lys	Ser	Asn	Gly	Thr	Ile	Ile	His	Val	Lys	Gly	Lys
		275					280					285			
His	Leu	Cys	Pro	Ser	Pro	Leu	Phe	Pro	Gly	Pro	Ser	Lys	Pro	Phe	Trp
	290					295					300				
Val	Leu	Val	Val	Val	Gly	Gly	Val	Leu	Ala	Cys	Tyr	Ser	Leu	Leu	Val
305					310					315					320
Thr	Val	Ala	Phe	Ile	Ile	Phe	Trp	Val	Arg	Ser	Lys	Arg	Ser	Arg	Leu
				325					330					335	
Leu	His	Ser	Asp	Tyr	Met	Asn	Met	Thr	Pro	Arg	Arg	Pro	Gly	Pro	Thr
			340					345					350		
Arg	Lys	His	Tyr	Gln	Pro	Tyr	Ala	Pro	Pro	Arg	Asp	Phe	Ala	Ala	Tyr
		355					360					365			
Arg	Ser	Arg	Val	Lys	Phe	Ser	Arg	Ser	Ala	Asp	Ala	Pro	Ala	Tyr	Gln
	370					375					380				
Gln	Gly	Gln	Asn	Gln	Leu	Tyr	Asn	Glu	Leu	Asn	Leu	Gly	Arg	Arg	Glu
385					390					395					400
Glu	Tyr	Asp	Val	Leu	Asp	Lys	Arg	Arg	Gly	Arg	Asp	Pro	Glu	Met	Gly
				405					410					415	
Gly	Lys	Pro	Arg	Arg	Lys	Asn	Pro	Gln	Glu	Gly	Leu	Tyr	Asn	Glu	Leu
			420					425					430		
Gln	Lys	Asp	Lys	Met	Ala	Glu	Ala	Tyr	Ser	Glu	Ile	Gly	Met	Lys	Gly
		435					440					445			

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
450 455 460

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
465 470 475 480

Pro Arg

<210> 155
<211> 1449
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> RY-21527CARDNALxH

<400> 155
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggacatcc agttgaccca gtctccatct tccgtgtctg catctgtagg agacagagtc 120
accatcactt gtcgggcgag tcagggtatt agcagctggg tagcctggta tcagcagaaa 180
ccagggaaag cccctaagct cctgatctat ggtgcatcca gtttgcaaag tgggggtccca 240
tcaaggttca gcggcagtgg atctgggaca gatttcactc tcaccatcag cagcctgcag 300
cctgaagatt ttgcaactta ttactgtcag cagatataca ccttcccttt cacttttggc 360
ggagggacca aggtttagat caaacggggg tctacatccg gctccgggaa gcccggaagt 420
ggcgaaggta gtacaaaggg gcaggtgcag ctggtggagt ctgggggagg cgtggtccag 480
cctgggaggt ccctgagact ctctgtgca gcgtctggat tcaccttcag tagctatggc 540
atgcactggg tccgccaggc tccaggcaag gggctggagt ggggtggcagt tatatcgtat 600
gatggaagta ataaatacta tgcagactcc gtgaagggcc gattcaccat ctccagagac 660
aattccaaga acacgctgta tctgcaaattg aacagcctga gagccgagga cacggcggtg 720
tactactgcg ccagaactga cttctggagc ggatcccctc caggcttaga ttactgggga 780
cagggtagat tggtcaccgt ctctcagcc gctgcccttg ataataaaaa gtcaaacgga 840

acaatcattc acgtgaaggg caagcacctc tgtccgtcac cttgtttccc tgggtccatcc	900
aagccattct ggggtgttggc cgtagtgggt ggagtcctcg cttgttactc tctgctcgtc	960
accgtggcctt ttataatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat	1020
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca	1080
ccacctagag atttcgctgc ctatcggagc aggggtgaagt tttccagatc tgcagatgca	1140
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa	1200
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga	1260
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc	1320
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac	1380
cagggactca gcaactgtac gaaggatact tatgacgctc tccacatgca agccctgcca	1440
cctaggtaa	1449

<210> 156

<211> 482

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> RY-21527CARLxH

<400> 156

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5				10					15		

His	Ala	Ala	Arg	Pro	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Val
			20					25					30		

Ser	Ala	Ser	Val	Gly	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln
		35					40				45				

Gly	Ile	Ser	Ser	Trp	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala
	50					55					60				

Pro	Lys	Leu	Leu	Ile	Tyr	Gly	Ala	Ser	Ser	Leu	Gln	Ser	Gly	Val	Pro
65					70					75				80	

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile
100 105 110

Tyr Thr Phe Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125

Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140

Thr Lys Gly Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
145 150 155 160

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
165 170 175

Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
180 185 190

Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
195 200 205

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
210 215 220

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
225 230 235 240

Tyr Tyr Cys Ala Arg Thr Asp Phe Trp Ser Gly Ser Pro Pro Gly Leu
245 250 255

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala
260 265 270

Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
275 280 285

His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
290 295 300

Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
305 310 315 320

Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
325 330 335

Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
340 345 350

Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
355 360 365

Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
370 375 380

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
385 390 395 400

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
405 410 415

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
420 425 430

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
435 440 445

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
450 455 460

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
465 470 475 480

Pro Arg

<210> 157

<211> 1479

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> PP-21528CARDNAHxL

<400> 157

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcaggtgc agctggtgca gtctggggct gaggtgaaga agcctgggtc ctcggtgaag	120
gtctcctgca aggcttctgg aggcaccttc agcagctatg ctatcagctg ggtgcgacag	180
gcccctggac aagggttga gtggatggga gggatcatcc ctatctttgg tacagcaaac	240
tacgcacaga agttccaggg cagagtcacg attaccgcgg acgaatccac gagcacagcc	300
tacatggagc tgagcagcct gagatctgag gacacggcgg tgtactactg cgccagaact	360
cctgaatact cctccagcat atggcactat tactacggca tggacgtatg gggccaggga	420
acaactgtca ccgtctcctc agggctctaca tccggctccg ggaagcccgg aagtggcgaa	480
ggtagtacia agggggacat cgtgatgacc cagtctccag actccctggc tgtgtctctg	540
ggcgagaggg ccaccatcaa ctgcaagtcc agccagagtg ttttatacag ctccaacaat	600
aagaactact tagcttggtg ccagcagaaa ccaggacagc ctcctaagct gctcatttac	660
tgggcatcta cccgggaatc cgggggtccct gaccgattca gtggcagcgg gtctgggaca	720
gatttcactc tcaccatcag cagcctgcag gctgaagatg tggcagttta ttactgtcag	780
cagttcgccc acactccttt cacttttggc ggagggacca aggttgagat caaacgggcc	840
gctgcccttg ataataaaaa gtcaaacgga acaatcattc acgtgaaggg caagcacctc	900
tgtccgtcac cttgtttccc tgggtccatcc aagccattct gggtgttggt cgtagtgggt	960
ggagtcctcg cttgttactc tctgctcgtc accgtggctt ttataatctt ctgggttaga	1020
tccaaaagaa gccgcctgct ccatagcgat tacatgaata tgactccacg ccgccctggc	1080
cccacaagga aacactacca gccttacgca ccacctagag atttcgctgc ctatcggagc	1140
agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg	1200
tataacgagc tcaacctggg acgcagggaa gagtatgacg ttttggacaa gcgcagagga	1260
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat	1320

gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg 1380
 agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact 1440
 tatgacgctc tccacatgca agccctgccca cctaggtaa 1479

<210> 158
 <211> 492
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 polypeptide

<220>
 <223> PP-21528CARHxL

<400> 158
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
 20 25 30

Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly
 35 40 45

Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln
 50 55 60

Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn
 65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser
 85 90 95

Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
 100 105 110

Ala Val Tyr Tyr Cys Ala Arg Thr Pro Glu Tyr Ser Ser Ser Ile Trp
 115 120 125

His Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr

130

135

140

Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu
145 150 155 160

Gly Ser Thr Lys Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu
165 170 175

Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln
180 185 190

Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln
195 200 205

Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr
210 215 220

Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
225 230 235 240

Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val
245 250 255

Tyr Tyr Cys Gln Gln Phe Ala His Thr Pro Phe Thr Phe Gly Gly Gly
260 265 270

Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser
275 280 285

Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
290 295 300

Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
305 310 315 320

Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
325 330 335

Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
340 345 350

Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
355 360 365

Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe
370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 159
<211> 1479
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> PP-21528CARDNALxH

<400> 159
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggacatcg tgatgaccga gtctccagac tccttggtg tgtctctggg cgagagggcc 120

accatcaact gcaagtccag ccagagtgtt ttatacagct ccaacaataa gaactactta	180
gcttgggtacc agcagaaaacc aggacagcct cctaagctgc tcattttactg ggcatcttacc	240
cgggaatccg ggggtccctga ccgattcagt ggcagcgggt ctgggacaga tttcactctc	300
accatcagca gcctgcaggc tgaagatgtg gcagttttatt actgtcagca gttcgcccac	360
actcctttca cttttggcgg agggaccaag gttgagatca aacgggggtc tacatccggc	420
tccgggaagc ccggaagtgg cgaaggtagt acaaaggggc aggtgcagct ggtgcagtct	480
ggggctgagg tgaagaagcc tgggtcctcg gtgaaggtct cctgcaaggc ttctggaggc	540
accttcagca gctatgctat cagctgggtg cgacaggccc ctggacaagg gcttgagtgg	600
atgggaggga tcatccctat ctttgggtaca gcaaactacg cacagaagtt ccagggcaga	660
gtcacgatta ccgcggacga atccacgagc acagcctaca tggagctgag cagcctgaga	720
tctgaggaca cggcgggtgta ctactgcgcc agaactcctg aatactcctc cagcatatgg	780
cactattact acggcatgga cgtatggggc cagggaacaa ctgtcaccgt ctcctcagcc	840
gctgcccttg ataatgaaaa gtcaaacgga acaatcattc acgtgaaggg caagcacctc	900
tgtccgtcac ctttgttccc tgggtccatcc aagccattct ggggtgttggc cgtagtgggt	960
ggagtcctcg cttgttactc tctgctcgtc accgtggctt ttataatctt ctgggttaga	1020
tccaaaagaa gccgcctgct ccatagcgat tacatgaata tgactccacg ccgccctggc	1080
cccacaagga aacactacca gccttacgca ccacctagag atttcgctgc ctatcggagc	1140
agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggccga gaaccaactg	1200
tataacgagc tcaacctggg acgcaggga gagtatgacg ttttggacaa gcgcagagga	1260
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat	1320
gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg	1380
agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact	1440
tatgacgctc tccacatgca agccctgcc cctaggtaa	1479

<210> 160

<211> 492

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

polypeptide

<220>

<223> PP-21528CARLxH

<400> 160

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu
20 25 30

Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln
35 40 45

Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln
50 55 60

Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr
65 70 75 80

Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
85 90 95

Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val
100 105 110

Tyr Tyr Cys Gln Gln Phe Ala His Thr Pro Phe Thr Phe Gly Gly Gly
115 120 125

Thr Lys Val Glu Ile Lys Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro
130 135 140

Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Gln Leu Val Gln Ser
145 150 155 160

Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys
165 170 175

Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln
180 185 190

Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe
195 200 205

Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr
210 215 220

Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg
225 230 235 240

Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Pro Glu Tyr Ser
245 250 255

Ser Ser Ile Trp His Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly
260 265 270

Thr Thr Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser
275 280 285

Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
290 295 300

Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
305 310 315 320

Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
325 330 335

Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
340 345 350

Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
355 360 365

Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe
370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 161
<211> 1452
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> RD-21530CARDNAHxL

<400> 161
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgga gtctggggga ggcgtggtcc agcctgggag gtccctgaga 120
ctctcctgtg cagcgtctgg attcaccttc agtagctatg gcatgcactg ggtccgccag 180
gtccaggca aggggctgga gtgggtggca gttatatcgt atgatggaag taataaatac 240
tatgcagact ccgtgaaggg ccgattcacc atctccagag acaattccaa gaacacgctg 300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgtcaagggg 360
ccgttgcagg agccgccata cgattatgga atggacgtat ggggccaggg aacaactgtc 420
accgtctcct cagggtctac atccggctcc gggaagcccg gaagtggcga aggtagtaca 480
aagggggaaa tagtgatgac gcagtctcca gccaccctgt ctgtgtctcc aggggaaaga 540
gccaccctct cctgcagggc cagtcagagt gttagcagca acttagcctg gtaccagcag 600

aaacctggcc aggctcccag gtcctcatc tatagcgcac ccaccagggc cactggtatc 660
ccagccaggt tcagtggcag tgggtctggg acagagttca ctctcaccat cagcagcctg 720
cagtctgaag attttgcagt ttattactgt cagcagcacc acgtctggcc tctcactttt 780
ggcggaggga ccaaggttga gatcaaacgg gccgctgccc ttgataatga aaagtcaaac 840
ggaacaatca ttcacgtgaa gggcaagcac ctctgtccgt cacccttggt ccctggtcca 900
tccaagccat tctgggtggt ggtcgtagt ggtggagtcc tcgcttggtta ctctctgctc 960
gtcaccgtgg cttttataat cttctgggtt agatccaaaa gaagccgcct gtcctatagc 1020
gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggctctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaatagggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452

<210> 162
<211> 483
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<220>
<223> RD-21530CARHxL

<400> 162
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe

35

40

45

Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
 50 55 60

Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr
 65 70 75 80

Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 85 90 95

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 100 105 110

Ala Val Tyr Tyr Cys Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp
 115 120 125

Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 130 135 140

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
 145 150 155 160

Lys Gly Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser
 165 170 175

Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser
 180 185 190

Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
 195 200 205

Leu Ile Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe
 210 215 220

Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu
 225 230 235 240

Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His His Val Trp
 245 250 255

Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala
260 265 270

Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285

Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300

Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320

Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335

Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350

Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365

Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu

465

470

475

480

Pro Pro Arg

<210> 163

<211> 1452

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> RD-21530CARDNALxH

<400> 163

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccggaaatag tgatgacgca gtctccagcc accctgtctg tgtctccagg ggaaagagcc	120
accctctcct gcagggccag tcagagtgtt agcagcaact tagcctggta ccagcagaaa	180
cctggccagg ctcccaggct cctcatctat agcgcattcca ccagggccac tggatatcca	240
gccaggttca gtggcagtgg gtctgggaca gagttcactc tcaccatcag cagcctgcag	300
tctgaagatt ttgcagttta ttactgtcag cagcaccacg tctggcctct cacttttggc	360
ggagggacca aggttgagat caaacggggg tctacatccg gctccgggaa gcccggaagt	420
ggcgaaggta gtacaaaggg gcaggtgcag ctgggtggagt ctgggggagg cgtgggtccag	480
cctgggaggt ccctgagact ctctgtgca gcgtctggat tcaccttcag tagctatggc	540
atgcactggg tccgccaggc tccaggcaag gggctggagt ggggtggcagt tatatcgtat	600
gatggaagta ataaatacta tgcagactcc gtgaagggcc gattcaccat ctccagagac	660
aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga cacggcggtg	720
tactactgcg tcaaggggcc gttgcaggag ccgccatacg attatggaat ggacgtatgg	780
ggccagggaa caactgtcac cgtctcctca gccgctgccc ttgataatga aaagtcaaac	840
ggaacaatca ttcacgtgaa gggcaagcac ctctgtccgt cacccttggt ccctgggtcca	900
tccaagccat tctgggtggt ggtcgtagtg ggtggagtcc tcgcttggtta ctctctgctc	960
gtcaccgtgg cttttataat cttctggggt agatccaaaa gaagccgcct gtcctatagc	1020

gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcaggggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgtttttgga caagcgcaga ggacggggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggctctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaatagggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452

<210> 164
<211> 483
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<220>
<223> RD-21530CARLxH

<400> 164
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30

Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45

Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60

Pro Arg Leu Leu Ile Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
85 90 95

Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His
100 105 110

His Val Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125

Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140

Thr Lys Gly Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
145 150 155 160

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
165 170 175

Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
180 185 190

Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
195 200 205

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
210 215 220

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
225 230 235 240

Tyr Tyr Cys Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly
245 250 255

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ala
260 265 270

Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285

Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300

Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320

Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335

Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350

Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365

Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
465 470 475 480

Pro Pro Arg

<210> 165

<211> 1440

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 165

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcaggtcc aactgcaaga aagcggaccc ggactggtga agccttctga gacacttagt	120
ctgacgtgca cggtcagtgg cggctccatc tcctcctatt attggtcatg gatacgacaa	180
cccccaggta agggcctgga atggattggc tatacttact attcaggaag cacgaactac	240
aatcccagcc tgaagtcccg agtgacaatt tcagtagata ccagtaaaaa ccagttcagt	300
cttaaaactgt caagcgtgac agctgccgac accgctgtgt attactgcgt ctactggtg	360
tattgtggag gggattgtta tagcgggttc gattattggg gacagggaac cctggtgact	420
gtatcttccg gcggcggcgg ctgagggggt ggcggtagtgc gcggtggggg ttccgatatt	480
caactgacac aatccccag ctactcagc gccagcgtgg gggacagggt tagctttacc	540
tgtcaagcct ctgagatat aaataacttt ctgaactggt atcaacagaa gcctgggaag	600
gcgcccaaac tcctgatcta tgatgcgtcc aacctggaaa ctggcgtgcc ttcacgcttt	660
agcggctctg gcagtggtag agacttcact tttaccatct cttcacttca gccggaggac	720
atgccacat attactgtca acagtacgga aacttgcctt ttacttttgg aggcggcacc	780
aaagttgaaa tcaaaagggc cgctgccctg gataacgaaa agagcaatgg gactataata	840
catgttaaag gaaaacacct gtgtccatct cccctgttcc ctggaccgtc aaagccattt	900
tgggtgctcg tggttgtcgg tggcgttctc gcctgttata gcttgctggt gacagtagcc	960
ttcattatct tttgggtgag atccaaaaga agccgcctgc tccatagcga ttacatgaat	1020
atgactccac gccgccctgg cccacaagg aaacactacc agccttacgc accacctaga	1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat	1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac	1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac	1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa	1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc	1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa	1440

<210> 166
<211> 479
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<220>
<223> anti-CLL-1 CAR construct

<400> 166
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45

Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60

Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80

Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95

Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110

Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125

Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160

Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg

165

170

175

Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
 180 185 190

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
 195 200 205

Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
 210 215 220

Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
 225 230 235 240

Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
 245 250 255

Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn
 260 265 270

Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
 275 280 285

Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
 290 295 300

Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
 305 310 315 320

Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
 325 330 335

Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
 340 345 350

Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
 355 360 365

Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
 370 375 380

Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400

Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415

Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430

Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445

Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460

Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 167
<211> 1374
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 167
caggtccaac tgcaagaaag cggacccgga ctggtgaagc cttctgagac acttagtctg 60
acgtgcacgg tcagtggcgg ctccatctcc tcctattatt ggtcatggat acgacaaccc 120
ccaggtaagg gcctggaatg gattggctat atctactatt caggaagcac gaactacaat 180
cccagcctga agtcccgagt gacaatttca gtagatacca gtaaaaacca gttcagtctt 240
aaactgtcaa gcgtgacagc tgccgacacc gctgtgtatt actgcgtctc actggtgtat 300
tgtggagggg attgttatag cgggttcgat tattggggac agggaaccct ggtgactgta 360
tcttccggcg gcggcggctc agggggtggc ggtagtggcg gtgggggttc cgatattcaa 420
ctgacacaat ccccagctc actcagcgcc agcgtggggg acagggttag ctttacctgt 480

caagcctctc aggatataaa taactttctg aactggtatc aacagaagcc tgggaaggcg	540
cccaaactcc tgatctatga tgcgtccaac ctggaaactg gcgtgccttc acgctttagc	600
ggctctggca gtggtacaga cttcactttt accatctctt cacttcagcc ggaggacatc	660
gccacatatt actgtcaaca gtacggaaac ttgcccttta cttttggagg cggcaccaaa	720
gttgaaatca aaagggccgc tgccctggat aacgaaaaga gcaatgggac tataatacat	780
gttaaaggaa aacacctgtg tccatctccc ctgttccttg gaccgtcaaa gccattttgg	840
gtgctcgtgg ttgtcggtag cgttctcgcc tgttatagct tgctggtgac agtagccttc	900
attatctttt gggtgagatc caaaagaagc cgctgtctcc atagcgatta catgaatatg	960
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat	1020
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag	1080
cagggccaga accaactgta taacgagctc aacctgggac gcaggggaaga gtatgacgtt	1140
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc	1200
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata	1260
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc	1320
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc tagg	1374

<210> 168

<211> 458

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 168

Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Gly	Leu	Val	Lys	Pro	Ser	Glu
1				5					10					15	

Thr	Leu	Ser	Leu	Thr	Cys	Thr	Val	Ser	Gly	Gly	Ser	Ile	Ser	Ser	Tyr
			20					25					30		

Tyr	Trp	Ser	Trp	Ile	Arg	Gln	Pro	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Ile
		35					40					45			

Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95

Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160

Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190

Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205

Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220

Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240

Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
245 250 255

Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
260 265 270

Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
275 280 285

Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
290 295 300

Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
305 310 315 320

Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
325 330 335

Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
340 345 350

Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
355 360 365

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
370 375 380

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
385 390 395 400

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
405 410 415

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
420 425 430

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
435 440 445

Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455

<210> 169

<211> 1467

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 169

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcaggtgc agctgcagga atccggaccg gggctgggtga agcccagcga gactctgagt	120
ctcacgtgta cagtttctgg aggtagcatt agctcctact attggtcatt gataaggcag	180
ccccccggga agggattgga atggatcggc tatattttact acagtgggag caccaattac	240
aaccctcac tgaagtctag agttacaatc agcgttgaca cctcaaagaa tcagttcagt	300
ttgaaattgt ctagcgtcac agcagctgat acagccgtct attattgtgt ttctctggtc	360
tattgcggtg gggattgtta cagtggcttt gactattggg ggcagggtac tctggttaca	420
gtttcttccg gggggggagg ctctgggggc ggaggctcag gtgggtggagg cagcgacatc	480
cagttgacac agagcccagag ttccttgtcc gcctccgtcg gggatagagt gtcatttacc	540
tgtaggcct ctcaggatat taataacttt ctgaattggg atcagcaaaa gcccggaag	600
gcaccaagc tgttgattta cgacgccagt aacctggaga caggcgtgcc ctcccggttt	660
agtggtagcg gaagcggtac ggattttacc ttactatca gctctctcca acccgaagac	720
attgcaacct actattgtca acaatatgga aacctgcctt ttacatttgg cggcggcacc	780
aaggtggaga ttaagcgggc ggcagctatt gaggtgatgt atccaccgcc ttacctggat	840
aacgaaaaga gtaacggtac catcattcac gtgaaaggta aacacctgtg tccttctccc	900
ctcttccccg ggccatcaaa gcccttctgg gttcttgtgg tcgtgggagg cgtgcttgct	960
tggtattctc tgctcgttac cgtggcggtt atcatttttt gggtttagatc caaaagaagc	1020
cgctgctcc atagcgatta catgaatatg actccacgcc gccctggccc cacaaggaaa	1080
cactaccagc cttacgcacc acctagagat ttcgctgcct atcggagcag ggtgaagttt	1140
tccagatctg cagatgcacc agcgtatcag cagggccaga accaactgta taacgagctc	1200
aacctgggac gcagggaaga gtatgacgtt ttggacaagc gcagaggacg ggaccctgag	1260
atgggtggca aaccaagacg aaaaaacccc caggagggtc tctataatga gctgcagaag	1320

gataagatgg ctgaagccta ttctgaaata ggcatgaaag gagagcggag aaggggaaaa 1380
 gggcacgacg gtttgtacca gggactcagc actgctacga aggatactta tgacgctctc 1440
 cacatgcaag ccctgccacc taggtaa 1467

<210> 170
 <211> 488
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 170
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
 20 25 30

Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
 35 40 45

Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
 50 55 60

Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
 65 70 75 80

Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
 85 90 95

Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
 100 105 110

Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
 115 120 125

Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly

130

135

140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
 145 150 155 160

Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
 165 170 175

Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
 180 185 190

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
 195 200 205

Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
 210 215 220

Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
 225 230 235 240

Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
 245 250 255

Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val
 260 265 270

Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
 275 280 285

Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly
 290 295 300

Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala
 305 310 315 320

Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg
 325 330 335

Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro
 340 345 350

Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro
355 360 365

Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala
370 375 380

Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu
385 390 395 400

Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
405 410 415

Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu
420 425 430

Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
435 440 445

Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
450 455 460

Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
465 470 475 480

His Met Gln Ala Leu Pro Pro Arg
485

<210> 171
<211> 1401
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 171
caggtgcagc tgcaggaatc cggaccgggg ctggtgaagc ccagcgagac tctgagtctc 60
acgtgtacag tttctggagg tagcattagc tcctactatt ggcatggat aaggcagccc 120

cccggaagg gattggaatg gatcggctat atttactaca gtgggagcac caattacaac	180
ccctcactga agtctagagt tacaatcagc gttgacacct caaagaatca gttcagtttg	240
aaattgtcta gcgtcacagc agctgataca gccgtctatt attgtgtttc tctgggtctat	300
tgcggtgggg attgttacag tggctttgac tattgggggc aggggtactct ggttacagtt	360
tcttccgggg ggggaggctc tgggggcgga ggctcagggtg gtggaggcag cgacatccag	420
ttgacacaga gcccaggttc cttgtccgcc tccgtcgggg atagagtgtc atttacctgt	480
caggcctctc aggatattaa taactttctg aattgggtatc agcaaaagcc cggaaaggca	540
cccaagctgt tgatttacga cgccagtaac ctggagacag gcgtgccctc ccggtttagt	600
ggtagcgga gcggtacgga ttttaccttt actatcagct ctctccaacc cgaagacatt	660
gcaacctact attgtcaaca atatggaaac ctgcctttta catttggcgg cggcaccaag	720
gtggagatta agcgggcggc agctattgag gtgatgtatc caccgcctta cctggataac	780
gaaaagagta acggtaccat cattcacgtg aaaggtaaac acctgtgtcc ttctcccctc	840
ttccccgggc catcaaagcc cttctgggtt cttgtggtcg tgggaggcgt gcttgcttgt	900
tattctctgc tcgttaccgt ggcgtttatc attttttggg ttagatccaa aagaagccgc	960
ctgctcata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac	1020
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc	1080
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac	1140
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg	1200
ggtggcaaac caagacgaaa aaacccccag gagggctctt ataatgagct gcagaaggat	1260
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaagg	1320
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac	1380
atgcaagccc tgccacctag g	1401

<210> 172

<211> 467

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 172

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95

Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160

Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190

Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205

Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220

Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240

Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
245 250 255

Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
260 265 270

Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
275 280 285

Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
290 295 300

Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
305 310 315 320

Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
325 330 335

Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
340 345 350

Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
355 360 365

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
370 375 380

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
385 390 395 400

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
405 410 415

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
420 425 430

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
435 440 445

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
450 455 460

Pro Pro Arg
465

<210> 173
<211> 1548
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 173
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc aattgcaaga gtccggcccc ggactcgta aaccagtgga gacgcttagc 120
ctgacctgta ccgtctcagg gggcagcatc tcctcttatt actggagctg gatcaggcag 180
cctccaggaa aaggccttga atggattggg tacatctact actctggctc aacaaattat 240
aatccatccc tgaagtcccg cgtgactatc tctgtggaca ccagcaagaa tcagttttca 300
ctgaagttgt ctagtgttac gcgggccgac accgccgtat actactgtgt gtctcttgtg 360
tactgtggcg gcgactgcta ttccgggttc gactactggg gccaagggac tctggtaacc 420
gtgtcctcag gcggcggcgg gtcaggagga ggcggcagtg gaggtggcgg ctccgacatc 480
cagctgacac aatcaccatc ttccctttca gcttcagtcg gggacagagt gtccttcaca 540
tgccaggcca gccaggatat caataacttc ctgaactggg accaacagaa acccggaag 600
gtccaaagc tcctgatcta tgatgcttcc aacctggaga ccggcgtgcc ctccagggtc 660
agtggttcag gatcaggcac tgactttacg ttcaccatat ccagtcttca gcccgaagac 720
attgcaacct attactgcca acaatacggg aaccttcctt ttacattcgg aggcggcacc 780

aaggtggaaa tcaaaagggc tgcagcattg agcaactcaa taatgtatTT tagtcacttt	840
gtaccagtgt tcttgccggc taagcctact accacacccg ctccacggcc acctacccca	900
gctcctacca tcgcttcaca gcctctgtcc ctgcgcccag aggcttgccg accggccgca	960
gggggcgctg ttcataccag aggactggat ttgcctgctg atatctatat ctgggcaccc	1020
ctggccggaa cctgcggcgt actcctgctg tccctgggtca tcacgctcta ttgtaatcac	1080
aggaacagat ccaaaagaag cgcctgctc catagcgatt acatgaatat gactccacgc	1140
cgccctggcc ccacaaggaa aactaccag cttacgcac cacctagaga tttcgctgcc	1200
tatcggagca ggggtgaagtt ttccagatct gcagatgcac cagcgtatca gcagggccag	1260
aaccaactgt ataacgagct caacctggga cgcagggaag agtatgacgt tttggacaag	1320
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt	1380
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa	1440
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg	1500
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa	1548

<210> 174

<211> 515

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 174

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5				10					15	

His	Ala	Ala	Arg	Pro	Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Gly	Leu
			20					25					30		

Val	Lys	Pro	Ser	Glu	Thr	Leu	Ser	Leu	Thr	Cys	Thr	Val	Ser	Gly	Gly
		35						40				45			

Ser	Ile	Ser	Ser	Tyr	Tyr	Trp	Ser	Trp	Ile	Arg	Gln	Pro	Pro	Gly	Lys
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

50

55

60

Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80

Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95

Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110

Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125

Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160

Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
165 170 175

Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
180 185 190

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
195 200 205

Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
210 215 220

Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
225 230 235 240

Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255

Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn
260 265 270

Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys
275 280 285

Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
290 295 300

Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
305 310 315 320

Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
325 330 335

Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
340 345 350

Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg
355 360 365

Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
370 375 380

Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
385 390 395 400

Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu

485

490

495

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
 500 505 510

Pro Pro Arg
 515

<210> 175
 <211> 1482
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 polynucleotide

<220>
 <223> anti-CLL-1 CAR construct

<400> 175
 caggtgcaat tgcaagagtc cggccccgga ctcgttaaac ccagtgagac gcttagcctg 60
 acctgtaccg tctcaggggg cagcatctcc tcttattact ggagctggat caggcagcct 120
 ccaggaaaag gccttgaatg gattgggtac atctactact ctggctcaac aaattataat 180
 ccatccctga agtcccgcgt gactatctct gtggacacca gcaagaatca gttttcactg 240
 aagttgtcta gtgttaccgc ggccgacacc gccgtatact actgtgtgtc tcttgtgtac 300
 tgtggcggcg actgctattc cgggttcgac tactggggcc aagggactct ggtaaccgtg 360
 tcctcaggcg gcggcgggtc aggaggaggc ggcagtgagg gtggcggctc cgacatccag 420
 ctgacacaat caccatcttc cttttcagct tcagtcgggg acagagtgtc cttcacatgc 480
 caggccagcc aggatatcaa taacttcctg aactgggtacc aacagaaacc cggaaaggct 540
 ccaaagctcc tgatctatga tgcttccaac ctggagaccg gcgtgccctc caggttcagt 600
 ggttcaggat caggcactga ctttacgttc accatatcca gtcttcagcc cgaagacatt 660
 gcaacctatt actgccaaca atacgggaac cttcccttta cattcggagg cggcaccaag 720
 gtggaaatca aaagggtgc agcattgagc aactcaataa tgtatttttag tcactttgta 780
 ccagtgttct tgccggctaa gcctactacc acacccgctc cacggccacc taccacagct 840
 cctaccatcg cttcacagcc tctgtccctg cgcccagagg cttgccgacc ggccgcaggg 900

ggcgctgttc ataccagagg actggatttc gcctgcgata tctatatctg ggcacccctg 960
 gccggaacct gcggcggtact cctgctgtcc ctgggtcatca cgctctattg taatcacagg 1020
 aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1080
 cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1140
 cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1200
 caactgtata acgagctcaa cctggggacgc aggggaagagt atgacgtttt ggacaagcgc 1260
 agaggacggg accctgagat ggggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1320
 tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1380
 gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1440
 gatacttatg acgctctcca catgcaagcc ctgccaccta gg 1482

<210> 176
 <211> 494
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 176
 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
 20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95

Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160

Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190

Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205

Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220

Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240

Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
245 250 255

Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
325 330 335

Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
340 345 350

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
355 360 365

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
370 375 380

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
385 390 395 400

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
405 410 415

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
420 425 430

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
435 440 445

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
450 455 460

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
465 470 475 480

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 177

<211> 1440

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 177

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccggatatcc agctcacgca atccccctca agcttgagtg cctccgtggg cgaccgggtg	120
tccttcacat gtcaggcaag ccaagacata aataatttcc tgaattggta ccaacaaaaa	180
cccggcaagg ctcccaaact cctgatttat gatgcctcca atctggagac cggggtcctt	240
tctagattca gcggaagtgg cagcggcaca gactttacat ttactatctc ttctctgcaa	300
ccagaggaca tcgccacata ctattgccag caatacggca atctgccctt caccttcgga	360
ggcggaaacca aggtagaaat taaaaggggc ggtggaggct ccggaggggg gggctctggc	420
ggagggggct cccaagtaca attgcaggag tcagggcctg gactcgtgaa gccttcagaa	480
actttgtcac tgacatgtac agtgtccggc ggaagcattt ccagttacta ttggtcctgg	540
attagacagc caccggcaa aggactggaa tggattggat atatctacta ctctggatct	600
acaaactata atcccagcct caaatccagg gtcactatta gtgtggatac atcaaagaat	660
cagttctcct tgaagctgag ctcagtcact gctgccgaca ccgcagtga ctattgtgtg	720
agcctgggtct actgcggcgg agattgctac agcggtttcg attactgggg ccagggcacc	780
ctggttaccg ttagttccgc ggctgctctt gataacgaga agtccaacgg tacgattatc	840
cacgttaagg gtaagcacct ttgccctagc ccgctgttcc caggccccag taagcccttt	900
tgggtcctcg ttgtggtagg tgggggtactc gcctgctact ccctgctcgt cactgtcgca	960
ttcatcatct tctgggtcag atccaaaaga agccgcctgc tccatagcga ttacatgaat	1020
atgactccac gccgccctgg cccacaagg aaacactacc agccttacgc accacctaga	1080
gatttcgctg cctatcggag caggggtgaag ttttccagat ctgcagatgc accagcgtat	1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac	1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac	1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa	1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc	1380

agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa 1440

<210> 178

<211> 479

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 178

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
20 25 30

Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln
35 40 45

Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
50 55 60

Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
65 70 75 80

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
85 90 95

Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
100 105 110

Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125

Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

145		150		155		160									
Thr	Leu	Ser	Leu	Thr	Cys	Thr	Val	Ser	Gly	Gly	Ser	Ile	Ser	Ser	Tyr
			165						170					175	
Tyr	Trp	Ser	Trp	Ile	Arg	Gln	Pro	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Ile
			180					185					190		
Gly	Tyr	Ile	Tyr	Tyr	Ser	Gly	Ser	Thr	Asn	Tyr	Asn	Pro	Ser	Leu	Lys
		195					200					205			
Ser	Arg	Val	Thr	Ile	Ser	Val	Asp	Thr	Ser	Lys	Asn	Gln	Phe	Ser	Leu
	210					215					220				
Lys	Leu	Ser	Ser	Val	Thr	Ala	Ala	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Val
225					230					235					240
Ser	Leu	Val	Tyr	Cys	Gly	Gly	Asp	Cys	Tyr	Ser	Gly	Phe	Asp	Tyr	Trp
				245					250					255	
Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ala	Ala	Leu	Asp	Asn
			260					265					270		
Glu	Lys	Ser	Asn	Gly	Thr	Ile	Ile	His	Val	Lys	Gly	Lys	His	Leu	Cys
		275					280					285			
Pro	Ser	Pro	Leu	Phe	Pro	Gly	Pro	Ser	Lys	Pro	Phe	Trp	Val	Leu	Val
		290				295					300				
Val	Val	Gly	Gly	Val	Leu	Ala	Cys	Tyr	Ser	Leu	Leu	Val	Thr	Val	Ala
305					310					315					320
Phe	Ile	Ile	Phe	Trp	Val	Arg	Ser	Lys	Arg	Ser	Arg	Leu	Leu	His	Ser
				325					330					335	
Asp	Tyr	Met	Asn	Met	Thr	Pro	Arg	Arg	Pro	Gly	Pro	Thr	Arg	Lys	His
			340					345					350		
Tyr	Gln	Pro	Tyr	Ala	Pro	Pro	Arg	Asp	Phe	Ala	Ala	Tyr	Arg	Ser	Arg
		355					360					365			

Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380

Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400

Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415

Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430

Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445

Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460

Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 179
<211> 1374
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 179
gatatccagc tcacgcaatc cccctcaagc ttgagtgcct ccgtgggcga ccgggtgtcc 60
ttcacatgtc aggcaagcca agacataaat aatttcctga attggtacca acaaaaaccc 120
ggcaaggctc ccaaactcct gatttatgat gcctccaatc tggagaccgg ggtcccttct 180
agattcagcg gaagtggcag cggcacagac ttacattta ctatctcttc tctgcaacca 240
gaggacatcg ccacatacta ttgccagcaa tacggcaatc tgcccttcac cttcggaggc 300
ggaaccaagg tagaaattaa aaggggcggt ggaggctccg gagggggggg ctctggcgga 360

gggggctccc aagtacaatt gcaggagtca gggcctggac tcgtgaagcc ttcagaaact	420
ttgtcactga catgtacagt gtccggcgga agcattttcca gttactattg gtcctggatt	480
agacagccac ccggcaaagg actggaatgg attggatata tctactactc tggatctaca	540
aactataatc ccagcctcaa atccagggtc actatttagtg tggatacatc aaagaatcag	600
ttctccttga agctgagctc agtcactgct gccgacaccg cagtgtacta ttgtgtgagc	660
ctggtctact gcggcggaga ttgctacagc ggtttcgatt actggggcca gggcacctg	720
gttaccgtta gttccgcggc tgctcttgat aacgagaagt ccaacggtag gattatccac	780
gttaagggtg agcacctttg ccctagcccg ctgttcccag gccccagtaa gcccttttgg	840
gtcctcgttg tggtaggtgg ggtactcgcc tgctactccc tgctcgtcac tgtcgcattc	900
atcatcttct gggtcagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg	960
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat	1020
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag	1080
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt	1140
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc	1200
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata	1260
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc	1320
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc tagg	1374

<210> 180

<211> 458

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 180

Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5				10						15	

Asp	Arg	Val	Ser	Phe	Thr	Cys	Gln	Ala	Ser	Gln	Asp	Ile	Asn	Asn	Phe
			20					25					30		

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125

Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140

Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160

Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175

Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190

Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205

Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys
210 215 220

Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
225 230 235 240

Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
245 250 255

Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
260 265 270

Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
275 280 285

Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
290 295 300

Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
305 310 315 320

Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
325 330 335

Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
340 345 350

Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
355 360 365

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
370 375 380

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
385 390 395 400

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
405 410 415

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
420 425 430

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
435 440 445

Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455

<210> 181
<211> 1467
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 181
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggatatcc agctgaccca gtctccatcc tctttgagtg cctccgtggg tgaccgcgtc 120
tctttcactt gccaaagccag ccaagacatc aacaactttc tgaattggta ccagcagaaa 180
ccaggcaaag caccaaagct cctcatctac gacgcctcca acctggaaac cgggggtgcc 240
agcaggttta gcgggagcgg ttctggcacg gattttacgt tcaccatctc ctctctgcag 300
cccgaggata tagctactta ttactgtcag cagtacggga atctgccatt tacttttggg 360
ggtggaacta aggtggaaat caaaaggggc ggcgggggaa gcgggggcgg gggctcaggt 420
ggcggaggga gccaggtgca actccaggaa agtggcccag gattggtgaa gcccagcgag 480
accctttccc ttacttgtac tgttagcggg ggcagcataa gcagctacta ttggtcctgg 540
atcagacagc caccagggaag agggcttgaa tggattggct acatttacta ttccgggtcc 600
accaactaca acccatccct caagtcccgc gtgacaattt ccgtcgacac aagcaagaac 660
cagttctccc tgaaacttag tagcgtcact gctgcagata cagcagtgtg ctattgtgtc 720
agccttgtct actgtggcgg cgactgctac agtggctttg attactgggg acagggcacg 780
ctcgtgacag tgtccagcgc tgcggctatc gaggtaatgt atccgccacc gtatctggac 840
aacgagaagt ctaatgggac aatcattcac gtgaagggga agcacctgtg tccatcccc 900
ctgtttccgg gtcccagtaa acccttctgg gtgcttggtg tcgttggcgg ggtgctggcc 960
tgctattccc tgctgggtgac cgtcgcgttt attattttct gggttagatc caaaagaagc 1020
cgcttgctcc atagcgatta catgaatatg actccacgcc gccctggccc cacaaggaaa 1080
cactaccagc cttacgcacc acctagagat ttcgctgcct atcgagcag ggtgaagttt 1140
tccagatctg cagatgcacc agcgtatcag cagggccaga accaactgta taacgagctc 1200

aacctgggac gcaggaaga gtatgacgtt ttggacaagc gcagaggacg ggaccctgag	1260
atgggtggca aaccaagacg aaaaaacccc caggagggtc tctataatga gctgcagaag	1320
gataagatgg ctgaagccta ttctgaaata ggcatgaaag gagagcggag aaggggaaaa	1380
gggcacgacg gtttgtacca gggactcagc actgctacga aggatactta tgacgctctc	1440
cacatgcaag ccctgccacc taggtaa	1467

<210> 182
 <211> 488
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 182
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

 His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
 20 25 30

 Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln
 35 40 45

 Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
 50 55 60

 Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
 65 70 75 80

 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
 85 90 95

 Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
 100 105 110

 Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

115

120

125

Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 130 135 140

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 145 150 155 160

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
 165 170 175

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 180 185 190

Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
 195 200 205

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 210 215 220

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
 225 230 235 240

Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
 245 250 255

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val
 260 265 270

Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
 275 280 285

Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly
 290 295 300

Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala
 305 310 315 320

Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg
 325 330 335

Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro
340 345 350

Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro
355 360 365

Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala
370 375 380

Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu
385 390 395 400

Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
405 410 415

Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu
420 425 430

Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
435 440 445

Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
450 455 460

Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
465 470 475 480

His Met Gln Ala Leu Pro Pro Arg
485

<210> 183

<211> 1401

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 183

gatatccagc tgacccagtc tccatcctct ttgagtgcct ccgtgggtga ccgctctct	60
ttcacttgcc aagccagcca agacatcaac aacttttctga attggtacca gcagaaacca	120
ggcaaagcac caaagctcct catctacgac gcctccaacc tggaaaccgg ggtgcccagc	180
aggttttagcg ggagcggttc tggcacggat ttacgttca ccatctcctc tctgcagccc	240
gaggatatag ctacttatta ctgtcagcag tacgggaatc tgccatttac ttttgggggt	300
ggaactaagg tggaaatcaa aaggggcggc gggggaagcg ggggcggggg ctgaggtggc	360
ggagggagcc aggtgcaact ccaggaaagt ggcccaggat tggatgaagcc cagcgagacc	420
ctttccctta cttgtactgt tagcggaggc agcataagca gctactattg gtcctggatc	480
agacagccac cagggaaagg gcttgaatgg attggctaca ttactattc cgggtccacc	540
aactacaacc catccctcaa gtcccgcgtg acaatttccg tcgacacaag caagaaccag	600
ttctccctga aacttagtag cgtcactgct gcagatacag cagtgtacta ttgtgtcagc	660
cttgtctact gtggcggcga ctgctacagt ggctttgatt actggggaca gggcacgctc	720
gtgacagtgt ccagcgtgc ggctatcgag gtaatgtatc cgccaccgta tctggacaac	780
gagaagtcta atgggacaat cattcacgtg aaggggaagc acctgtgtcc atccccctg	840
tttccgggtc ccagtaaacc cttctgggtg cttgttgtcg ttggcggggg gctggcctgc	900
tattccctgc tggatgaccgt cgcgtttatt attttctggg ttagatccaa aagaagccgc	960
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac	1020
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc	1080
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac	1140
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg	1200
ggtggcaaac caagacgaaa aaacccccag gagggctctt ataatagagct gcagaaggat	1260
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg	1320
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac	1380
atgcaagccc tgccacctag g	1401

<210> 184

<211> 467

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 184

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125

Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140

Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160

Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175

Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190

Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205

Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys
210 215 220

Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
225 230 235 240

Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
245 250 255

Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
260 265 270

Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
275 280 285

Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
290 295 300

Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
305 310 315 320

Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
325 330 335

Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
340 345 350

Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
355 360 365

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
370 375 380

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
385 390 395 400

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
405 410 415

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
420 425 430

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
435 440 445

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
450 455 460

Pro Pro Arg
465

<210> 185
<211> 1548
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 185
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggacattc aattgaccca gtcccctagc agtctctcag caagtgtggg agatagggtg 120
tcattcacct gtcaggcttc acaggacatc aacaacttcc tcaattggta tcagcagaag 180
ccagggaagg caccaaagct gtcatatat gacgcttcaa accttgaaac cggagtacct 240
agccgcttca gcggaagcgg atcagggact gacttcactt ttaccatctc ttactgcag 300
cccgaagaca tcgccacata ctactgccag cagtacggaa acttgccttt tacatttggg 360
ggcggcacca aagtggagat taagcgaggg ggaggcggct caggaggcgg tggctccgga 420
ggcggggggtt cccaggtcca gtcaggaa tccggcccag gtctgggtaa gccagtgaa 480
actttgtccc tcacgtgtac tgtgagcggg ggttcaatct cctcatacta ttggtcttgg 540
atacggcaac ctcttgaaa gggcctcgag tggatcggct atatctacta tagtggctcc 600
actaattaca acccttcct caagtccaga gtcaccattt ccgtggacac atctaagaac 660

cagttcagtc tgaagttgtc cagcgttaca gccgcagaca cagccgttta ttactgtgtg	720
tctcttgttt actgcggggg agactgttat agcggcttcg attactgggg ccagggcacc	780
ttggtcacag tctcttccgc ggccgccctc tctaacagta ttatgtactt ttctcathtt	840
gtacccgtgt tccttccgc taagccaact actaccccg cccacggcc gcctaccct	900
gcaccacaa tagccagtca gcctttgagc ctgagacctg aggcttgtcg gccggctgct	960
gggggtgcag tgcacacacg aggtcttgat tttgcttgcg acatatacat ctgggccct	1020
ctggccggga cctgtgggt gctgcttctg agcttggta tcacgtcta ttgcaaccat	1080
cgcaacagat ccaaaagaag cgcctgctc catagcgatt acatgaatat gactccacgc	1140
cgccctggcc ccacaaggaa aactaccag cttacgcac cacctagaga tttcgctgcc	1200
tatcggagca gggatgaagt ttccagatct gcagatgcac cagcgatatca gcagggccag	1260
aaccaactgt ataacgagct caacctggga cgcaggaag agtatgacgt tttggacaag	1320
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt	1380
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcataaaa	1440
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg	1500
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa	1548

<210> 186
 <211> 515
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 186
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
 20 25 30

Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln

35

40

45

Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
 50 55 60

Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
 65 70 75 80

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
 85 90 95

Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
 100 105 110

Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 115 120 125

Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 130 135 140

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 145 150 155 160

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
 165 170 175

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 180 185 190

Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
 195 200 205

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 210 215 220

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
 225 230 235 240

Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
 245 250 255

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Leu Ser Asn
260 265 270

Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys
275 280 285

Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
290 295 300

Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
305 310 315 320

Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
325 330 335

Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
340 345 350

Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg
355 360 365

Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
370 375 380

Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
385 390 395 400

Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys

<400>	187						
gacattcaat	tgacccagtc	ccctagcagt	ctctcagcaa	gtgtgggaga	taggggtgtca	60	
ttcacctgtc	aggcttcaca	ggacatcaac	aacttcctca	attggtatca	gcagaagcca	120	
gggaaggcac	caaagctgct	catatatgac	gcttcaaacc	ttgaaaccgg	agtacctagc	180	
cgcttcagcg	gaagcggatc	agggactgac	ttcactttta	ccatctcttc	actgcagccc	240	
gaagacatcg	ccacatacta	ctgccagcag	tacggaaact	tgcctttttac	at ttggggggc	300	
ggcaccaaag	tggagattaa	gcgaggggga	ggcggctcag	gaggcggtgg	ctccggaggc	360	
ggggggttccc	agggtccagct	ccaggaatcc	ggcccagggtc	tggttaagcc	cagtgaaact	420	
ttgtccctca	cgtgtactgt	gagcgggtgt	tcaatctcct	catactattg	gtcttggata	480	
cggcaacctc	ctggaaaggg	cctcgagtgg	atcggctata	tctactatag	tggctccact	540	
aattacaacc	cttccctcaa	gtccagagtc	accattttccg	tggacacatc	taagaaccag	600	
ttcagttctga	agttgtccag	cgttacagcc	gcagacacag	ccgtttatta	ctgtgtgtct	660	
cttgtttact	gcggggggaga	ctgttatagc	ggcttcgatt	actgggggcca	gggcaccttg	720	
gtcacagtct	cttccgcggc	cgccctctct	aacagtatta	tgtacttttc	tcattttgta	780	

```

cccggtgttcc ttcccgctaa gccaaactact accccggccc cacggccgcc tacccctgca      840
cccacaatag ccagtcagcc tttagacctg agacctgagg cttgtcggcc ggctgctggg      900
ggtgcagtgc acacacgagg tcttgatfff gcttgcgaca tatacatctg ggcccctctg      960
gccgggacct gtgggggtgct gcttctgagc ttgggtcatca cgctctattg caaccatcgc    1020
aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc      1080
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat      1140
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgatatcagca gggccagaac      1200
caactgtata acgagctcaa cctgggacgc aggggaagagt atgacgtttt ggacaagcgc      1260
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc      1320
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga      1380
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag      1440
gatacttatg acgctctcca catgcaagcc ctgccaccta gg                          1482

```

<210> 188

<211> 494

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 188

```

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10           15

```

```

Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
          20           25           30

```

```

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
          35           40           45

```

```

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60

```

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125

Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140

Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160

Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175

Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190

Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205

Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys
210 215 220

Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
225 230 235 240

Val Thr Val Ser Ser Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
245 250 255

Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
260 265 270

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
275 280 285

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
290 295 300

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
305 310 315 320

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
325 330 335

Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
340 345 350

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
355 360 365

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
370 375 380

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
385 390 395 400

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
405 410 415

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
420 425 430

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
435 440 445

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
450 455 460

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
465 470 475 480

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 189
<211> 1446
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 189
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtac agctgcagga atctgggccc ggacttgtca agccaagtca gacactttct 120
cttacatgta ccgtgagcgg cggaagtata agcagtggag gcttttactg gtcttggata 180
cggcagcacc caggcaaagg cttggagtgg attggataca ttcatcattc aggatctaca 240
cactataatc catcccttaa gtcccgggtc accattagca ttgatacgtc taagaatctg 300
ttcagtctca ggctgtcctc cgtcactgct gccgacacag ccgtgtacta ctgcgctcc 360
ttggtttact gcggaggcga ctgttatagc ggctttgatt attgggggca ggggacctc 420
gtaaccgtga gctctggagg ggggtgggagc gggggaggag gttcaggggg gggcggctcc 480
gatatccagc tactcaaag cccctctagt ctctctgcct cagtggggga tcgggtcagt 540
tttacttgtc aagcttcaca ggatatcaac aacttcctta attggtatca gcagaagcca 600
ggaaaagcac ccaagctgct catctatgat gcctcaaatt tggagacggg tgttcccagt 660
cgattctctg ggtcagggtc cgggaccgac ttacgttta cgatctcctc tctgcagccc 720
gaagacatcg ccacatacta ttgtcaacag tacggcaact tgcctttcac atttgggggc 780
gggactaagg ttgaaatcaa gagggccgct gcactggaca atgagaagtc caacggcacc 840
atcatccacg tgaagggcaa gcacctgtgc ctagtcctc tgttcccagg cccatccaaa 900
cctttttggg ttcttgttgt ggtcgggggg gtgctggcct gctattctct gctggtcacg 960
gtggccttca taattttctg ggtagatcc aaaagaagcc gcctgctcca tagcgattac 1020
atgaatatga ctccacgccg ccctggcccc acaaggaaac actaccagcc ttacgcacca 1080
cctagagatt tcgctgccta tcggagcagg gtgaagtttt ccagatctgc agatgcacca 1140
gcgtatcagc agggccagaa ccaactgtat aacgagctca acctgggacg cagggaagag 1200
tatgacgttt tggacaagcg cagaggacgg gaccctgaga tgggtggcaa accaagacga 1260

aaaaaccccc aggagggtct ctataatgag ctgcagaagg ataagatggc tgaagcctat	1320
tctgaaatag gcatgaaagg agagcggaga aggggaaaag ggcacgacgg tttgtaccag	1380
ggactcagca ctgctacgaa ggatacttat gacgctctcc acatgcaagc cctgccacct	1440
aggtaa	1446

<210> 190
 <211> 481
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 190
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
 20 25 30

Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
 35 40 45

Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
 50 55 60

Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
 65 70 75 80

His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
 85 90 95

Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
 100 105 110

Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
 115 120 125

Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175

Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
210 215 220

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
225 230 235 240

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
245 250 255

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu
260 265 270

Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His
275 280 285

Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val
290 295 300

Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr
305 310 315 320

Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu
325 330 335

His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg

340

345

350

Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg
 355 360 365

Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln
 370 375 380

Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
 385 390 395 400

Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
 405 410 415

Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
 420 425 430

Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
 435 440 445

Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
 450 455 460

Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
 465 470 475 480

Arg

<210> 191

<211> 1380

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 191

caggtacagc tgcaggaatc tgggcccgga cttgtcaagc caagtcagac actttctctt

60

acatgtaccg tgagcggcgg aagtataagc agtggaggct tttactggtc ttggatacgg	120
cagcaccag gcaaaggctt ggagtggatt ggatacattc atcattcagg atctacacac	180
tataatccat cccttaagtc ccgggtcacc attagcattg atacgtctaa gaatctgttc	240
agtctcaggc tgtcctccgt cactgctgcc gacacagccg tgtactactg cgcctccttg	300
gtttactgcg gaggcgactg ttatagcggc tttgattatt gggggcaggg gaccctcgta	360
accgtgagct ctggaggggg tgggagcggg ggaggagggt cagggggggg cggctccgat	420
atccagctca ctcaaagccc ctctagtctc tctgcctcag tgggggatcg ggtcagtttt	480
acttgtcaag cttcacagga tatcaacaac ttccttaatt ggtatcagca gaagccagga	540
aaagcaccca agctgctcat ctatgatgcc tcaaatttgg agacgggtgt tcccagtcga	600
ttctctgggt caggggtccgg gaccgacttt acgtttacga tctcctctct gcagcccgaa	660
gacatcgcca catactattg tcaacagtac ggcaacttgc ctttcacatt tgggggcggg	720
actaaggttg aaatcaagag ggccgctgca ctggacaatg agaagtcaa cggcaccatc	780
atccacgtga agggcaagca cctgtgccct agtcctctgt tcccaggccc atccaaacct	840
ttttgggttc ttgttgtggt cgggggggtg ctggcctgct attctctgct ggtcacggtg	900
gccttcataa ttttctgggt tagatccaaa agaagccgcc tgctccatag cgattacatg	960
aatatgactc cacgccgccc tggccccaca aggaaacact accagcctta cgcaccacct	1020
agagatttcg ctgcctatcg gagcagggtg aagttttcca gatctgcaga tgcaccagcg	1080
tatcagcagg gccagaacca actgtataac gagctcaacc tgggacgcag ggaagagtat	1140
gacgttttgg acaagcgag aggacgggac cctgagatgg gtggcaaacc aagacgaaaa	1200
aacccccagg agggctctta taatgagctg cagaaggata agatggctga agcctattct	1260
gaaataggca tgaaaggaga gcggagaagg ggaaaagggc acgacggttt gtaccaggga	1320
ctcagcactg ctacgaagga tacttatgac gctctccaca tgcaagccct gccacctagg	1380

<210> 192

<211> 460

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 192

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30

Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80

Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140

Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160

Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175

Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190

Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205

Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220

Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240

Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser
245 250 255

Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
260 265 270

Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
275 280 285

Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
290 295 300

Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
305 310 315 320

Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
325 330 335

Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe
340 345 350

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
355 360 365

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
370 375 380

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
385 390 395 400

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
405 410 415

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
420 425 430

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
435 440 445

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460

<210> 193
<211> 1473
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 193
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctgcagga aagcgggtccg ggacttgtca agccgtccca aacgtgagtt 120
ctgacgtgta ctgtctctgg tggctctatt tcttccgggg gctttttattg gtcttggatc 180
agacaacacc ctggcaaagg gctggagtggt ataggggtata ttcaccactc tgggtccact 240
cactacaacc catcattgaa atccagagtg actatctcaa tcgacacatc caagaacctt 300
ttcagcctga ggttgtcatc agttaccgcc gctgacaccg cgggtgtatta ttgctcctct 360
ctcgtgtact gcggtggcga ttgttatagt ggctttgact actggggggca ggggacattg 420
gttaccgttt caagtggagg cgggtgggtct ggccgggggcg gtagcggagg tggggggagc 480
gacatacagc ttacgcagag cccctccagc ctttcagcct ccgtggggga tagggtgtcc 540
tttacctgcc aggcttccca ggacataaac aacttcctca attggtatca gcaaaagccc 600
gggaaagcac caaagctgct catctacgat gccagcaacc tggaaaccgg agtgccgtct 660
cgcttctctg gaagtggcag tgggaccgat ttacttttta caatctcaag tttgcagcca 720
gaagacattg caacatacta ctgtcaacag tacggcaatc tcccctttac atttgggggg 780
ggaactaaag tggagattaa gcgcgtgca gccattgaag ttatgtatcc gccccgtat 840
ctggataacg agaaatctaa tgggtaccata atacatgtga aggggaagca cctctgtcca 900

tcaccgctgt	tccccggccc	ttcaaaacct	ttctgggtac	tcgttgctgt	gggtggagtt	960
ctggcctgct	atagtctgct	ggtgaccgtg	gcgtttatca	tcttctgggt	aagatccaaa	1020
agaagccgcc	tgctccatag	cgattacatg	aatatgactc	cacgccgccc	tggccccaca	1080
aggaaacct	accagcctta	cgcaccacct	agagatttcg	ctgcctatcg	gagcaggggtg	1140
aagttttcca	gatctgcaga	tgcaccagcg	tatcagcagg	gccagaacca	actgtataac	1200
gagctcaacc	tgggacgcag	ggaagagtat	gacgttttgg	acaagcgcag	aggacggggac	1260
cctgagatgg	gtggcaaacc	aagacgaaaa	aacccccagg	agggtctcta	taatgagctg	1320
cagaaggata	agatggctga	agcctattct	gaaataggca	tgaaaggaga	gcggagaagg	1380
ggaaaagggc	acgacggttt	gtaccagggg	ctcagcactg	ctacgaagga	tacttatgac	1440
gctctccaca	tgcaagccct	gccacctagg	taa			1473

```

<400> 194
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu
1                    5                      10                      15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
                20                      25                      30

Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
        35                      40                      45

Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
        50                      55                      60

Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
65                      70                      75                      80

```

His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
85 90 95

Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
100 105 110

Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
115 120 125

Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175

Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
210 215 220

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
225 230 235 240

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
245 250 255

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile
260 265 270

Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly
275 280 285

Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe

290

295

300

Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
 305 310 315 320

Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
 325 330 335

Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
 340 345 350

Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
 355 360 365

Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
 370 375 380

Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
 385 390 395 400

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
 405 410 415

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
 420 425 430

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
 435 440 445

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
 450 455 460

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
 465 470 475 480

Ala Leu His Met Gln Ala Leu Pro Pro Arg
 485 490

<210> 195

<211> 1407

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 195

caggtgcagc tgcaggaaag cgggtccggga cttgtcaagc cgtcccaaac gctgagtctg	60
acgtgtactg tctctggtgg ctctatttct tccgggggct tttattgggtc ttggatcaga	120
caacaccctg gcaaagggtt ggagtggata gggatatattc accactctgg gtccactcac	180
tacaacccat cattgaaatc cagagtgact atctcaatcg acacatccaa gaaccttttc	240
agcctgaggt tgtcatcagt taccgccgct gacaccgcgg tgtattattg cgcctctctc	300
gtgtactgcg gtggcgattg ttatagtggc tttgactact gggggcaggg gacattgggtt	360
accgtttcaa gtggaggcgg tgggtctggc gggggcggta gcggagggtg ggggagcgac	420
atacagctta cgcagagccc ctccagcctt tcagcctccg tgggggatag ggtgtccttt	480
acctgccagg cttcccagga cataaacaac ttcctcaatt ggtatcagca aaagcccggg	540
aaagcaccaa agctgctcat ctacgatgcc agcaacctgg aaaccggagt gccgtctcgc	600
ttctctggaa gtggcagtgg gaccgatttc acttttataa tctcaagttt gcagccagaa	660
gacattgcaa catactactg tcaacagtac ggcaatctcc cctttacatt tgggggggga	720
actaaagtgg agattaagcg cgctgcagcc attgaagtta tgtatccgcc cccgtatctg	780
gataacgaga aatctaattg taccataata catgtgaagg ggaagcacct ctgtccatca	840
ccgctgttcc ccggcccttc aaaacctttc tgggtactcg ttgtcgtggg tggagtcttg	900
gcctgctata gtctgctggt gaccgtggcg tttatcatct tctgggtaag atccaaaaga	960
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg cccacaagg	1020
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag cagggtgaag	1080
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag	1140
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct	1200
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag	1260
aaggataaga tggctgaagc ctattctgaa ataggcatga aaggagagcg gagaagggga	1320

aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct 1380
 ctccacatgc aagccctgcc acctagg 1407

<210> 196
 <211> 469
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 196
 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
 20 25 30

Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
 35 40 45

Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
 50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
 65 70 75 80

Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
 85 90 95

Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
 100 105 110

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
 115 120 125

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
 130 135 140

Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160

Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175

Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190

Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205

Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220

Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240

Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro
245 250 255

Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
260 265 270

Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
275 280 285

Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
290 295 300

Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
305 310 315 320

Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
325 330 335

Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
340 345 350

Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
355 360 365

Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
370 375 380

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
385 390 395 400

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
405 410 415

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
420 425 430

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
435 440 445

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
450 455 460

Ala Leu Pro Pro Arg
465

<210> 197
<211> 1554
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 197
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttgcagga aagcgggcct ggccttgtga aaccaagcca gacactgagc 120
ctgacatgca ctgtgtccgg cgggtccata tcttccgggg gtttttattg gtcctggata 180
cgccagcatc ccgggaaagg acttgaatgg attggatata tccaccattc cggaagcacc 240
cactacaatc caagccttaa atcccgggtg acaatctcca tcgacacctc aaagaatctt 300
ttttccctgc ggttgtcttc agtaactgcc gccgataccg ctgtgtacta ctgtgccagc 360

ctcgtctatt gcggcggaga ttgttattct gggttcgatt attgggggtca aggcacactg	420
gtaactgtca gcagcggagg cggcggttcc gggggcgggg gcagtggagg gggcggatct	480
gacattcagc ttacgcagtc cccatcttca cttagcgcca gcgttggcga tcgggtcagc	540
ttcacgtgtc aagcaagtca ggatatcaac aactttctta actggtacca gcagaagcca	600
ggcaaggcac ccaagttgct gattttacgat gcttctaacc tcgagacggg agtgcctagc	660
cgcttctccg ggagcggcag cggcacagac tttaacctta cgatttccag tctgcagcca	720
gaggatatag caacttatta ctgtcagcag tatggcaacc tcccttttac cttcggtggt	780
ggcacaaagg tcgagattaa aagagccgca gcgttgtcca actccataat gtatTTTTTct	840
cattttgtgc ccgtctttct gcctgcaaaa cctaccacca ccccgcccc acgaccacct	900
actccagccc ccaccatcgc ctcccagccc ctacgcctga ggccagaggc ttgtcgccct	960
gctgcggggg gcgctgtcca taccagagga ctcgacttcg cctgcgatat ttatatatgg	1020
gccccctcg ccggcacctg cggagtcttg ctcttgagcc ttgtgatcac gctttattgt	1080
aaccatcgga atagatccaa aagaagccgc ctgctccata gcgattacat gaatatgact	1140
ccacgccgcc ctggccccac aaggaaacac taccagcctt acgcaccacc tagagatttc	1200
gctgcctatc ggagcagggt gaagttttcc agatctgcag atgcaccagc gtatcagcag	1260
ggccagaacc aactgtataa cgagctcaac ctgggacgca gggaagagta tgacgttttg	1320
gacaagcgca gaggacggga ccctgagatg ggtggcaaac caagacgaaa aaacccccag	1380
gagggtctct ataatgagct gcagaaggat aagatggctg aagcctattc tgaaataggc	1440
atgaaaggag agcggagaag gggaaaaggg cacgacgggt tgtaccaggg actcagcact	1500
gctacgaagg atacttatga cgctctccac atgcaagccc tgccacctag gtaa	1554

<210> 198

<211> 517

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 198

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30

Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45

Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
50 55 60

Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
65 70 75 80

His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
85 90 95

Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
100 105 110

Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
115 120 125

Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175

Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly

210

215

220

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
 225 230 235 240

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
 245 250 255

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu
 260 265 270

Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro
 275 280 285

Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro
 290 295 300

Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro
 305 310 315 320

Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
 325 330 335

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
 340 345 350

Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg
 355 360 365

Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
 370 375 380

Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
 385 390 395 400

Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
 405 410 415

Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
 420 425 430

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
435 440 445

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
450 455 460

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
465 470 475 480

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
485 490 495

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
500 505 510

Ala Leu Pro Pro Arg
515

<210> 199
<211> 1488
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 199
caggtgcagt tgcaggaaag cgggcctggc cttgtgaaac caagccagac actgagcctg 60
acatgcactg tgtccggcgg gtccatatct tccgggggtt tttattgggtc ctggatacgc 120
cagcatcccg ggaaaggact tgaatggatt ggatatatcc accattccgg aagcaccac 180
tacaatccaa gccttaaadc ccgggtgaca atctccatcg acacctcaaa gaatcttttt 240
tccctgcggt tgtcttcagt aactgccgcc gataccgctg tgtactactg tgccagcctc 300
gtctattgcg gcggagattg ttattctggg ttcgattatt ggggtcaagg cacactggta 360
actgtcagca gcggaggcgg cggttccggg ggcgggggca gtggaggggg cggatctgac 420
attcagctta cgcagtcccc atcttcactt agcgcacgagc ttggcgatcg ggtcagcttc 480

Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80

Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140

Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160

Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175

Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190

Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205

Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220

Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240

Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met
245 250 255

Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr
260 265 270

Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
275 280 285

Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
290 295 300

Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
305 310 315 320

Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr
325 330 335

Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His
340 345 350

Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys
355 360 365

His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser
370 375 380

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
385 390 395 400

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
405 410 415

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
420 425 430

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
435 440 445

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
450 455 460

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
 465 470 475 480

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 485 490 495

<210> 201
 <211> 1437
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 polynucleotide

<220>
 <223> anti-CLL-1 CAR construct

<400> 201
 atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
 ccgcaggtcc aactggtgca gtccggagcc gaagtcaaga aaccaggtgc ctccgttaaa 120
 gtgagttgca aagtctctgg atacactctg accgagctct ctatgcactg ggtccggcag 180
 gccccggca agggattgga atggatgggc gggttcgatc ctgaggacgg agagactatc 240
 tacgctcaaa aattccaggg acgagtgact gtgaccgaag acactagtagc cgacactgcc 300
 tacatggaac tttcctctct gcgatcagaa gataccgcag tgtactactg tgctactgaa 360
 tctaggggca ttggatggcc ctacttcgat tactgggggtc agggaaactct ggtgactgtc 420
 tccagcgggtg gaggtggcag cgggtggtggc ggaagcgggg ggggcggctc tgatattcag 480
 atgactcaat ctctttcttc tctgtccgct tccgtgggcg atagagtgac cattacttgt 540
 agggcgtccc agtcaatctc cagttatttg aattggtatc agcagaagcc cgggaaagca 600
 cctaagctgt tgatcagcgg ggcttctagc ctgaagagtg ggggtaccttc acggttcagc 660
 ggaagcggaa gcggaaccga tttcaccttg actatcagca gcctgccacc tgaggacttt 720
 gcaacttact actgccaaca gtcatacagc actccgatca ctttcggcca gggcacccgg 780
 ctcgaaatca agcgcgctgc tgctttggac aatgagaagt caaacggcac catcatacat 840
 gttaaaggta aacatctgtg tccctccccg ctgttccccg gcccttccaa accgttctgg 900
 gttctggtgg tggtcggagg cgtactcgct tgctatagtc tgctggtaac tgtcgccttc 960

atcatctttt gggtagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg	1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat	1080
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag	1140
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt	1200
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc	1260
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata	1320
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc	1380
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc taggtaa	1437

<210> 202

<211> 478

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 202

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5					10					15	

His	Ala	Ala	Arg	Pro	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val
			20					25					30		

Lys	Lys	Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Val	Ser	Gly	Tyr
		35					40					45			

Thr	Leu	Thr	Glu	Leu	Ser	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys
	50					55					60				

Gly	Leu	Glu	Trp	Met	Gly	Gly	Phe	Asp	Pro	Glu	Asp	Gly	Glu	Thr	Ile
65					70					75					80

Tyr	Ala	Gln	Lys	Phe	Gln	Gly	Arg	Val	Thr	Val	Thr	Glu	Asp	Thr	Ser
				85					90					95	

Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125

Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160

Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175

Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190

Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala
195 200 205

Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
210 215 220

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
225 230 235 240

Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
245 250 255

Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu
260 265 270

Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
275 280 285

Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
290 295 300

Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe

305		310		315		320
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp						
		325		330		335
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr						
		340		345		350
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val						
		355		360		365
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn						
		370		375		380
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val						
385		390		395		400
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg						
		405		410		415
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys						
		420		425		430
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg						
		435		440		445
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys						
		450		455		460
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg						
465		470		475		

<210> 203

<211> 1371

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 203

caggtccaac	tggtgcagtc	cggagccgaa	gtcaagaaac	caggtgcctc	cgtaaagt	60
agttgcaaag	tctctggata	cactctgacc	gagctctcta	tgactgggt	ccggcaggcc	120
cccggcaagg	gattggaatg	gatgggcggg	ttcgatcctg	aggacggaga	gactatctac	180
gctcaaaaat	tccaggacg	agtgactgtg	accgaagaca	ctagtaccga	cactgcctac	240
atggaacttt	cctctctgcg	atcagaagat	accgcagtgt	actactgtgc	tactgaatct	300
aggggcattg	gatggcccta	cttcgattac	tggggtcagg	gaactctggt	gactgtctcc	360
agcgggtggag	gtggcagcgg	tggtggcgga	agcggggggg	gcggctctga	tattcagatg	420
actcaatctc	cttcttctct	gtccgcttcc	gtgggcgata	gagtgaccat	tactttagg	480
gcgtcccagt	caatctccag	ttatttgaat	tggtatcagc	agaagcccgg	gaaagcacct	540
aagctgttga	tcagcggggc	ttctagcctg	aagagtgggg	taccttcacg	gttcagcgga	600
agcgggaagcg	gaaccgattt	caccctgact	atcagcagcc	tgccacctga	ggactttgca	660
acttactact	gccaacagtc	atacagcact	ccgatcactt	tcggccaggg	cacccggctc	720
gaaatcaagc	gcgctgctgc	tttggacaat	gagaagtcaa	acggcaccat	catacatgtt	780
aaaggtaaac	atctgtgtcc	ctccccgctg	ttccccggcc	cttccaaacc	gttctgggtt	840
ctggtggtgg	tcggaggcgt	actcgcttgc	tatagtctgc	tggtaaactgt	cgccttcac	900
atcttttggg	tgagatccaa	aagaagccgc	ctgctccata	gcgattacat	gaatatgact	960
ccacgccgcc	ctggccccac	aaggaaacac	taccagcctt	acgcaccacc	tagagatttc	1020
gctgcctatc	ggagcagggt	gaagttttcc	agatctgcag	atgcaccagc	gtatcagcag	1080
ggccagaacc	aactgtataa	cgagctcaac	ctgggacgca	gggaagagta	tgacgttttg	1140
gacaagcgca	gaggacggga	ccctgagatg	ggtggcaaac	caagacgaaa	aaacccccag	1200
gagggtctct	ataatgagct	gcagaaggat	aagatggctg	aagcctattc	tgaaataggc	1260
atgaaaggag	agcggagaag	gggaaaaggg	cacgacgggt	tgtaccaggg	actcagcact	1320
gctacgaagg	atacttatga	cgctctccac	atgcaagccc	tgccacctag	g	1371

<210> 204

<211> 457

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 204

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30

Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140

Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160

Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175

Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205

Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220

Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240

Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr
245 250 255

Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro
260 265 270

Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu
275 280 285

Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
290 295 300

Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
305 310 315 320

Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
325 330 335

Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
340 345 350

Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
355 360 365

Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
370 375 380

Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
385 390 395 400

Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
405 410 415

Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
420 425 430

Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
435 440 445

Leu His Met Gln Ala Leu Pro Pro Arg
450 455

<210> 205

<211> 1464

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 205

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcaggtgc agcttgtgca gagcggggcc gaggtgaaga agcccggggc cagcgtcaaa	120
gtgtcctgta aggtcagcgg ttacaccctc accgagctga gcatgcactg ggtacggcag	180
gctcccgga aaggtcttga gtggatgggt ggatttgatc cagaagatgg agagactatc	240
tacgcccaga agttccaggg ccgggtcacc gtaacagaag acacctcaac tgacaccgct	300
tacatggagc tgagttcact gcggtccgag gacacggccg tgtattattg tgccaccgag	360
agccgcggaa tcggatggcc ttacttcgac tactggggac aggttacact tgttacagta	420
tcatccgggg gtggcggctc tgggtggggc ggctccggag ggggtggatc agatatccaa	480
atgactcaaa gtccaagttc cctgtctgcc tcagtcggag atagagtcac cataacctgc	540
agggcaagtc agtccatctc ctcttatctg aactgggtacc aacagaaacc tggaaaggcg	600
cctaagctcc tgatctccgg agcctcatct ttgaaatccg gtgtcccatc tcgcttcagt	660
ggctctggaa gcggtacaga ttttactttg accattagca gcctcccacc ggaagacttt	720
gctacatatt actgccagca gtcttactca accccaatca ccttcgggca aggcaccaga	780

ctcgaaataa aaagagcagc tgctatcgag gttatgtacc caccgccgta cttggataac	840
gaaaaaagca atgggaccat cattcatgtg aagggtgaagc acctttgccc tagcccactg	900
tttcctggcc cgagtaaacc cttttgggta cttgtggtcg tcggcggcgt gctggcctgc	960
tactcactcc tggttaccgt cgcattcatc atcttttggg tgagatccaa aagaagccgc	1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac	1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc	1140
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac	1200
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg	1260
ggtggcaaac caagacgaaa aaacccccag gagggctctt ataatgagct gcagaaggat	1320
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg	1380
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac	1440
atgcaagccc tgccacctag gtaa	1464

<210> 206

<211> 487

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 206

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5				10					15		

His	Ala	Ala	Arg	Pro	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val
			20					25					30		

Lys	Lys	Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Val	Ser	Gly	Tyr
		35					40					45			

Thr	Leu	Thr	Glu	Leu	Ser	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys
	50					55					60				

Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile
65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser
85 90 95

Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125

Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160

Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175

Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190

Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala
195 200 205

Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
210 215 220

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
225 230 235 240

Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
245 250 255

Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met
260 265 270

Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile

275

280

285

His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
 290 295 300

Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
 305 310 315 320

Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
 325 330 335

Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
 340 345 350

Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
 355 360 365

Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
 370 375 380

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
 385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
 405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
 420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
 435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
 450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
 465 470 475 480

Met Gln Ala Leu Pro Pro Arg
 485

<210> 207
<211> 1398
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 207
caggtgcagc ttgtgcagag cggggccgag gtgaagaagc ccggggccag cgtcaaagtg 60
tcctgtaagg tcagcggtta caccctcacc gagctgagca tgcactgggt acggcaggct 120
cccggcaaag gtcttgagtg gatgggtgga tttgatccag aagatggaga gactatctac 180
gcccagaagt tccagggccg ggtcaccgta acagaagaca cctcaactga caccgcttac 240
atggagctga gttcactgcg gtccgaggac acggccgtgt attattgtgc caccgagagc 300
cgcggaatcg gatggcctta cttcgactac tggggacagg gtacacttgt tacagtatca 360
tccgggggtg gcggctctgg tgggggcggc tccggagggg gtggatcaga tatccaaatg 420
actcaaagtc caagttccct gtctgcctca gtcggagata gagtcaccat aacctgcagg 480
gcaagtcagt ccatctcctc ctatctgaac tggtaccaac agaaacctgg aaaggcgcct 540
aagctcctga tctccggagc ctcatctttg aaatccggtg tcccattctg cttcagtggc 600
tctggaagcg gtacagattt tactttgacc attagcagcc tcccaccgga agactttgct 660
acatattact gccagcagtc ttactcaacc ccaatcacct tcgggcaagg caccagactc 720
gaaataaaaa gagcagctgc tatcgagggt atgtaccac cgccgtactt ggataacgaa 780
aaaagcaatg ggaccatcat tcatgtgaag ggtaagcacc tttgccctag cccactgttt 840
cctggcccga gtaaaccctt ttgggtactt gtggtcgtcg gcggcgtgct ggcttgctac 900
tcactcctgg ttaccgtcgc attcatcatc ttttgggtga gatccaaaag aagccgcctg 960
ctccatagcg attacatgaa tatgactcca cgccgccctg gccccacaag gaaacactac 1020
cagccttacg caccacctag agatttcgct gcctatcgga gcagggtgaa gttttccaga 1080
tctgcagatg caccagcgta tcagcagggc cagaaccaac tgtataacga gctcaacctg 1140
ggacgcaggg aagagtatga cgttttggac aagcgcagag gacgggaccc tgagatgggt 1200

ggcaaaccaa gacgaaaaaa cccccaggag ggtctctata atgagctgca gaaggataag	1260
atggctgaag cctattctga aatagggcatg aaaggagagc ggagaagggg aaaagggcac	1320
gacggtttgt accaggggact cagcactgct acgaaggata cttatgacgc tctccacatg	1380
caagccctgc cacctagg	1398

<210> 208
 <211> 466
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 208
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
 20 25 30

Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45

Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
 115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140

Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160

Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175

Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205

Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220

Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240

Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr
245 250 255

Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
260 265 270

His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
275 280 285

Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
290 295 300

Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
305 310 315 320

Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
325 330 335

Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
340 345 350

Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
355 360 365

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
370 375 380

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
385 390 395 400

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
405 410 415

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
420 425 430

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
435 440 445

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
450 455 460

Pro Arg
465

<210> 209
<211> 1545
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 209
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttggtgca aagcggcgca gaagttaaga aacctggggc gtcagttaag 120
gtgtcttgca aagtatctgg ctataccctc actgagctgt ccatgcattg ggtaaggcag 180
gctcctggaa aggggctcga atggatggga ggatttgacc ctgaagacgg agagaccatc 240

tacgcccaga aattccaggg tagagtaaca gtgactgagg acactagcac tgacacagcg	300
tacatggagc tgagttctct gagaagtgag gacacagccg tttactactg cgctaccgag	360
tccagaggta ttggctggcc atacttcgac tattgggggtc agggcaccct ggttacagtg	420
agttcaggag gcgggggctc tggggggggc gggtccggag gggggggctc agatatacag	480
atgacgcaga gtccatcaag tctctcagcc agcgtgggag atcgcgtagc tattacttgc	540
cgcgccagcc agagtattag ctcctatctg aattgggtacc agcaaaagcc cgggaaggcc	600
cctaagcttc tgatttctgg cgctcctct ttgaagtcag gtgtgccaag cagatttagc	660
gggtctggaa gtggcactga ctttacactt actatctcca gcctgcccc agaggatttt	720
gccacatatt actgtcagca aagctactct actccaatca ctttcggcca gggcacaaga	780
ttggagatta agagggtgc cgcactttca aattccatca tgtatttcag ccattttgtg	840
cctgtttttc ttccggccaa acctacaacc actcccgccc cagccccacc tactcccgcc	900
cctaccattg cctcccagcc tctgtctctt agacctgagg cttgtagacc tgctgccggc	960
ggagccgtgc acactcgcg tctggacttc gcctgcgaca tctatatctg ggcccctctg	1020
gccggcacct gcggcgttct ctttctctca ctcgtaatca cactctattg caatcacagg	1080
aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc	1140
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat	1200
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac	1260
caactgtata acgagctcaa cctgggacgc aggggaagagt atgacgtttt ggacaagcgc	1320
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc	1380
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga	1440
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag	1500
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa	1545

<210> 210

<211> 514

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 210

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr
35 40 45

Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60

Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile
65 70 75 80

Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser
85 90 95

Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125

Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160

Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175

Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190

Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala

195

200

205

Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
 210 215 220

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
 225 230 235 240

Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
 245 250 255

Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser
 260 265 270

Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro
 275 280 285

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala
 290 295 300

Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly
 305 310 315 320

Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile
 325 330 335

Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val
 340 345 350

Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu
 355 360 365

Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
 370 375 380

Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
 385 390 395 400

Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
 405 410 415

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
420 425 430

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
435 440 445

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
450 455 460

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
465 470 475 480

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
485 490 495

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
500 505 510

Pro Arg

<210> 211
<211> 1479
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 211
caggtgcagt tgggtgcaaag cggcgcagaa gttaagaaac ctggggcgctc agttaaggtg 60
tcttgcaaag tatctggcta taccctcact gagctgtcca tgcattgggt aaggcaggct 120
cctggaaagg ggctcgaatg gatgggagga tttgaccctg aagacggaga gaccatctac 180
gcccagaaat tccagggtag agtaacagtg actgaggaca ctagcactga cacagcgtac 240
atggagctga gttctctgag aagtgaggac acagccgttt actactgcgc taccgagtcc 300
agaggtattg gctggccata cttcgactat tggggtcagg gcaccctggt tacagtgagt 360

tcaggaggcg ggggctctgg ggggggcggt tccggagggg ggggctcaga tatacagatg	420
acgcagagtc catcaagtct ctcagccagc gtgggagatc gcgtgactat tacttgccgc	480
gccagccaga gtattagctc ctatctgaat tggtagcagc aaaagcccgg gaaggcccct	540
aagcttctga tttctggcgc ctctctttg aagtcagggtg tgccaagcag atttagcggg	600
tctggaagtg gcaactgactt tacacttact atctccagcc tgccccaga ggattttgcc	660
acatattact gtcagcaaag ctactctact ccaatcactt tcggccaggg cacaagattg	720
gagattaaga gggctgccgc actttcaaat tccatcatgt atttcagcca ttttgtgcct	780
gtttttcttc cggccaaacc tacaaccact cccgccccac gcccacctac tcccgcccct	840
accattgcct cccagcctct gtctcttaga cctgaggctt gtagacctgc tgccggcgga	900
gccgtgcaca ctcgcggtct ggacttcgcc tgcgacatct atatctgggc ccctctggcc	960
ggcacctgcg gcgttctcct tctctcactc gtaatcacac tctattgcaa tcacaggaac	1020
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgcct	1080
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg	1140
agcagggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa	1200
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgttttgga caagcgaga	1260
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggctcttat	1320
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag	1380
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat	1440
acttatgacg ctctccacat gcaagccctg ccacctagg	1479

<210> 212

<211> 493

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 212

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10					15	

Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30

Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140

Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160

Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175

Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205

Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220

Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240

Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser
245 250 255

His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala
260 265 270

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
275 280 285

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr
290 295 300

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
305 310 315 320

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
325 330 335

Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
340 345 350

Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
355 360 365

Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys
370 375 380

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
385 390 395 400

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
405 410 415

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
420 425 430

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
435 440 445

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
450 455 460

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
465 470 475 480

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 213

<211> 1425

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 213

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcaggtcc agttggtcga aagtggcggt ggtgtagtgc agccgggccg cagtttgagg	120
ctttcctgtg cggcttcagg ctttactttt tccagctatg gaatgcactg ggtgcggcag	180
gccccgggca aaggacttga gtgggtggcc gtcatttctt atgacggatc agataagtac	240
tacgtggaca gcgtcaaggg cagattcacc atctctaggg acaacagtaa aaatagactc	300
tacctccaga tgaatagcct cagagctgaa gacacggccg tctactattg tgctcgggag	360
cggatatagt gcagagacta ctggggggcag ggcacactcg ttacagttag tagcggcgga	420
ggagggagtg ggggcggtgg ctccggtgga ggaggttctg agattgttat gaccagagt	480
cctgcgaccc tctcagtcag ccccggggag cgcgcaactt tgtcttgcag agctagtcag	540
tccgtgtcct ctcttctgac atggtaccag caaaagcccg ggcaggctcc gcgccttttg	600
atctttgggg cttcaacaag agccactggg attcccgcac gattctctgg ctccgggagc	660
ggtactggtt tcaccctgac gattagcagt ctccagagcg aggacttcgc cgtatactac	720
tgccagcagt acgatacgtg gccattcact tttggaccag ggactaaagt ggattttaag	780
cgcgccgccg ctctcgataa cgaaaagtca aatggcacca taatccacgt caaaggcaag	840

cacctgtgcc cttccccgct cttccccgga cccagtaaac catttttgggt gctggttgtt	900
gtggggggcg tgctggcctg ctatagcctt ttgggtactg tagccttcat tatttttttg	960
gtcagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc	1020
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat	1080
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac	1140
caactgtata acgagctcaa cctgggacgc aggggaagagt atgacgtttt ggacaagcgc	1200
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc	1260
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga	1320
gagcggagaa ggggaaaagg gcacgacggg ttgtaccagg gactcagcac tgctacgaag	1380
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa	1425

<210> 214

<211> 474

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 214

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5				10					15		

His	Ala	Ala	Arg	Pro	Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val
			20					25					30		

Val	Gln	Pro	Gly	Arg	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe
		35					40					45			

Thr	Phe	Ser	Ser	Tyr	Gly	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys
	50					55					60				

Gly	Leu	Glu	Trp	Val	Ala	Val	Ile	Ser	Tyr	Asp	Gly	Ser	Asp	Lys	Tyr
65					70					75				80	

Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95

Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser
145 150 155 160

Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys
165 170 175

Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys
180 185 190

Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala
195 200 205

Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe
210 215 220

Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr
225 230 235 240

Cys Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys
245 250 255

Val Asp Phe Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
260 265 270

Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
275 280 285

Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val

290

295

300

Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
305 310 315 320

Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
325 330 335

Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
340 345 350

Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
355 360 365

Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
370 375 380

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
385 390 395 400

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
405 410 415

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
420 425 430

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
435 440 445

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
450 455 460

Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470

<210> 215

<211> 1359

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 215

caggtccagt tggtcgaaag tggcgggtggt gtagtgcagc cgggccgcag tttgaggctt	60
tcctgtgcgg cttcaggctt tactttttcc agctatggaa tgcactgggt gcggcaggcc	120
cccggcaaag gacttgagtg ggtggccgtc atttcttatg acggatcaga taagtactac	180
gtggacagcg tcaagggcag attcaccatc tctagggaca acagtaaaaa tagactctac	240
ctccagatga atagcctcag agctgaagac acggccgtct actattgtgc tcgggagcgg	300
tatagtggca gagactactg ggggcagggc acactcgta cagtgagtag cggcggagga	360
gggagtgggg gcggtggctc cgggtggagga ggttctgaga ttgttatgac ccagagtcct	420
gcgaccctct cagtcagccc cggggagcgc gcaactttgt cttgcagagc tagtcagtcc	480
gtgtcctctc ttctgacatg gtaccagcaa aagcccgggc aggtcccgcg ccttttgatc	540
tttggggctt caacaagagc cactgggatt cccgcacgat tctctggctc cgggagcgg	600
actggtttca ccctgacgat tagcagtctc cagagcgagg acttcgccgt atactactgc	660
cagcagtacg atacgtggcc attcactttt ggaccaggga ctaaagtgga ttttaagcgc	720
gccgccgctc tcgataacga aaagtcaa at ggaccataa tccacgtcaa aggcaagcac	780
ctgtgccctt ccccgctctt ccccggaacc agtaaaccat tttgggtgct ggttgttgtg	840
ggggggcgtgc tggcctgcta tagccttttg gtcactgtag ccttcattat tttttgggtc	900
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgcct	960
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg	1020
agcaggggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa	1080
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgtttttgga caagcgcaga	1140
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggctctctat	1200
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag	1260
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat	1320
acttatgacg ctctccacat gcaagccctg ccacctagg	1359

<210> 216

<211> 453
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 216

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly
115 120 125

Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140

Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160

Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175

Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205

Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220

Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240

Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
245 250 255

Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
260 265 270

Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
275 280 285

Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
290 295 300

Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
305 310 315 320

Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
325 330 335

Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
340 345 350

Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
355 360 365

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
370 375 380

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
385 390 395 400

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
405 410 415

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
420 425 430

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
435 440 445

Ala Leu Pro Pro Arg
450

<210> 217
<211> 1452
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 217
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctcgtgga gtctggcggc ggcgtggtcc agcccggccg gtccctgcgc 120
ctgtcctgcg ccgccagcgg gtttactttt tcctcctacg gcatgcactg ggtgcgccag 180
gctcccggca agggcctcga gtgggtcgcc gtgatctcat acgatgggtc agacaaatac 240
tatgtcgatt ctgttaaagg gcggtttacc atttcaagag ataactctaa gaataggctg 300
tatttgaga tgaacagcct gagggctgaa gataccgcag tgtactattg cgctagggag 360
cggtatagtg gccgcgatta ctggggacag ggtacactgg tgaccgtgag ctctgggggt 420
ggcgggaagcg ggggtggcgg aagcggcgga ggggtagtg aaattgtgat gaccagtc 480
ccggctacac tttcagtctc ccctggggag agagctacac tgtcatgcag agcgtcccag 540
tccgtctctt ctctccttac ctggtatcag cagaagccc gccaggctcc tcgactgctg 600
atcttcggtg cctccacaag ggcgaccggg attccagccc gcttctcagg ttctgggagc 660

ggaactgggtt tcactttgac aatcagttca ctgcagtcag aggatttcgc cgtgtactac	720
tgccagcaat acgacacatg gccattcact ttcggacccg gtaccaaagt cgatttcaag	780
agagccgcgg ccatcgaggt tatgtacca ccaccatatac tggacaatga aaaaagcaat	840
ggaaccatta tccatgtgaa gggtaaacac ctctgcccta gcccactttt ccctggccca	900
tcaaagccct tctgggtcct ggtggtcgtg ggggggtgtgc tggcctgtta cagccttctg	960
gtgacgggtt ctttcattat cttctgggtt agatccaaaa gaagccgcct gctccatagc	1020
gattacatga atatgactcc acgccgcctt ggccccacaa ggaaacacta ccagccttac	1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat	1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg	1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca	1260
agacgaaaaa acccccagga gggctctctat aatgagctgc agaaggataa gatggctgaa	1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg	1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg	1440
ccacctaggt aa	1452

<210> 218
 <211> 483
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 218
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
 20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
 35 40 45

Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60

Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr
65 70 75 80

Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95

Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser
145 150 155 160

Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys
165 170 175

Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys
180 185 190

Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala
195 200 205

Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe
210 215 220

Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr
225 230 235 240

Cys Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys
245 250 255

Val Asp Phe Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro

260

265

270

Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
 275 280 285

Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
 290 295 300

Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
 305 310 315 320

Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
 325 330 335

Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
 340 345 350

Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
 355 360 365

Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
 370 375 380

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
 385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
 405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
 420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
 435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
 450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
 465 470 475 480

Pro Pro Arg

<210> 219

<211> 1386

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 219

caggtgcagc tcgtggagtc tggcggcggc gtggtccagc ccggccggtc cctgcgctg	60
tcctgcgccg ccagcgggtt tactttttcc tcctacggca tgcactgggt gcgccaggct	120
cccggcaagg gcctcgagtg ggtcgccgtg atctcatagc atgggtcaga caaatactat	180
gtcgattctg ttaaagggcg gtttaccatt tcaagagata actctaagaa taggctgtat	240
ttgcagatga acagcctgag ggctgaagat accgcagtgt actattgcgc tagggagcgg	300
tatagtggcc gcgattactg gggacagggt acactgggtga ccgtgagctc tgggggtggc	360
ggaagcgggg gtggcgggaag cggcggaggg ggtagtga aa ttgtgatgac ccagtctccg	420
gctacacttt cagtctcccc tggggagaga gctacactgt catgcagagc gtcccagtcc	480
gtctcttctc tccttacctg gtatcagcag aagcccggcc aggctcctcg actgctgac	540
ttcgggtgcct ccacaagggc gaccgggatt ccagcccgt tctcagggtc tgggagcggg	600
actggtttca ctttgacaat cagttcactg cagtcagagg atttcgccgt gtactactgc	660
cagcaatacg acacatggcc attcactttc ggacccggta ccaaagtcga tttcaagaga	720
gccgcggcca tcgaggttat gtaccaccca ccatatctgg acaatgaaaa aagcaatgga	780
accattatcc atgtgaaggg taaacacctc tgccctagcc cactttttccc tggcccatca	840
aagcccttct gggctcttggg ggtcgtgggg ggtgtgctgg cctgttacag ccttctgggtg	900
acggttgctt tcattatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat	960
tacatgaata tgactccacg ccgccctggc ccacaagga aacactacca gccttacgca	1020
ccacctagag atttcgtgc ctatcggagc aggggtgaagt tttccagatc tgcagatgca	1080

ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1140
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1200
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1260
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1320
cagggactca gcaactgtac gaaggatact tatgacgctc tccacatgca agccctgcca 1380
cctagg 1386

<210> 220

<211> 462

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 220

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125

Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140

Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160

Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175

Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205

Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220

Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240

Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
245 250 255

Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
260 265 270

Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
275 280 285

Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
290 295 300

Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
305 310 315 320

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
325 330 335

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
340 345 350

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
355 360 365

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
370 375 380

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
385 390 395 400

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
405 410 415

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
420 425 430

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
435 440 445

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460

<210> 221
<211> 1533
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 221
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttggttga atcaggaggg ggtgtggtgc aaccgggtcg gtcactgcgc 120
ctcagttgtg ctgcttccgg gtttactttc agctcatatg ggatgcactg ggtacggcag 180
gctccaggta aaggcttgga atgggtggcg gtgatcagct atgacggctc tgacaaatat 240

tatgtggact ccgtgaaagg cagattcacc atcagtcgag acaactcaaa gaatagactc	300
tacttgcaga tgaatagcct ccggggccgaa gatactgcag tctattattg cgcccgggag	360
cgctacagtg gaagagacta ttggggggcaa ggaactcttg tcacagtctc atctggcggc	420
ggcggcagcg gtggggggcgg atctggcggg ggcggcagcg aaatcgttat gactcagagt	480
cctgccacac tgagcgttag ccctggtgag agagcaacac ttagctgcag agctagtcag	540
agtgtttcca gtcttttgac atggtaccaa cagaagcccg gtcaagctcc acgactgctc	600
atcttcggtg catccacccg cgcaaccggg ataccgccc ggttttccgg ttctggaagt	660
ggcacaggat tcacgctcac catttcttct ctgcagtctg aagactttgc cgtgtattac	720
tgccagcagt acgatacctg gccctttacc tttggcccag gtactaaagt ggattttaaa	780
cgagctgctg cactttccaa tagtattatg tacttttcac attttgtgcc cgtgttcctg	840
cctgcgaagc ctacgacaac ccagcccct aggccgccc caccggcccc aactattgcc	900
tcccagccat tgtctctgag acccgaagct tgcagacctg ctgctggagg cgccgttcac	960
acccgaggat tggatttcgc atgtgacatt tacatctggg cccctttggc cggaacctgc	1020
ggtgtgctgc tgctgtcact cgtgattaca ctttactgca accaccgaaa cagatccaaa	1080
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgcc tggccccaca	1140
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagcagggtg	1200
aagttttcca gatctgcaga tgcaccagcg tatcagcagg gccagaacca actgtataac	1260
gagctcaacc tgggacgcag ggaagagtat gacgttttgg acaagcgcag aggacgggac	1320
cctgagatgg gtggcaaacc aagacgaaaa aacccccagg agggctctta taatgagctg	1380
cagaaggata agatggctga agcctattct gaaataggca tgaaaggaga gcggagaagg	1440
ggaaaagggc acgacggttt gtaccaggga ctcagcactg ctacgaagga tacttatgac	1500
gctctccaca tgcaagccct gccacctagg taa	1533

<210> 222

<211> 510

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 222

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45

Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60

Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr
65 70 75 80

Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95

Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125

Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140

Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser
145 150 155 160

Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys
165 170 175

Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys
180 185 190

Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala

195

200

205

Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe
 210 215 220

Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr
 225 230 235 240

Cys Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys
 245 250 255

Val Asp Phe Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
 260 265 270

Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
 275 280 285

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 290 295 300

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 305 310 315 320

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
 325 330 335

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
 340 345 350

Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
 355 360 365

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
 370 375 380

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
 385 390 395 400

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
 405 410 415

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
420 425 430

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
435 440 445

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
450 455 460

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
465 470 475 480

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
485 490 495

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
500 505 510

<210> 223

<211> 1467

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 223

caggtgcagt tggttgaatc aggaggggggt gtggtgcaac ccggtcggtc actgcgcctc	60
agttgtgctg cttccggggtt tacttttcagc tcatatggga tgactgggt acggcaggct	120
ccaggtaaag gcttggaatg ggtggcggtg atcagctatg acggctctga caaatattat	180
gtggactccg tgaaaggcag attcaccatc agtcgagaca actcaaagaa tagactctac	240
ttgcagatga atagcctccg ggccgaagat actgcagtct attattgcgc ccgggagcgc	300
tacagtggaa gagactattg ggggcaagga actcttgtca cagtctcatc tggcggcggc	360
ggcagcggtg ggggcggatc tggcgggggc ggcagcgaaa tcgttatgac tcagagtcct	420
gccacactga gcgttagccc tggtagagaga gcaacactta gctgcagagc tagtcagagt	480

gtttccagtc ttttgacatg gtaccaacag aagcccggtc aagctccacg actgctcatc	540
ttcgggtgcat ccacccgcgc aaccgggata cccgcccggc tttccgggtc tggaagtggc	600
acaggattca cgctcaccat ttcttctctg cagtctgaag actttgccgt gtattactgc	660
cagcagtacg atacctggcc ctttaccttt ggcccaggta ctaaagtgga ttttaaacga	720
gctgctgcac tttccaatag tattatgtac ttttcacatt ttgtgcccgt gttcctgcct	780
gcgaagccta cgacaacccc agcccctagg ccgcccacac cggccccaac tattgcctcc	840
cagccattgt ctctgagacc cgaagcttgc agacctgctg ctggaggcgc cgttcacacc	900
cgaggattgg atttcgcatg tgacatttac atctggggccc ctttggccgg aacctgcggt	960
gtgctgctgc tgtcactcgt gattacactt tactgcaacc accgaaacag atccaaaaga	1020
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg cccacaagg	1080
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag cagggtgaag	1140
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag	1200
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct	1260
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag	1320
aaggataaga tggctgaagc ctattctgaa atagggcatga aaggagagcg gagaagggga	1380
aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct	1440
ctccacatgc aagccctgcc acctagg	1467

<210> 224

<211> 489

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 224

Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg
1				5					10					15	

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
			20					25					30		

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125

Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140

Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160

Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175

Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190

Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205

Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220

Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240

Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
245 250 255

Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
325 330 335

Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
340 345 350

Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
355 360 365

Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
370 375 380

Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
385 390 395 400

Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
405 410 415

Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
420 425 430

Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
435 440 445

Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460

Gly	Leu	Tyr	Gln	Gly	Leu	Ser	Thr	Ala	Thr	Lys	Asp	Thr	Tyr	Asp	Ala
465					470					475					480

Leu	His	Met	Gln	Ala	Leu	Pro	Pro	Arg
					485			

<210> 225
 <211> 1425
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
 <223> anti-CLL-1 CAR construct

<400> 225	
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccggagattg tgatgaccca gtcccctgct accctgtccg tcagtccggg cgagagagcc	120
accttgtcat gccgggccag ccagtccgtc agcagtctcc tgacttggtg tcagcaaaaa	180
ccagggcagg caccgcggct tttgattttt ggtgcaagca cacgcgccac tggcattcca	240
gctaggtttt ctggaagtgg atctgggaca ggcttcactc tgacaatcag tagcctgcag	300
agtgaggact ttgctgttta ctactgtcaa cagtacgaca cctggccatt cacattcggg	360
cccggcacca aggtcgactt caagaggggc ggtggagggt cagggtgggtg cgggtcaggc	420
ggcgggtgggt ctcaggttca actggtggaa tcagggtggcg gcgttgtcca accggggcga	480
tcacttcgac tttcctgtgc tgcctcaggc tttacttttt catcctatgg gatgcactgg	540
gttcggcagg ctcccggaaa aggactcgag tgggttgagc tgatctctta cgatgggtca	600
gacaagtatt atgtggactc agtcaagggg agattcacia taagccgaga caactccaaa	660
aaccggcctt atctccagat gaacagcctt agagcggaag ataccgcggt atactactgt	720
gcccgcgaga ggtattccgg cagagactac tggggacagg gcacactggg caccgtgagt	780
tctgccgcag cgctcgataa cgaaaagagc aacggaacca ttatccacgt taagggcaag	840
cacctgtgcc ccagtcccct cttcccagga ccatctaaac ctttctgggt tctggtagta	900
gttggagggg tccttgcatt ttactccctt ttggtcaccg tcgccttcat tttttctgg	960

gtgagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc	1020
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat	1080
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac	1140
caactgtata acgagctcaa cctgggacgc aggggaagagt atgacgtttt ggacaagcgc	1200
agaggacggg accctgagat ggggtggcaaa ccaagacgaa aaaaccccca ggagggtctc	1260
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga	1320
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag	1380
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa	1425

<210> 226

<211> 474

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 226

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5					10					15	

His	Ala	Ala	Arg	Pro	Glu	Ile	Val	Met	Thr	Gln	Ser	Pro	Ala	Thr	Leu
			20					25					30		

Ser	Val	Ser	Pro	Gly	Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln
			35				40					45			

Ser	Val	Ser	Ser	Leu	Leu	Thr	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala
			50			55					60				

Pro	Arg	Leu	Leu	Ile	Phe	Gly	Ala	Ser	Thr	Arg	Ala	Thr	Gly	Ile	Pro
65					70					75					80

Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Gly	Phe	Thr	Leu	Thr	Ile
				85					90					95	

Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110

Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125

Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190

Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
210 215 220

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
225 230 235 240

Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
245 250 255

Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
260 265 270

Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
275 280 285

Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
290 295 300

Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp

305		310		315		320									
Val	Arg	Ser	Lys	Arg	Ser	Arg	Leu	Leu	His	Ser	Asp	Tyr	Met	Asn	Met
				325					330					335	
Thr	Pro	Arg	Arg	Pro	Gly	Pro	Thr	Arg	Lys	His	Tyr	Gln	Pro	Tyr	Ala
			340					345					350		
Pro	Pro	Arg	Asp	Phe	Ala	Ala	Tyr	Arg	Ser	Arg	Val	Lys	Phe	Ser	Arg
		355					360					365			
Ser	Ala	Asp	Ala	Pro	Ala	Tyr	Gln	Gln	Gly	Gln	Asn	Gln	Leu	Tyr	Asn
	370					375					380				
Glu	Leu	Asn	Leu	Gly	Arg	Arg	Glu	Glu	Tyr	Asp	Val	Leu	Asp	Lys	Arg
385					390					395					400
Arg	Gly	Arg	Asp	Pro	Glu	Met	Gly	Gly	Lys	Pro	Arg	Arg	Lys	Asn	Pro
			405						410					415	
Gln	Glu	Gly	Leu	Tyr	Asn	Glu	Leu	Gln	Lys	Asp	Lys	Met	Ala	Glu	Ala
			420					425					430		
Tyr	Ser	Glu	Ile	Gly	Met	Lys	Gly	Glu	Arg	Arg	Arg	Gly	Lys	Gly	His
		435					440					445			
Asp	Gly	Leu	Tyr	Gln	Gly	Leu	Ser	Thr	Ala	Thr	Lys	Asp	Thr	Tyr	Asp
	450					455					460				
Ala	Leu	His	Met	Gln	Ala	Leu	Pro	Pro	Arg						
465					470										

<210> 227

<211> 1359

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 227

gagattgtga tgaccagtc ccctgctacc ctgtccgtca gtccgggcga gagagccacc	60
ttgtcatgcc gggccagcca gtccgtcagc agtctcctga cttggtatca gcaaaaacca	120
gggcaggcac cgcggctttt gatTTTTTggt gcaagcacac gcgccactgg cattccagct	180
aggttttctg gaagtggatc tgggacaggc ttcactctga caatcagtag cctgcagagt	240
gaggactttg ctgtttacta ctgtcaacag tacgacacct ggccattcac attcgggccc	300
ggcaccaagg tcgacttcaa gaggggcggt ggaggttcag gtggtggcgg gtcaggcggc	360
ggtgggtctc aggttcaact ggtggaatca ggtggcggcg ttgtccaacc ggggcgatca	420
cttcgacttt cctgtgctgc ctccaggcttt actttttcat cctatgggat gcactgggtt	480
cggcaggctc ccggaaaagg actcgagtgg gttgcagtga tctcttacga tggctcagac	540
aagtattatg tggactcagt caaggggaga ttcacaataa gccgagacaa ctccaaaaac	600
cggctttatc tccagatgaa cagccttaga gcggaagata ccgcggtata ctactgtgcc	660
cgcgagaggt attccggcag agactactgg ggacagggca cactggtcac cgtgagttct	720
gccgcagcgc tcgataacga aaagagcaac ggaaccatta tccacgttaa gggcaagcac	780
ctgtgccccca gtcccctctt cccaggacca tctaaacctt tctgggttct ggtagtagtt	840
ggaggggtcc ttgcatgtta ctcccttttg gtcaccgtcg ccttcattat tttctgggtg	900
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgcct	960
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg	1020
agcagggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa	1080
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgttttgga caagcgcaga	1140
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggctcttat	1200
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag	1260
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat	1320
acttatgacg ctctccacat gcaagccctg ccacctagg	1359

<210> 228

<211> 453

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 228

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95

Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
100 105 110

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
115 120 125

Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140

Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160

Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175

Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190

Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205

Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220

Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240

Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
245 250 255

Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
260 265 270

Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
275 280 285

Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
290 295 300

Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
305 310 315 320

Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
325 330 335

Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
340 345 350

Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
355 360 365

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
370 375 380

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
385 390 395 400

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
405 410 415

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
420 425 430

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
435 440 445

Ala Leu Pro Pro Arg
450

<210> 229

<211> 1452

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 229

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccggagatcg tcatgacaca gagtccagct accctgagcg tgtcccctgg agagagagcc	120
accctgtcct gtagggctag tcagagtgtg tccagcctcc tcacctggta tcaacagaag	180
cctggtcaag ctccccggct gcttatcttc ggggccagca cgcgagccac aggcatcccg	240
gccagattct ctggctctgg cagtggcacc gggttcactc tcacgatctc atccctgcag	300
tcagaggatt tcgctgtgta ttactgtcag cagtacgata catggccctt caccttcggc	360
ccgggcacaa aagtagattt caagcgcggc ggcgggggta gtgggggcgg gggatcagga	420
ggagggggct cccaagtaca gctggttgag agcggcggcg gggtggttca gcccgggcgc	480
agcctcaggc tgagttgcgc agcatcagga ttcacattca gttcttatgg aatgcattgg	540
gtcagacagg ctccccggaa gggccttgaa tgggtggcag tcattagcta cgacggaagc	600
gataagtact atgtggactc agttaaaggg agatttacta tcagccgcga caattccaaa	660
aacagattgt atttgcagat gaactccctc agggcggagg aactgctgt atattactgc	720
gcacgagaga gatactccgg ccgagactat tggggccaag gaacattggt aactgtgagc	780

tccgccgcag ctattgaggt catgtacccc ccaccttatc tcgataatga gaagagtaat 840
gggactataa ttcacgtaaa gggcaaacac ctgtgccctt ccccgctgtt tccaggtcca 900
agtaagccgt tctgggtcct ggttgtggtg ggaggggtgc tggcctgcta ttctctgttg 960
gttaccgtgg cctttatcat tttctgggtg agatccaaaa gaagccgcct gctccatagc 1020
gattacatga atatgactcc acgccgcctt ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcaggggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttggg caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggctctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452

<210> 230
<211> 483
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<220>
<223> anti-CLL-1 CAR construct

<400> 230
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30

Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45

Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60

Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
85 90 95

Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110

Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125

Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190

Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
210 215 220

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
225 230 235 240

Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
245 250 255

Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
260 265 270

Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly

275

280

285

Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
 290 295 300

Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
 305 310 315 320

Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
 325 330 335

Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
 340 345 350

Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
 355 360 365

Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
 370 375 380

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
 385 390 395 400

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
 405 410 415

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
 420 425 430

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
 435 440 445

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
 450 455 460

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
 465 470 475 480

Pro Pro Arg

<210> 231
<211> 1386
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 231
gagatcgtca tgacacagag tccagctacc ctgagcgtgt cccctggaga gagagccacc 60
ctgtcctgta gggctagtca gagtgtgtcc agcctcctca cctggatatca acagaagcct 120
ggtcaagctc cccggctgct tatcttcggg gccagcacgc gagccacagg catcccggcc 180
agattctctg gctctggcag tggcaccggg ttactctca cgatctcatc cctgcagtca 240
gaggatttcg ctgtgtatta ctgtcagcag tacgatacat ggcccttcac cttcggccccg 300
ggcacaaaag tagatttcaa gcgcggcggc gggggtagtg ggggcggggg atcaggagga 360
gggggctccc aagtacagct ggttgagagc ggcggcgggg tggttcagcc cgggcgcagc 420
ctcaggctga gttgcgcagc atcaggattc acattcagtt cttatggaat gcattgggtc 480
agacaggctc ccgggaaggg cttgaatgg gtggcagtca ttagctacga cggaagcgat 540
aagtactatg tggactcagt taaagggaga ttactatca gccgcgacaa ttcaaaaaac 600
agattgtatt tgcagatgaa ctccctcagg gcggaggaca ctgctgtata ttactgcgca 660
cgagagagat actccggccg agactattgg ggccaaggaa cattggtaac tgtgagctcc 720
gccgcagcta ttgaggtcat gtacccccca cttatctcg ataatgagaa gagtaatggg 780
actataattc acgtaaaggg caaacacctg tgcccttccc cgctgtttcc aggtccaagt 840
aagccgttct gggtcctggt tgtggtggga ggggtgctgg cctgctattc tctgttggtt 900
accgtggcct ttatcatttt ctgggtgaga tccaaaagaa gccgcctgct ccatagcgat 960
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1020
ccacctagag atttcgctgc ctatcggagc aggggtgaagt tttccagatc tgcagatgca 1080
ccagcgtatc agcagggccca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1140
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1200

cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc	1260
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac	1320
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca	1380
cctagg	1386

<210> 232
 <211> 462
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> anti-CLL-1 CAR construct

<400> 232
 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
 20 25 30
 Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
 85 90 95
 Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
 100 105 110
 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
 115 120 125

Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140

Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160

Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175

Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190

Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205

Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220

Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240

Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
245 250 255

Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
260 265 270

Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
275 280 285

Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
290 295 300

Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
305 310 315 320

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
325 330 335

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
340 345 350

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
355 360 365

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
370 375 380

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
385 390 395 400

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
405 410 415

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
420 425 430

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
435 440 445

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460

<210> 233

<211> 1533

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> anti-CLL-1 CAR construct

<400> 233

atggcactcc ccgtaactgc tctgctgctg ccgttgcat tgctcctgca cgccgcacgc 60

ccggaaatag tgatgactca gtccccggcc accctcagcg tgtcccccg ggagcgagcg 120

accctgtcat gcagggcttc ccagagtgtc agctccctgc tcacttggtgta tcagcaaaag 180

ccggggcagg ctccccgcct cctcatcttc ggggcatcaa ctagggccac cggcattcct 240

gcaagatddd ccgggtctgg cagcggcacc ggcttcaccc ttaccattag ctctctgcag 300

tctgaggact tcgccgttta ctattgtcag cagtatgata cttggccctt taccttcggt 360

cccggaacta aggtggactt caagcgcggg gggggtggat ctggaggtgg tggctccggg	420
ggcgggtggaa gccaggtcca gttggttgag agcggcggcg gagtggtgca gcccgggagg	480
tccttgcggc tgagctgtgc agcctccggt tttacttttt ctagctatgg aatgcattgg	540
gtaagacagg ctcccgaaa aggcctcgag tgggtggcgg tcattagcta tgatggatct	600
gataaatact atgtggactc agttaagggg cgcttcacaa tctcaagaga caatagcaaa	660
aatagactgt acctgcagat gaatagtctg cgcgccgagg aactgcccgt gtactactgc	720
gcccgcgaga gatacagcgg acgggattac tggggccagg gtaccctcgt aacggtgtcc	780
tccgctgccg cccttagcaa cagcattatg tacttttctc atttcgtgcc agtctttctc	840
ccagcaaagc ccaccactac cccggcccc aggccgccta ctcctgcccc cactatcgcg	900
tctcagcctc tctccttgcg gcccgaggcc tgccggccag ccgcaggggg cgccgtacat	960
actcgggggtt tggatttcgc ttgcgacata tatatttggg cccccctcgc cggcacatgt	1020
ggagtgctgc tcctgagtct cgttataacc ctctattgca accatagaaa cagatccaaa	1080
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgcc tggccccaca	1140
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagcagggtg	1200
aagttttcca gatctgcaga tgcaccagcg tatcagcagg gccagaacca actgtataac	1260
gagctcaacc tgggacgcag ggaagagtat gacgttttgg acaagcgag aggacgggac	1320
cctgagatgg gtggcaaacc aagacgaaaa aacccccagg agggctctta taatgagctg	1380
cagaaggata agatggctga agcctattct gaaataggca tgaaaggaga gcggagaagg	1440
ggaaaagggc acgacggttt gtaccaggga ctcagcactg ctacgaagga tacttatgac	1500
gctctccaca tgcaagccct gccacctagg taa	1533

<210> 234

<211> 510

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 234

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30

Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45

Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60

Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
85 90 95

Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110

Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125

Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190

Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr

210

215

220

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 225 230 235 240

Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
 245 250 255

Val Thr Val Ser Ser Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
 260 265 270

Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
 275 280 285

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 290 295 300

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 305 310 315 320

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
 325 330 335

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
 340 345 350

Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
 355 360 365

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
 370 375 380

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
 385 390 395 400

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
 405 410 415

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
 420 425 430

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
435 440 445

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
450 455 460

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
465 470 475 480

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
485 490 495

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
500 505 510

<210> 235
<211> 1467
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> anti-CLL-1 CAR construct

<400> 235
gaaatagtga tgactcagtc cccggccacc ctcagcgtgt cccccgggga gcgagcgacc 60
ctgtcatgca gggcttccca gagtgtcagc tccctgctca cttggtatca gcaaaagccg 120
gggcaggctc cccgcctcct catcttcggg gcatcaacta gggccaccgg cattcctgca 180
agattttccg ggtctggcag cggcaccggc ttcaccctta ccattagctc tctgcagtct 240
gaggacttcg ccgtttacta ttgtcagcag tatgatactt ggccctttac cttcggtccc 300
ggaactaagg tggacttcaa gcgcgggggg ggtggatctg gaggtggtgg ctccgggggc 360
ggtggaagcc aggtccagtt ggttgagagc ggcggcggag tgggtgcagcc cgggaggtcc 420
ttgcggctga gctgtgcagc ctccggtttt actttttcta gctatggaat gcattgggta 480
agacaggctc ccggaagagg cctcagatgg gtggcgggtca ttagctatga tggatctgat 540
aaatactatg tggactcagt taaggggagc ttcacaatct caagagacaa tagcaaaaat 600

agactgtacc tgcagatgaa tagtctgcgc gccgaggaca ctgccgtgta ctactgcgcc	660
cgcgagagat acagcggacg ggattactgg ggccagggta ccctcgtaac ggtgtcctcc	720
gctgccgccc ttagcaacag cattatgtac ttttctcatt tcgtgccagt ctttctccca	780
gcaaagccca ccactacccc ggccccaggg ccgcctactc ctgccccac tatcgcgtct	840
cagcctctct ccttgcggcc cgaggcctgc cggccagccg cagggggcgc cgtacatact	900
cggggtttgg atttcgcttg cgacatatat atttgggccc ccctcgccgg cacatgtgga	960
gtgctgctcc tgagtctcgt tataaccctc tattgcaacc atagaaacag atccaaaaga	1020
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg cccacaagg	1080
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag caggggtgaag	1140
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag	1200
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct	1260
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag	1320
aaggataaga tggctgaagc ctattctgaa ataggcatga aaggagagcg gagaagggga	1380
aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct	1440
ctccacatgc aagccctgcc acctagg	1467

<210> 236

<211> 489

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> anti-CLL-1 CAR construct

<400> 236

Glu	Ile	Val	Met	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Val	Ser	Pro	Gly
1				5				10						15	

Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser	Val	Ser	Ser	Leu
			20					25					30		

Leu	Thr	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile
		35					40					45			

Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95

Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
100 105 110

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
115 120 125

Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140

Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160

Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175

Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190

Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205

Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220

Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240

Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
245 250 255

Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
260 265 270

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
275 280 285

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
290 295 300

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
325 330 335

Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
340 345 350

Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
355 360 365

Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
370 375 380

Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
385 390 395 400

Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
405 410 415

Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
420 425 430

Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
435 440 445

Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460

Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
465 470 475 480

Leu His Met Gln Ala Leu Pro Pro Arg
485

<210> 237
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> scFv G4s linker

<400> 237
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 238
<211> 288
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
polynucleotide

<220>
<223> CD8 extracellular

<400> 238
gctgcagcat tgagcaactc aataatgtat tttagtcact ttgtaccagt gttcttgccg 60
gctaagccta ctaccacacc cgctccacgg ccacctaccc cagctcctac catcgcttca 120
cagcctctgt ccctgcgccc agaggcttgc cgaccggccg cagggggcgc tgttcatacc 180
agaggactgg atttcgcctg cgatatctat atctgggcac ccctggccgg aacctgcggc 240
gtactcctgc tgtccctggt catcacgctc tattgtaatc acaggaac 288

<210> 239
<211> 96
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> Description of Combined DNA/RNA Molecule: Synthetic polypeptide

<220>

<223> CD8 extracellular

<400> 239

Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
1 5 10 15

Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
20 25 30

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
35 40 45

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
50 55 60

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
65 70 75 80

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
85 90 95

<210> 240

<211> 294

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> extracellular and intracellular domains

<400> 240

cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60

tcacccttgt tccctggtcc atccaagcca ttctgggtgt tggctgtagt ggggtggagtc 120

ctcgcttggt actctctgct cgtcaccgtg gcttttataa tcttctgggt tagatccaaa	180
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca	240
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagc	294

<210> 241
 <211> 98
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> extracellular and intracellular domains

<400> 241
 Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
 1 5 10 15

His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
 20 25 30

Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
 35 40 45

Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
 50 55 60

Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
 65 70 75 80

Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
 85 90 95

Arg Ser

<210> 242
 <211> 1482
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polynucleotide

<220>

<223> 10E3_CHD_DNA

<400> 242

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcaggtga ccctcaaaga gtctggaccc gtgctcgtaa aacctacgga gaccctgaca	120
ctcacctgca cagtctccgg cttcagcctc atcaatgcca ggatgggagt ttcctggatc	180
aggcaaccgc ccggaaggc cctggaatgg ctgcacata ttttcagtaa cgctgaaaaa	240
agctatcgga cttctctgaa aagtcggctc acgattagta aggacacatc caagagccaa	300
gtggtgctta cgatgactaa catggaccct gtggatactg caacctatta ctgtgctcga	360
atccctgggtt atggcggaag tggggactac cactactacg gtatggatgt ctggggccaa	420
gggaccacgg ttactgtttc aagcggaggg ggagggagtg ggggtggcgg atctggcggg	480
ggaggcagcg atatccagat gacgcagtcc ctagttcac tttccgcatc cctgggggat	540
cgggttacca ttacatgccg cgcgtcacag ggtatccgga atgatctggg atggtaccag	600
cagaagccgg gaaaggctcc taagcgcctc atctacgcca gctccaccct gcagagtgga	660
gtgccctccc ggttttcagg cagtggctcc ggtacggagt ttactcttac aattagcagc	720
ctgcagccag aagattttgc aacttactac tgtttgcagc ataataattt cccctggacc	780
tttggtcagg gcaccaaggt ggagatcaaa agagcagccg ccatcgaagt aatgtatccc	840
ccccgtacc ttgacaatga gaagtcaa at ggaaccatta tccatgttaa gggcaaacac	900
ctctgccctt ctccactgtt ccctggccct agtaagccgt tttgggtgct ggtggtagtc	960
ggtgggggtgc tggcttggtta ctctcttctc gtgaccgtcg cttttataat cttttgggtc	1020
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgcct	1080
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg	1140
agccgagtga aattttctag atcagctgat gctccgcct atcagcaggg acagaatcaa	1200
ctttacaatg agctgaacct gggtcgcaga gaagagtacg acgttttgga caaacgccgg	1260
ggccgagatc ctgagatggg ggggaagccg agaaggaaga atcctcaaga aggcctgtac	1320
aacgagcttc aaaaagacaa aatggctgag gcgtactctg agatcggcat gaagggcgag	1380

cggagacgag gcaaggggtca cgatggcttg tatcagggcc tgagtacagc cacaaaggac 1440
acctatgacg ccctccacat gcaggcactg cccccacgct ag 1482

<210> 243
<211> 493
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic polypeptide

<220>
<223> 10E3_CHD_AA

<400> 243
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu
20 25 30

Val Lys Pro Thr Glu Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe
35 40 45

Ser Leu Ile Asn Ala Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro
50 55 60

Gly Lys Ala Leu Glu Trp Leu Ala His Ile Phe Ser Asn Ala Glu Lys
65 70 75 80

Ser Tyr Arg Thr Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr
85 90 95

Ser Lys Ser Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp
100 105 110

Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Tyr Gly Gly Asn Gly
115 120 125

Asp Tyr His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val
130 135 140

Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
145 150 155 160

Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
165 170 175

Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile
180 185 190

Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
195 200 205

Arg Leu Ile Tyr Ala Ser Ser Thr Leu Gln Ser Gly Val Pro Ser Arg
210 215 220

Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
225 230 235 240

Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Asn
245 250 255

Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala
260 265 270

Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys
275 280 285

Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser
290 295 300

Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val
305 310 315 320

Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile
325 330 335

Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
340 345 350

Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
355 360 365

Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys
370 375 380

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
385 390 395 400

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
405 410 415

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
420 425 430

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
435 440 445

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
450 455 460

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
465 470 475 480

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 244
<211> 1455
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>
<223> 10E3_THD_DNA

<400> 244
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaagtta ctttgaagga gtctggacct gtactggtga agccaaccga gacactgaca 120
ctcacgtgta cagtgagtgg tttttccttg atcaacgcaa ggatgggCGT cagctggatc 180
aggcaacccc ctggcaaggc tctggaatgg ctgctcaca tattcagcaa tgccgaaaaa 240

agctaccgga caagcctgaa atcccgctg actattttcca aggacacttc taagtctcag	300
gtggtgctga ccatgaccaa catggacccg gtggacaccg ccacctatta ctgcgcaaga	360
atccctgggt atggtgggaa tgggtgactac cattattatg ggatggatgt gtgggggcaa	420
ggcacaaccg taacggtctc aagcgggtggg ggaggctcag ggggcggagg ctccggaggt	480
ggcgggtccg acattcagat gacccaaagc ccgtccagcc tgtccgccag cctgggagat	540
agagtgacaa tcacgtgtag agcttcccaa gggataagaa atgatctcgg gtggtatcag	600
cagaagcccg gcaaagcccc caaaaggctt atatatgcta gtagtacact gcagtctgga	660
gttccttccc gattttcagg tagcggctcc ggtacagagt tcaccctcac gataagctca	720
ctccagcctg aggatttcgc aacgtactac tgcctccagc acaacaattt tccctggact	780
ttcggccagg gcaccaaggt ggagatcaag agggccgctg cccttgataa tgaaaagtca	840
aacggaacaa tcattcacgt gaagggcaag cacctctgtc cgtcaccctt gttccctggt	900
ccatccaagc cattctgggt gttggtcgta gtgggtggag tcctcgcttg ttactctctg	960
ctcgtcaccg tggcttttat aatcttctgg gttagatcca aaagaagccg cctgctccat	1020
agcgattaca tgaatatgac tccacgccgc cctggcccca caaggaaaca ctaccagcct	1080
tacgcaccac ctagagattt cgctgcctat cggagccgag tgaaattttc tagatcagct	1140
gatgctcccg cctatcagca gggacagaat caactttaca atgagctgaa cctgggtcgc	1200
agagaagagt acgacgtttt ggacaaacgc cggggccgag atcctgagat gggggggaag	1260
ccgagaagga agaatcctca agaaggcctg tacaacgagc ttcaaaaaga caaaatggct	1320
gaggcgtagt ctgagatcgg catgaagggc gagcggagac gaggcaaggg tcacgatggc	1380
ttgtatcagg gcctgagtac agccacaaag gacacctatg acgccctcca catgcaggca	1440
ctgccccac gctag	1455

<210> 245

<211> 484

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> 10E3_THD_AA

<400> 245

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu
20 25 30

Val Lys Pro Thr Glu Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe
35 40 45

Ser Leu Ile Asn Ala Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro
50 55 60

Gly Lys Ala Leu Glu Trp Leu Ala His Ile Phe Ser Asn Ala Glu Lys
65 70 75 80

Ser Tyr Arg Thr Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr
85 90 95

Ser Lys Ser Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp
100 105 110

Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Tyr Gly Gly Asn Gly
115 120 125

Asp Tyr His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val
130 135 140

Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
145 150 155 160

Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
165 170 175

Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile
180 185 190

Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
195 200 205

Arg Leu Ile Tyr Ala Ser Ser Thr Leu Gln Ser Gly Val Pro Ser Arg
210 215 220

Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
225 230 235 240

Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Asn
245 250 255

Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala
260 265 270

Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys
275 280 285

Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro
290 295 300

Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
305 310 315 320

Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser
325 330 335

Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly
340 345 350

Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala
355 360 365

Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala
370 375 380

Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
385 390 395 400

Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu
405 410 415

Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn

420

425

430

Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
 435 440 445

Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
 450 455 460

Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala
 465 470 475 480

Leu Pro Pro Arg

<210> 246

<211> 1464

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 polynucleotide

<220>

<223> 8B5_CHD_DNA

<400> 246

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcagatcc agttggtgga atcagggggc ggtgtggtgc agccgggtag gagcctgaga	120
ctgtcatgcg tggcgtctgg cttcacattc aagaactacg gcatgcactg ggtgcgacag	180
gccccggaa agggtttggga gtgggtcgcc gtgatctggt acgacggatc taatgagtat	240
tacggagatc ctgtgaaggg aaggttcacc atctcccgcg acaatagcaa aaatatgctc	300
tacctgcaaa tgaactcact cagggcggat gatacggcgg tctactattg cgctcgctca	360
gggattgctg tggccggcgc attcgattac tggggacagg gtaccctggt gacagtatca	420
agcggaggcg gcggctctgg cggcggcgga tctggcgggg ggggaagtga gattgtgttg	480
acacagtctc ccgataccct gtcactgtca cccggcgaga aggcaacgct gagttgcaga	540
gcaagccagt cagtctcctc ttcttttctg gcctggatatc agcaaaaacc aggtcaggca	600
ccatctctcc tgatttacgt tgccagcaga cgggcggctg gcattcccga caggttctct	660

ggaagcggat ctgggaccga ttttaccctg acaattagcc gcttggagcc cgaagacttt	720
ggtatgtttt actgccagca ctacggaagg acacctttca catttggccc gggcacgaaa	780
gtcgatataa aacgcgcagc cgccattgaa gtaatgtacc caccacctta tttggacaat	840
gaaaagtcca atggtaccat tattcacgtc aagggaagc atctctgtcc aagccctctg	900
ttccccggcc cctccaaacc attctgggtg ctggtggtcg tcggcggagt tctggcctgc	960
tattctctgc tcgtgactgt tgcattcatc attttctggg tgagatccaa aagaagccgc	1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac	1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagccgagt gaaattttct	1140
agatcagctg atgctcccg cctatcagcag ggacagaatc aactttacaa tgagctgaac	1200
ctgggtcgca gagaagagta cgacgttttg gacaaacgcc ggggccgaga tcctgagatg	1260
ggggggaagc cgagaaggaa gaatcctcaa gaaggcctgt acaacgagct tcaaaaagac	1320
aaaatggctg aggcgtactc tgagatcggc atgaagggcg agcggagacg aggcaagggt	1380
cacgatggct tgtatcaggg cctgagtaca gccacaaagg acacctatga cgccctccac	1440
atgcaggcac tgccccacg ctag	1464

<210> 247

<211> 487

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<223> 8B5_CHD_AA

<400> 247

Met	Ala	Leu	Pro	Val	Thr	Ala	Leu	Leu	Leu	Pro	Leu	Ala	Leu	Leu	Leu
1				5				10					15		

His	Ala	Ala	Arg	Pro	Gln	Ile	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val
			20					25					30		

Val	Gln	Pro	Gly	Arg	Ser	Leu	Arg	Leu	Ser	Cys	Val	Ala	Ser	Gly	Phe
		35					40					45			

Thr Phe Lys Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60

Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Glu Tyr
65 70 75 80

Tyr Gly Asp Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95

Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr
100 105 110

Ala Val Tyr Tyr Cys Ala Arg Ser Gly Ile Ala Val Ala Gly Ala Phe
115 120 125

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu
145 150 155 160

Thr Gln Ser Pro Asp Thr Leu Ser Leu Ser Pro Gly Glu Lys Ala Thr
165 170 175

Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala Trp
180 185 190

Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ser Leu Leu Ile Tyr Val Ala
195 200 205

Ser Arg Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser
210 215 220

Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe
225 230 235 240

Gly Met Phe Tyr Cys Gln His Tyr Gly Arg Thr Pro Phe Thr Phe Gly
245 250 255

Pro Gly Thr Lys Val Asp Ile Lys Arg Ala Ala Ala Ile Glu Val Met
260 265 270

Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile
275 280 285

His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
290 295 300

Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320

Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335

Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350

Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365

Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
370 375 380

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480

Met Gln Ala Leu Pro Pro Arg
485

<210> 248

<211> 1437

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
polynucleotide

<220>

<223> 8B5_THD_DNA

<400> 248

atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc	60
ccgcagattc agctcgtgga gtcagggtggg ggcgtgggttc agcccggacg gtccctgcga	120
ctctcttggtg tggcaagcgg atttaccttt aagaactatg gcatgcactg ggtgaggcag	180
gcccctggaa aaggactgga gtgggttgct gtgatctggg acgacgggtc caacgaatat	240
tatggcgatc ctgtgaaggg acggtttaca atctcacgcg ataactcaaa gaacatgctg	300
tacctgcaaa tgaactctct gcgcgctgat gacactgccg tgtattattg cgctcggagt	360
ggatatgccg tcgcaggagc atttgattat tgggggcaag ggaccctcgt gacagtgagt	420
tccggagggg gaggttctgg tggaggcggc tctggtgggg gaggcagcga gatcgttctg	480
accagttctc ctgacacact gtcactgtcc cctggtgaaa aggccacact gtctttaga	540
gcgtcccaga gcgtttccag ttccttcctt gcatggatat aacaaaaacc cgggcaggct	600
ccaagcttgc tgatctacgt ggccagccgc cgggccgcag gcatccctga taggtttagc	660
ggttctggga gcgggacgga cttcaccttg acaatatcac ggctggaacc cgaagacttc	720
ggaatgtttt attgccagca ctacggaaga actccattca cttttggccc gggaacgaag	780
gtagacatca agagagcagc agccctcgac aacgagaaat ccaatggaac cattatccat	840
gtgaagggga aacatctctg cccttcacca ttgttccctg gaccagcaa gcctttttgg	900
gttctggctg tgggtgggggg cgtcctggct tgttactccc tcctcggtac agtcgccttc	960
ataatctttt gggtttagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg	1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat	1080
ttcgctgcct atcggagccg agtgaaattt tctagatcag ctgatgctcc cgcctatcag	1140

cagggacaga atcaacttta caatgagctg aacctgggtc gcagagaaga gtacgacgtt	1200
ttggacaaac gccggggccg agatcctgag atggggggga agccgagaag gaagaatcct	1260
caagaaggcc tgtacaacga gcttcaaaaa gacaaaatgg ctgaggcgta ctctgagatc	1320
ggcatgaagg gcgagcggag acgaggcaag ggtcacgatg gcttgatca gggcctgagt	1380
acagccacaa aggacaccta tgacgccctc cacatgcagg cactgcccc acgctag	1437

<210> 249
 <211> 478
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>
 <223> 8B5_THD_AA

<400> 249
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Gln Ile Gln Leu Val Glu Ser Gly Gly Gly Val
 20 25 30

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe
 35 40 45

Thr Phe Lys Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
 50 55 60

Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Glu Tyr
 65 70 75 80

Tyr Gly Asp Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 85 90 95

Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr
 100 105 110

Ala Val Tyr Tyr Cys Ala Arg Ser Gly Ile Ala Val Ala Gly Ala Phe

115

120

125

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
 130 135 140

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Leu
 145 150 155 160

Thr Gln Ser Pro Asp Thr Leu Ser Leu Ser Pro Gly Glu Lys Ala Thr
 165 170 175

Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala Trp
 180 185 190

Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ser Leu Leu Ile Tyr Val Ala
 195 200 205

Ser Arg Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser
 210 215 220

Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe
 225 230 235 240

Gly Met Phe Tyr Cys Gln His Tyr Gly Arg Thr Pro Phe Thr Phe Gly
 245 250 255

Pro Gly Thr Lys Val Asp Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu
 260 265 270

Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
 275 280 285

Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
 290 295 300

Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
 305 310 315 320

Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
 325 330 335

Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
340 345 350

Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
355 360 365

Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
370 375 380

Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
385 390 395 400

Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
405 410 415

Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
420 425 430

Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
435 440 445

Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
450 455 460

Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 250
<211> 9
<212> PRT
<213> Homo sapiens

<400> 250
Ile Glu Val Met Tyr Pro Pro Pro Tyr
1 5

<210> 251
<211> 112
<212> PRT
<213> Homo sapiens

<400> 251
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly

1	5	10	15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr	20	25	30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys	35	40	45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys	50	55	60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg	65	70	75
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala	85	90	95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg	100	105	110

<210> 252
 <211> 6762
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic polynucleotide

<400> 252	
ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtgggttacg cgcagcgtga	60
ccgctacact tgccagcgcc ctagcgcccg ctcttttcgc tttcttccct tcctttctcg	120
ccacgttcgc cggctttccc cgtcaagctc taaatcgggg gctcccttta gggttccgat	180
ttagtgcttt acggcacctc gaccccaaaa aacttgatta gggatgatggg tcacgtagtg	240
ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata	300
gtggactctt gttccaaact ggaacaacac tcaaccctat ctcgggtctat tcttttgatt	360
tataagggat tttgccgatt tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat	420
ttaacgcgaa ttttaacaaa atattaacgc ttacaatttg ccattcgcca ttcaggctgc	480
gcaactgttg ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaag	540

ggggatgtgc tgcaaggcga ttaagttggg taacgccagg gttttcccag tcacgacgtt	600
gtaaaacgac ggccagtga ttgtaatacg actcactata gggcgacccg gggatggcgc	660
gccagtaatc aattacgggg tcattagttc atagcccata tatggagttc cgcgttacat	720
aacttacggt aaatggcccg cctggctgac cgcccaacga ccccgccca ttgacgtcaa	780
taatgacgta tgttcccata gtaacgcaa tagggacttt ccattgacgt caatgggtgg	840
agtatttacg gtaaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc	900
cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgccag tacatgacct	960
tatgggactt tcctacttgg cagtacatct acgtattagt catcgctatt accatgctga	1020
tgcggttttg gcagtacatc aatgggcgtg gatagcgggt tgactcacgg ggatttcaa	1080
gtctccacc cattgacgtc aatgggagtt tgttttggca ccaaaatcaa cgggactttc	1140
caaaatgtcg taacaactcc gcccattga cgcaaattgg cggtaggcgt gtacgggtggg	1200
aggtctatat aagcagagct ggtttagtga accgggggtct ctctggtag accagatctg	1260
agcctgggag ctctctggct aactagggaa cccactgctt aagcctcaat aaagcttgcc	1320
ttgagtgcct caagtagtgt gtgcccgtct gttgtgtgac tctggtaact agagatccct	1380
cagacccttt tagtcagtgt ggaaaatctc tagcagtggc gcccgaacag ggacttgaaa	1440
gcgaaaggga aaccagagga gctctctcga cgcaggactc ggcttgctga agcgcgcacg	1500
gcaagaggcg aggggcggcg actggtgagt acgccaaaaa ttttgactag cggaggctag	1560
aaggagagag atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgcgatgg	1620
gaaaaaattc ggttaaggcc agggggaaag aaaaaatata aattaaaca tatagtatgg	1680
gcaagcaggg agctagaacg attcgcagtt aatcctggcc tgtagaaaac atcagaaggc	1740
tgtagacaaa tactgggaca gctacaacca tcccttcaga caggatcaga agaacttaga	1800
tcattatata atacagtagc aaccctctat tgtgtgcatc aaaggataga gataaaagac	1860
accaaggaag ctttagacaa gatagaggaa gagcaaaaca aaagtaagac caccgcacag	1920
caagccgccg ctgatcttca gacctggagg aggagatatg agggacaatt ggagaagtga	1980
attatataaa tataaagtag taaaaattga accattagga gtagcaccca ccaaggcaaa	2040
gagaagagtg gtgcagagag aaaaaagagc agtgggaata ggagctttgt tccttgggtt	2100
cttgggagca gcaggaagca ctatgggcgc agcgtcaatg acgctgacgg tacaggccag	2160

acaattattg tctggtatag tgcagcagca gaacaatttg ctgagggcta ttgaggcgca	2220
acagcatctg ttgcaactca cagtctgggg catcaagcag ctccaggcaa gaatcctggc	2280
tgtggaaaga tacctaaagg atcaacagct cctgggggatt tggggttgct ctggaaaact	2340
catttgcacc actgctgtgc cttggaatgc tagttggagt aataaatctc tggaacagat	2400
ttggaatcac acgacctgga tggagtggga cagagaaatt aacaattaca caagcttaat	2460
acactcctta attgaagaat cgcaaaacca gcaagaaaag aatgaacaag aattattgga	2520
attagataaa tgggcaagtt tgtggaattg gtttaacata acaaattggc tgtggtatat	2580
aaaattattc ataatgatag taggaggctt ggtaggttta agaatagttt ttgctgtact	2640
ttctatagtg aatagagtta ggcagggata ttcaccatta tcgtttcaga cccacctccc	2700
aaccccgagg ggacccgaca ggcccgaagg aatagaagaa gaagggtggag agagagacag	2760
agacagatcc attcgattag tgaacggatc tcgacggtat cggttaactt ttaaaagaaa	2820
aggggggatt ggggggtaca gtgcagggga aagaatagta gacataatag caacagacat	2880
acaaactaaa gaattacaaa aacaaattac aaaattcaaa attttatcgc gatcgcggaa	2940
tgaaagaccc cacctgtagg tttggcaagc tagcttaagt aacgccattt tgcaaggcat	3000
ggaaaataca taactgagaa tagagaagtt cagatcaagg ttaggaacag agagacagca	3060
gaatatgggc caaacaggat atctgtggta agcagttcct gccccggctc agggccaaga	3120
acagatggtc cccagatgcg gtcccgccct cagcagtttc tagagaacca tcagatgttt	3180
ccagggtgcc ccaaggacct gaaaatgacc ctgtgcctta tttgaactaa ccaatcagtt	3240
cgcttctcgc ttctgttcgc gcgcttctgc tccccgagct caataaaaga gccacaacc	3300
cctcactcgg cgcgccagtc cttcgaagta gatctttgtc gatcctacca tccactcgac	3360
acacccgcca gcggccgctg ccaagcttcc gagctctcga attaattcac ggtaccacc	3420
atggcctagg gagactagtc gaatcgatat caacctctgg attacaaaat ttgtgaaaga	3480
ttgactggta ttcttaacta tgttgctcct ttacgctat gtggatacgc tgctttaatg	3540
cctttgtatc atgctattgc ttcccgtatg gctttcattt tctcctcctt gtataaatcc	3600
tggttgctgt ctctttatga ggagttgtgg cccgttgtca ggcaacgtgg cgtgggtgtgc	3660
actgtgtttg ctgacgcaac cccactgggt tggggcattg ccaccacctg tcagctcctt	3720
tccgggactt tcgctttccc cctccctatt gccacggcgg aactcatcgc cgcctgcctt	3780

gcccgctgct	ggacaggggc	tcggctgttg	ggcactgaca	attccgtggt	gttgtcgggg	3840
aagctgacgt	ccttttcatg	gctgctcgcc	tgtgttgcca	cctggattct	gcgcggggacg	3900
tccttctgct	acgtcccttc	ggccctcaat	ccagcggacc	ttccttcccg	cggcctgctg	3960
ccggctctgc	ggcctcttcc	gcgtcttcgc	cttcgccctc	agacgagtcg	gatctccctt	4020
tgggccgcct	ccccgcctgg	ttaattaaag	tacctttaag	accaatgact	tacaaggcag	4080
ctgtagatct	tagccacttt	ttaaaagaaa	aggggggact	ggaagggcga	attcactccc	4140
aacgaagaca	agatctgctt	tttgcttgta	ctgggtctct	ctggttagac	cagatctgag	4200
cctgggagct	ctctggctaa	ctagggaacc	cactgcttaa	gcctcaataa	agcttgccctt	4260
gagtgcctca	agtagtgtgt	gcccgtctgt	tgtgtgactc	tggtaaactag	agatccctca	4320
gaccctttta	gtcagtgtgg	aaaatctcta	gcaggcatgc	cagacatgat	aagatacatt	4380
gatgagtttg	gacaaaccac	aactagaatg	cagtgaaaaa	aatgctttat	ttgtgaaatt	4440
tgtgatgcta	ttgctttatt	tgtaaccatt	ataagctgca	ataaacaagt	taacaacaac	4500
aattgcattc	attttatgtt	tcaggttcag	ggggaggtgt	gggagggtttt	ttggcgcgcc	4560
atcgtcgagg	ttccctttag	tgagggttaa	ttgcgagctt	ggcgtaatca	tggtcatagc	4620
tgtttcctgt	gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaagca	4680
taaagtgtaa	agcctggggg	gcctaatagag	tgagctaact	cacattaatt	gcgttgcgct	4740
cactgcccgc	tttccagtcg	ggaaacctgt	cgtgccagct	gcattaatga	atcggccaac	4800
gcgcggggag	aggcggtttg	cgtattgggc	gctcttccgc	ttcctcgctc	actgactcgc	4860
tgcgctcggt	cgttcggtg	cggcgagcgg	tatcagctca	ctcaaaggcg	gtaatacggt	4920
tatccacaga	atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaaggc	cagcaaaaagg	4980
ccaggaaccg	taaaaaggcc	gcgttgctgg	cgtttttcca	taggctccgc	ccccctgacg	5040
agcatcacia	aaatcgacgc	tcaagtcaga	ggtggcgaaa	cccgcagga	ctataaagat	5100
accaggcggt	tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgccgctta	5160
ccggatacct	gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcat	agctcacgct	5220
gtaggtatct	cagttcggtg	taggtcggtc	gctccaagct	gggctgtgtg	cacgaacccc	5280
ccgttcagcc	cgaccgtgc	gccttatccg	gtaactatcg	tcttgagtcc	aacccggtaa	5340
gacacgactt	atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	5400

taggcggtgc tacagagttc ttgaagtggg ggcctaacta cggctacact agaagaacag	5460
tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt	5520
gatccggcaa acaaaccacc gctggtagcg gtgggtttttt tgtttgcaag cagcagatta	5580
cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc	5640
agtggaacga aaactcacgt taagggattt tggatcatgag attatcaaaa aggatcttca	5700
cctagatcct tttaaattaa aaatgaagtt ttaaataaat ctaaagtata tatgagtaaa	5760
cttgggtctga cagttaccaa tgcttaata gtaggagcacc tatctcagcg atctgtctat	5820
ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct	5880
taccatctgg cccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt	5940
tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat	6000
ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta	6060
atagtttgcg caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg	6120
gtatggcttc attcagctcc gggtcccaac gatcaaggcg agttacatga tccccatgt	6180
tgtgcaaaaa agcgggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg	6240
cagtgttatc actcatgggt atggcagcac tgcataattc tcttactgtc atgccatccg	6300
taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc	6360
ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa	6420
ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac	6480
cgctgttgag atccagttcg atgtaacca ctctgtcacc caactgatct tcagcatctt	6540
ttactttcac cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg	6600
gaataagggc gacacggaaa tggtgaatac tcatactctt cttttttcaa tattattgaa	6660
gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata	6720
aacaaatagg gggtccgcgc acatttcccc gaaaagtgcc ac	6762

<210> 253

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR1

<400> 253
Gly Phe Thr Phe Ser Ser Tyr
1 5

<210> 254
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
VH CDR1

<400> 254
Gly Phe Thr Phe Ser Ser Tyr
1 5

<210> 255
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
VH CDR1

<400> 255
Gly Tyr Thr Phe Thr Ser Tyr
1 5

<210> 256
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
VH CDR1

<400> 256
Gly Gly Ser Ile Ser Ser Ser Ser Tyr
1 5

<210> 257
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR1

<400> 257

Gly Phe Thr Phe Ser Ser Tyr
1 5

<210> 258

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR1

<400> 258

Gly Phe Thr Phe Ser Ser Tyr
1 5

<210> 259

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR1

<400> 259

Gly Gly Thr Phe Ser Ser Tyr
1 5

<210> 260

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR1

<400> 260

Gly Phe Thr Phe Ser Ser Tyr
1 5

<210> 261

<211> 17

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR2

<400> 261

Ala	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	Lys
1				5					10					15	

Gly

<210> 262

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR2

<400> 262

Val	Ile	Ser	Tyr	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	Lys
1				5					10					15	

Gly

<210> 263

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR2

<400> 263

Ile	Ile	Asn	Pro	Gly	Gly	Gly	Ser	Thr	Ser	Tyr	Ala	Gln	Lys	Phe	Gln
1				5					10					15	

Gly

<210> 264

<211> 16

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR2

<400> 264

Ser	Ile	Ser	Tyr	Ser	Gly	Ser	Thr	Tyr	Tyr	Asn	Pro	Ser	Leu	Lys	Ser
1				5				10						15	

<210> 265

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR2

<400> 265

Thr	Ile	Ser	Ser	Ser	Ser	Ser	Thr	Ile	Tyr	Tyr	Ala	Asp	Ser	Val	Lys
1				5				10						15	

Gly

<210> 266

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR2

<400> 266

Val	Ile	Ser	Tyr	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	Lys
1				5				10						15	

Gly

<210> 267

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR2

<400> 267

Gly	Ile	Ile	Pro	Ile	Phe	Gly	Thr	Ala	Asn	Tyr	Ala	Gln	Lys	Phe	Gln
1				5					10					15	

Gly

<210> 268

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR2

<400> 268

Val	Ile	Ser	Tyr	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	Lys
1				5					10					15	

Gly

<210> 269

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR3

<400> 269

Ala	Arg	Ala	Glu	Met	Gly	Ala	Val	Phe	Asp	Ile
1				5					10	

<210> 270

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR3

<400> 270

Ala Arg Asp Gly Thr Tyr Leu Gly Gly Leu Trp Tyr Phe Asp Leu
1 5 10 15

<210> 271

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR3

<400> 271

Ala Arg Glu Ser Trp Pro Met Asp Val
1 5

<210> 272

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR3

<400> 272

Ala Arg Gly Arg Gly Tyr Ala Thr Ser Leu Ala Phe Asp Ile
1 5 10

<210> 273

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR3

<400> 273

Ala Arg Gly Ser Gln Glu His Leu Ile Phe Asp Tyr
1 5 10

<210> 274

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR3

<400> 274

Ala Arg Thr Asp Phe Trp Ser Gly Ser Pro Pro Gly Leu Asp Tyr
1 5 10 15

<210> 275

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR3

<400> 275

Ala Arg Thr Pro Glu Tyr Ser Ser Ser Ile Trp His Tyr Tyr Tyr Gly
1 5 10 15

Met Asp Val

<210> 276

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VH CDR3

<400> 276

Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly Met Asp Val
1 5 10 15

<210> 277

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VL CDR3

<400> 277

Gln Gln Arg Ile Ser Trp Pro Phe Thr Phe
1 5 10

<210> 278

<211> 10

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VL CDR3

<400> 278

Met	Gln	Gly	Leu	Gly	Leu	Pro	Leu	Thr	Phe
1			5					10	

<210> 279

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VL CDR3

<400> 279

Gln	Gln	Tyr	Ala	Ala	Tyr	Pro	Thr	Phe
1			5					

<210> 280

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VL CDR3

<400> 280

Gln	Gln	Arg	His	Val	Trp	Pro	Pro	Thr	Phe
1			5					10	

<210> 281

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
VL CDR3

<400> 281

Gln	Gln	Arg	Phe	Tyr	Tyr	Pro	Trp	Thr	Phe
1			5					10	

<210> 282
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
VL CDR3

<400> 282
Gln Gln Ile Tyr Thr Phe Pro Phe Thr Phe
1 5 10

<210> 283
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
VL CDR3

<400> 283
Gln Gln Phe Ala His Thr Pro Phe Thr Phe
1 5 10

<210> 284
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
VL CDR3

<400> 284
Gln Gln His His Val Trp Pro Leu Thr Phe
1 5 10